INTELLECTUAL
PROPERTY OFFICE
BRUNEI DARUSSALAM

28 February 2021

NO. 002/2021

PATENT JOURNAL

Brunei Darussalam Intellectual Property Office (BruIPO)
The Law Building, Ground Floor
Jalan Raja Isteri Pengiran Anak Saleha
Bandar Seri Begawan BA1910
Negara Brunei Darussalam
Tel: +673 2244873/4/5/6 Ext 102
Email: enquiries@bruipo.gov.bn

CONTENTS

******

General Information

The Brunei Darussalam Intellectual Property Office (BruIPO) is an Office under the Attorney General's Chamber and its premises with effect from the 1 April, 2019 and is situated at the following address:

Brunei Darussalam Intellectual Property Office (BruIPO)
Attorney General's Chamber
The Law Building,
Jalan Raja Isteri Pengiran Anak Hajah Saleha,
Bandar Seri Begawan BA1910
Brunei Darussalam
Tel: +673 2225919

Opening Hours

With effect from 1 January, 2020, the Brunei Intellectual Property Office (BruIPO) counter will operate as follows:

Monday to Thursday	:	8.00am to 12.00pm 2.00pm to 3.00pm
Saturday	:	8.00am to 11.00am
Friday and Sunday	:	CLOSED

Submission of Applications

1. All applications for the registration of patents must be lodged with the Registrar of Patents at the Brunei Darussalam Intellectual Property Office (BruIPO).

2. Submission of applications via fax is acceptable provided the documents transmitted are clear and legible (in particular, representations). For applications that require the payment of a fee, actual lodgement of the prescribed fee is required before such applications can be processed.

Enquiries

1. For enquiries relating to any information in this Journal, kindly contact the Office at telephone numbers +673 2225919. Hard copies of the Journal can be purchased upon request from the Office at a cost of B$10.00 per copy.

2. The website of the Brunei Darussalam Intellectual Property Office (BruIPO) is http://www.bruipo.gov.bn.

3. All Patent-related enquiries via email can be submitted to enquiries@bruipo.gov.bn

******

Patents Legislation

1. The legislation governing the registration of Patent in Brunei Darussalam is the Patents Order 2011, while the subsidiary legislation is the Patents Rule, 2012.

2. The hard copies of the legislation can be purchased from: Print Plus Sdn Bhd Prime Minister's Office Jalan Airport Lama Bandar Seri Begawan BB3510 Brunei Darussalam Tel: 238 2541

3. The soft copies of the legislation can be obtained from www.bruipo.gov.bn

Forms and Fees

1. For any proceedings before the Registry, the prescribed form to be used and the accompanying fee payable shall be in accordance with the First and Second Schedule of the Patents Rule, 2012.

2. Payment by cheque should be made out to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

Restrictions on Applications Abroad by Residents of Brunei Darussalam

1. Local applicants intending to file a patent abroad must first obtain the Registrar's written authority as prescribed under section 33(1) of the Patents Order, 2011.

2. Failure to observe this requirement is an offence under section 33(1)(b)(3) of the Order.

Transitional Applications

1. Transitional applications under Section 115 shall be lodged with the Registrar of Patents in the following manner:

- Request to the Registrar of Patents for re-registration of a Singapore, Malaysia or United Kingdom/European patent;
- Lodgement of Patent Form PF46;
- Certified true copy of the grant of patent in the relevant country;
- Prescribed fee of B$250.00; and
- Any other supporting documents that the Registrar deems necessary.

2. The filing of a Power of Attorney accompanying a request for re-registration is no longer a requirement with effect from 1 January 2012.

3. Any renewal due for patents registered under the repealed Inventions Act (Cap 72) on or after 1 January 2012 shall be made in accordance with Section 54 on Patents Form PF20. Applicants must furnish supporting documents proving the validity of the patents which are due for renewal.

4. Search on the Register of patents (re-registrations) can be conducted at the Office by completing a Search Form PF30 and the payment of a search fee of $6.50 per hour.

******

‘INID' NUMBERS IN USE ON BRUNEI PATENT DOCUMENTS

'INID' is an acronym for '**I**nternationally agreed **N**umbers for the **I**dentification of **D**ata'

(10) Document identification
- (11) Number of the document
- (12) Plain language designation of the kind of document
- (19) WIPO country code, or other identification, of the country publishing the document.

(20) Document filing data
- (21) Number(s) assigned to the application(s)
- (22) Date(s) of filing application(s)
- (23) Other date(s) of filing, including exhibition filing date and date of filing complete specification following provisional specification.
- (24) Date from which industrial property rights may have effect.

(30) Priority data
- (31) Number(s) assigned to priority application(s).
- (32) Date(s) of filing priority application(s).
- (33) Country (countries) in which the priority application(s) was (were) filed.

(40) Date(s) of making available to the public
- (43) Date of publication by printing or similar process of unexamined document, on which no grant has taken place on or before the said date.
- (44) Date of publication by printing or similar process of an examined document, on which no grant has taken place on or before the said date.
- (45) Date of publication by printing or similar process of a document, on which grant has taken place on or before the said date.
- (47) Date of making a granted patent available to the public by viewing, or copying on request

(50) Technical information
- (51) International Patent Classification
- (52) Domestic or national classification
- (54) Title of invention
- (56) List of prior art documents, if separate from descriptive text.
- (57) Abstract or claim.

(60) Reference(s) to other legally related domestic document(s)
- (60) Related by cognate(s).
- (61) Related by addition(s).
- (62) Related by division(s).

(70) Identification of parties concerned with the document

(70) Name(s) of nominated person
(71) Name(s) of applicant(s).
(72) Name(s) of inventor(s) if known to be such.
(74) Name(s) of attorney(s) or agent(s).
(75) Name(s) of inventor(s) who is (are) also applicant(s)

(80) Identification of data related to International Conventions other than the Paris Convention
(86) PCT Application Number.
(87) PCT Publication Number.

NOTE
(1) The classification used is the International Patent Classification and is identified by the INID code (51). Further editions of the classification are identified as (51)2, (51)3, (51)4 and (51)5.
(2) INID code 74 provides for the name of patent attorney, or firm of attorneys, prosecuting an application.

******

PRACTICE NOTE 2012/01

PATENT RENEWALS

- **RENEWAL OF PATENTS REGISTERED UNDER SECTION 115 OF THE PATENTS ORDER**

1. For Section 115 applications, the following original documents need to be signed and submitted to the Registry of Patents:

   (a) PF20;
   (b) PF46 (for the first instance of renewal payment if that agent is not previously appointed);
   (c) evidence of the original patent not having been revoked, and
   (d) a cheque drawn on a Brunei bank account including the correct fee for both the PF20 and PF46. Cheques must be made payable to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

2. PF20

The notes at the top of the form and applicable provisions in the Patents Order and Patent Rules should be followed strictly. Additional formatting guidelines are as follows:

Section 2: Brunei registration number in format RP/XX/YYYY for pre 2012 cases, and RE YYYY/XXXX for 2012 onwards.

Section 3: Original Patent number in the format UK: GBXXXXXXX or EPXXXXXXX; MY: MY-XXXXXX-A; and SG: XXXXX.

Section 4: This should match the current details on the Brunei Register (rather than the original patent register details).

Section 5: Agents attending to the renewal on behalf of the proprietor should leave Section 5 blank and instead fill in details in Section 7 and 8.

Section 6: The renewal deadline is calculated from the date of filing for all UK, MY and SG original cases.

3. PF46

Section 6: Most commonly the appointment is for renewal matters only, so the "for renewals only" box should be checked, assuming the agent has not been previously appointed.

4. PF21

Extension fees will become payable for renewals as of 1 January 2013.

5. Certification of original patent

Evidence must be provided that the original patent must not be "revoked" as of the date of the renewal being paid. Please note it does not matter if the original patent has "lapsed" or "ceased". Evidence can be in the form of a certified true copy of the applicable online register printed on the day of filing or a

statutory declaration to the same effect. The online register of the original patent can be printed and certified as a true copy by the authorised agent for the renewal using a suitable chop and signature.

- **EXPIRY OF PATENT AT THE END OF THE TERM OF THE PATENT**

6. Agents are reminded that under Section 115(4)(a), the term of a Section 115 patent is 20 years from the date of filing of the original (UK/MY/SG) patent; subject to Section 35 and 36. It does not make any difference which country the original patent is from.

AMENDMENT OF RULE 92 OF S 19/2012

Rule 92 of the Patent Rules, 2012, is amended by repealing sub-rule (1) and by substituting the following new sub-rule therefor –

"(1) Subject to this rule, in relation to an international application for a patent (Brunei Darussalam) which is, under section 82, to be treated as an application for a patent under the Order, the prescribed period for the purpose of section 83(3) and (5) shall be, in a case where Brunei Darussalam has been designated and/or elected in accordance with the Patent Co-operation Treaty, 30 months from the relevant date.".

AMENDMENTS AND CORRECTIONS

- **AMENDMENT OF SPECIFICATION (RULES 51) OR CORRECTION OF ERROR IN SPECIFICATION (RULE 64)**

1. Unless required by the Registry under rules 51, an application for amendment of specification or a request for correction of an error in proposed amendment/correction incorporated; only a copy of the specification with the amendment/ correction indicated clearly therein is required. If a copy of the specification with the proposed amendment/correction incorporated is nonetheless filed, please be informed that the Registry will not review that document or consider it in any proceedings before the Registry.

2. The registry would also like to point out the replacement sheets with clear markings will reduce the need for clarification or further correspondences and hence will help expedite the processing of such requests.

- **AMENDMENTS/CORRECTIONS TO SPECIFICATION AND ABSTRACT**

1. Amendments/corrections to patent specifications and abstracts are to be clearly marked and completed by striking through text/figure etc. to be replaced, and by underlining replacement text/figure etc.

2. The following 3 examples reflect 3 possible alternative ways to which the changes could be represented. Example 4 reflects a situation where Patents Form 19 is filed.

Example 1: Page 10 of 19 sheets (Specification) is amended



Example 2: Page 10 of 19 sheets (Specification) is amended



Example 3: Page 10 of 19 sheets (Specification) is amended



This vertical line indicates the matter replacing the whole of page 10. To facilitate the document reproduction process however, the line should be placed about 0.5 cm to 1cm away from the 2.5 cm margin of each sheet.

Example 4: Page 10 of 19 sheets (Specification) is amended



- **COMMONLY MADE MISTAKES WHEN FILING PATENTS FORM 17**

The following are some of the commonly made mistakes in relation to making a request for amendments –

- Replacement sheets for amendments are not filed with Patents Form 17. –
- There is no marked up copy enclosed with Patents Form 17. –
- Patents Form 17 is filed without any replacement sheet. -
- Amendments to be made given on Patents Form 17 are different from the replacement sheets.

REGISTRATION UNDER SECTION 115

The following applications were processed through the Registry of Patents under section 115 of the Patents Order, 2011. Application numbers beginning with 'RP' are applications which were filed under the repealed Inventions Act (Cap 72) and were pending on 1 January 2012. Application numbers beginning with 'RE' are new re-registration applications filed after the implementation of the new Patents Order, 2011.

Date of filing:	17 February, 2020
Application No.:	RE/R/2020/0001
Patent No.:	EP2580236 B1 and US352461 P
Date of Grant:	8 June, 2011
Applicant (s)/Proprietor(s):	ASTRAZENECA AB and PIERIS PHARMACEUTICALS GMBH
Title:	TEAR LIPOCALIN MUTEINS BINDING IL-4 R ALPHA

******

FIRST SCHEDULE

FEES PAYABLE

Matter	Fee	Corresponding Form(s)
1. On filing a request for the grant of a patent	$160.00	1
2. On reference under section 20(1) or 48(1)	$450.00	2
3. On filing a counter-statement in each of the following cases –	$40.00	3
(*a*) Opposing the making of an order under section 20 or 48		
(*b*) Opposing a request under section 22		
(*c*) In respect of a reference under section 23(5)		
(*d*) Opposing an application under section 24		
(*e*) In answer to a notice of opposition under section 38		
(*f*) In answer to a notice of opposition under section 41		
(*g*) In respect of a reference under section 49(5)		
(*h*) In respect of an application under section 55(3)		
(*i*) In answer to a notice of opposition under section 5 6(7)		
(*j*) In respect of a reference under section 65(3)		
(*k*) On contesting an application under section 76 for declaration of non- infringement		
(*l*) On contesting an application under section 77 for revocation of a patent		
(*m*) In answer to a notice of opposition under section 104(2) to the correction of an error, clerical error or mistake		
4. On application under section 20(5) or 48(3) for authorization by Registrar	$50.00	4
5. On request for directions under section 22	$450.00	5

6. On reference under section 23(5) or 49(5) to determine the question of licence	$450.00	6
7. On application to the Registrar under section 24(1) 450 7 and/or 24(3)	$450.00	7
8. On filing a statement of inventorship and of right to the grant of a patent	-	8
9. On request for early publication under section 27(2)	$50.00	9
10. On filing a notice of withdrawal of an application for a patent under section 27(1)	-	10
11. On filing a request for a search report or a supplementary search report	$1750.00	11
12. On filing a request for a search and examination report	$2600.00	12
13. On furnishing information referred to in rule 46(1)	-	14
14. On filing a notice of intention to rely on an international preliminary report on patentability	-	15
15. On filing a request for an examination report	$1100.00	16
16. On request to amend application before grant	-	17
17. On filing a response to a written opinion under section 31 or 39	-	18
18. On request that a certificate of grant be issued –		19
(*a*) where the application for a patent has not more than 25 claims in the patent specification when rule 49(3) is complied with	$200.00	
(*b*) where the application for a patent has more than 25 claims in the patent specification when rule 49(3) is complied with	$200.00 plus $20.00 for Each claim in excess of 25 claims	
19. On payment of renewal fee (not including payment of back renewal fees pursuant to restoration or cancellation of entry in the register that licences are available as of right)	-	20

(a) for each year in respect of the 5th. 6th or 7th year of the patent		
(b) for each year in respect of the 8th, 9th or 10th year of the patent	$160.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	$270.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	$350.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	$450.00	
(f) for the 20th year of the patent	$550.00	
(g) for each year after the 20th year of the patent	$650.00	
	$950.00	
20. On payment of an additional fee for renewal under section 35(3) –		21
(*a*) not exceeding one month	$50.00	
(*b*) each succeeding month (but not exceeding 6 months)	$100.00	
21. On application to amend specification after grant	$100.00	22
22. On notice of opposition to amendment of specification after grant	$480.00	23
23. On application for the restoration of a patent	$500.00	24
24. On payment of additional fee on the application for the restoration of a patent	$300.00	25
25. On filing an offer to surrender a patent	$70.00	26
26. On notice of opposition to offer to surrender a patent	$250.00	27
27. On application to register or give notice of a transaction, instrument or event affecting the rights in a patent or an application for a patent – for each patent or application for a patent affected by such transaction, instrument or event	$70.00	29
28. On filing a request, in respect of one or more patents or applications for patents, for –		
(*a*) each alteration or correction of name	$12.00	28

(*b*) each alteration or correction of address (not being an address for service)		
29. On filing a request, in respect of each patent or application for a patent, for –	$12.00	28
(*a*) each alteration or correction of address for service		
(*b*) each correction of an error in the register or any connected document		
(*c*) each correction of an error of translation or transcript or clerical error or mistake in the specification of a patent, in an application for a patent or in any document filed in connection with a patent or such an application		
30. On request for the furnishing of or access to miscellaneous information –		30
(*a*) fee for inspecting each file or document relating to a patent or patent application	$6.50	
(*b*) fee for furnishing each file or document	$6.00	
(*c*) fee for photocopying each page or part thereof of any other document by the staff of the Registry	$0.30	
(*d*) where the document is placed in the public search room –		
(i) fee for self-service photocopying of each page or part of the document using a stored-value card	$0.15	
(ii) fee for photocopying of each page or part thereof by the staff of the Registry	$0.30	
31. On request for certificate of the Registrar –		31
(*a*) by impressed stamp -		
(i) for the first 20 sheets	$18.00	
(ii) for each additional sheet thereafter	$0.30	
(*b*) sealed and attached to the documents -		
(i) for the first 20 sheets	$30.00	

(ii) for each additional sheet thereafter	$0.30	
(*c*) in respect of a priority document under rule 17.1(*b*) of the Regulations under the Patent Cooperation Treaty	$50.00	
(*d*) in respect of a certified copy of the international application for a patent under rule 124	$28.00	
32. On application for entry of order of court in the register	$10.00	32
33. On application by proprietor for entry to be made in the register to the effect that licences under the patent are to be available as of right	$70.00	33
34. On application for settlement of terms of licence of right	$380.00	34
35. On application under section 56(1) or section 56(3) for cancellation of entry in the register	$70.00	35
36. On notice of opposition to an application under section 56(1) or 56(3) for cancellation of entry in the register	$90.00	36
37. On reference to the Registrar of a dispute as to infringement	$280.00	37
38. On application for declaration of non- infringement	$280.00	38
39. On application under section 77 for the revocation of a patent	$500.00	40
40. On request for re-examination of a patent in response to the Registrar's direction	$900.00	41
41. On request for re-examination of a patent in response to the Registrar's direction	$160.00	42
42. On payment of prescribed fee and request for publication of translation	$70.00	43
43. On application to Registrar for an international application for a patent (Brunei Darussalam) to be treated as an application under the Order	$160.00	44
44. On request for the exercise of the discretionary powers of the Registrar	$100.00	48

45. On declaration of authorisation where agent appointed or in substitution for another	$10.00 for each patent or application for patent	46
46. On payment of the advertisement fee upon receipt of the Registrar's request under rule 97(4)	$18.00	47
47. On notice of opposition to the correction of an error, clerical error or mistake	$100.00	48
48. On request for information relating to a patent or an application for a patent	$24.00	49
49. On request for extension of each time or period under rule 114(4) - for each month or part of a month for which the extension is sought	$200.00	50
50. On request for extension of each time or period under rule 114(6)	$200.00	52
51. On payment of additional fee for extension of each time or period under rule 114(9) – for each month, or part of a month, for which the extension is granted	$200.00	53
52. On request for extension of periods under sections 51 29(7) and 30(1)(*a*) –		51
(a) where the application is not an international application for a patent (Brunel Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	$1800.00	
(b) where the application is an international application for patent (Brunei Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	Nil	
53. On payment of transmittal fee under rule 14 of the Regulations under the Patent Co-operation Treaty	$150.00	54
54. On payment of fee under rule 123(6) in respect of a request under rule 26 bis.3(*a*) of the Regulations under the Patent Co-operation Treaty	$250.00	-

55. On request for certificate authorising release of sample of micro-organism	$15.00	55
56. On notice of intention to restrict availability of samples of micro-organisms to experts	$15.00	56
57. On request for certificate authorising release of sample of micro-organism to an expert	$15.00	57
58. On payment of renewal fee under section 55 or 56 –		58
(a) for each year in respect of the 5th, 6th or 7th year of the patent	$80.00	
(b) for each year in respect of the 8th, 9th or 10th year of the patent	$135.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	$175.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	$225.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	$275.00	
(f) for the 20th year of the patent	$325.00	
(g) for each year after the 20th year of the patent	$475.00	
59. On application to extend the term of a patent under section 36	$950.00	59
60. On filing a request for a search and examination report 60 after grant under section 39 –		60
(a) where the Examiner is the Austrian Patent Office	$2680.00	
(b) where the Examiner is the Danish Patent and Trademark Office	$3100.00	
(c) where the Examiner is the Hungarian Patent Office	$2680.00	
61. On filing one or more documents under section 26(7)(*c*) or (8) or 28(8)	-	61

62. On filing a declaration under rule 9(2) or a request under rule 9(3)	$120.00	62
63. On filing a request under rule 10(2)	$250.00	62
64. On filing any miscellaneous document or documents	-	99
65. For using the patent computer facilities in the public search room of the Registry		
(a) for every half hour or part thereof of log on 2 access using the patent search terminal	$2.00	
(b) for each sheet of information printed	$0.30	
66. Purchase of a copy of —		
(a) Patents Journal A	$10.00	
(b) Patents Journal B	$36.00	

******

SECOND SCHEDULE

DESCRIPTIONS OF FORMS

No.	Description of Form	Corresponding Form No.
1	Certificate of Grant	Certificate Form 1
2	Certificate of Extension of Patent Term	Certificate Form 2
3	Request for the Grant of a Patent under section 25	Patents Form 1
4	Reference under section 20(1) or 48(1)	Patents Form 2
5	Counter statement	Patents Form 3
6	Application under section 20(5) or 48(3) for Authorisation by the Registrar	Patents Form 4
7	Request for Directions under section 22	Patents Form 5
8	Reference under section 23(5) or 48(5) to Determine the Question of a Licence	Patents Form 6
9	Application to Registrar under section 24(1) and/or 24(3)	Patents Form 7
10	Statement of Inventorship and of Right to the Grant of a Patent under section 24	Patents Form 8
11	Request for Early Publication under section 27(2)	Patents Form 9
12	Withdrawal of an Application for a Patent under section 27(1)	Patents Form 10
13	Request for a Search Report or Supplementary Search Report	Patents Form 11
14	Request for a Search and Examination Report	Patents Form 12
15	Furnishing of Prescribed Details	Patents Form 13
16	Furnishing of Prescribed Information	Patents Form 14
17	Notice of Intention to Rely on International Preliminary Report on Patentability under section 29(2)(*e*)(ii)	Patents Form 15
18	Request for an Examination Report	Patents Form 16
19	Request to Amend Application before Grant under section 31(2)	Patents Form 17

20	Response to Written Opinion under section 31 or 39	Patents Form 18
21	Payment of Fee for Grant of a Patent under section 30	Patents Form 19
22	Payment of Renewal Fee under section 35(2) or 56(2)	Patents Form 20
23	Payment of Additional Fee under section 35(3)	Patents Form 21
24	Application to Amend Specification after Grant under section 38	Patents Form 22
25	Notice of Opposition to Amendment of Specification after Grant under section 38 or 80	Patents Form 23
26	Application for Restoration of a Patent under section 40	Patents Form 24
27	Additional Fee on the Application for Restoration of a Patent under section 40	Patents Form 25
28	Offer to Surrender a Patent under section 4 1(1)	Patents Form 26
29	Notice of Opposition to Offer to Surrender a Patent under section 41(2)	Patents Form 27
30	Request for Alteration of Name, Address or Address for Service, or Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 28
31	Application to Register or to Give Notice of a Transaction, Instrument or Event Affecting the Rights in a Patent or an Application for a Patent under section 44	Patents Form 29
32	Request for Miscellaneous Information under section 43 or 105	Patents Form 30
33	Request for Certificate of the Registrar under section 46	Patents Form 31
34	Application for Entry of Order of Court in the Register under section 44	Patents Form 32
35	Application for Entry to be Made in the Register to the effect that Licences under the Patent are to be available as of Right under section 55(1)	Patents Form 33
36	Application for Settlement of Terms of a Licence of Right under section 55(3)	Patents Form 34
37	Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 35
38	Notice of Opposition to an Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 36

39	Reference to the Registrar of a Dispute as to Infringement under section 65(3)	Patents Form 37
40	Application for Declaration of Non-Infringement under section 76	Patents Form 38
41	Application for Information on Corresponding Applications for a Patent	Patents Form 39
42	Application for Revocation of a Patent under section 77	Patents Form 40
43	Request for Re-Examination of a Patent in Response to direction of the Registrar under section 77	Patents Form 41
44	Payment of Fee for Entry into National Phase under section 83(3)	Patents Form 42
45	Payment of Prescribed Fee and Request for Publication of Translation under section 83(7)	Patents Form 43
46	Application to the Registrar for an International Application to be Treated as an Application under section 82 of the Order	Patents Form 44
47	Request for the Exercise of the Registrar's Discretionary Powers under section 89	Patents Form 45
48	Declaration of Authorisation where an Agent is Appointed or where One Agent is Substituted for Another	Patents Form 46
49	Additional Fee for the Advertisement of Proposed Correction under section 104	Patents Form 47
50	Notice of Opposition to the Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 48
51	Request for Information Relating to a Patent or an Application for a Patent under section 105	Patents Form 49
52	Request for Extension of Time or Period under rule 114(4)	Patents Form 50
53	Request for Extension of Periods under sections 29 (7) and 30(1)(*a*)	Patents Form 51
54	Request for Extension of Time or Period under rule 114(6)	Patents Form 52
55	Additional Fee for Extension of Time or Period under rule 114(9)	Patents Form 53

56	Payment of Transmittal Fee under rule 14 of the Regulations under the Patent Co-Operation Treaty	Patents Form 54
57	Request for Certificate Authorising Release of Sample of Micro-Organism	Patents Form 55
58	Notice of Intention to Restrict Availability of Samples of Micro-Organisms to Experts	Patents Form 56
59	Request for Certificate Authorising Release of Sample of Micro-Organisms to an Expert	Patents Form 57
60	Payment of Renewal Fee pursuant to section 55(3)(*d*)	Patents Form 58
61	Request for an Extension of the Term of a Patent under section 36	Patents Form 59
62	Request for Search and Examination after Grant under section 39	Patents Form 60
63	Filing of Documents under section 26(7)(*c*) or (8) or 28(8)	Patents Form 61
64	Declaration under rule 9(2) or Request under rule 9(3) or 10(2)	Patents Form 62
65	Filing of Miscellaneous Document or Documents	Patents Form 99

******

THIRD SCHEDULE

SCALE OF COSTS

PART I

BASIC COST

Item	*Matter*	*Amount*
1	Drawing and filing notice of opposition or application for revocation together with statement of case	$200.00
2	Drawing and filing a counter-statement	$150.00
3	Preparing and lodging evidence for a notice of opposition, an application for revocation or a counter-statement	$200.00 - $800.00
4	Perusing a notice of opposition, an application for revocation or a counter-statement (per folio)	$2.00 per folio
5	Preparing for all interlocutory proceedings	$25.00 - $120.00
6	Attending all interlocutory proceedings	$25.00 - $50.00
7	Preparing for hearing	$500.00 - $1500.00
8	Attendance at hearing by patent agent without advocate or solicitor	$100.00 per hour up to a maximum of $450.00 per day
9	Attendance at hearing by patent agent with instructing advocate or solicitor	$60.00 per hour up to a maximum of $270.00 per day
10	Advocate or Solicitor fees	$120.00 per hour up to a maximum of $540.00 per day
11	Drawing bill of costs (per folio)	$2.00 per folio
12	Attending taxation, and obtaining the Registrar's certificate or order	$50.00 - $120.00

******

PART II

ADDITIONAL COSTS

1. A person who has paid a fee prescribed in these Rules in relation to proceedings before the Registrar shall be paid the amount of the fee.

2. A person attending proceedings before the Registrar shall be paid –

(a) a reasonable amount for expenses incurred for transport between the usual place of residence of the person and the place that he attends for that purpose; and

(b) if the person is required to be absent overnight from his usual place of residence, a reasonable amount as allowances up to a daily maximum of $250 for meals and accommodation.

3. A person who, because of his professional, scientific or other special skill or knowledge, is summoned to appear before the Registrar as a witness shall be paid –

(a) if the person is remunerated in his occupation by wages, salary or fees, an amount equal to the amount of wages, salary or fees not paid to the person because of his attendance before the Registrar for that purpose, but such amount should not exceed $150 per day; or

(b) in any other case, an amount of not less than $100 but not more than $150 for each day on which he so attends.

******

FOURTH SCHEDULE

MICRO-ORGANISMS

Applications.

1. (1) The specification of an application for a patent, or of a patent, for an invention which requires for its performance the use of a micro-organism –

(a) which is not available to the public at the date of filing of the application; and

(b) which cannot be described in the specification in such a manner as to enable the invention to be performed by a person skilled in the art, shall, in relation to the micro-organism itself, be treated for the purposes of the Order as disclosing the invention in such a manner only if one of the conditions set out in subparagraph (2), is satisfied.

(2) The conditions referred to in sub-paragraph (1) are –

(a) a condition that –

(i) not later than the date of filing of the application, a culture of the micro-organism has been deposited with any international depositary authority which is able to furnish a sample of the micro-organism; and

(ii) the name of the international depositary authority, the date when the culture was deposited and the accession number of the deposit are given in the specification of the application; and

(b) a condition, in the case of an international application for a patent (Brunei Darussalam) which is treated, by virtue of section 85 as a patent under the Order, or, as the case may be, an application for a patent under the Order, that the corresponding provisions of the Implementing Regulations to the Patent Co-operation Treaty have been complied with, and where a new deposit is made under paragraph 4, a further condition that the applicant or proprietor makes a new deposit in accordance with that paragraph.

(3) Where the condition of sub-paragraph (2)(*a*)(ii) is not satisfied at the time the application for a patent is filed, it shall be satisfied –

(a) within 16 months from –
(i) the declared priority date; or
(ii) the date of filing the application where there is no declared priority date;

(b) where, on a request made by the applicant, the Registrar publishes the application before the end of the period prescribed for the purposes of section 27(1), before the

date of the request; or

(c) where the Registrar sends notification to the applicant that, in accordance with section 105(4), he has received a request by any person for information and inspection of documents under subsection (1) of that section, before the end of one month after his sending to the applicant notification of his receipt of the request, whichever is the earliest.

(4) The giving of the information specified in sub-paragraph (2)(*a*)(ii) shall constitute the unreserved and irrecoverable consent of the applicant to the international depositary authority with which a culture (including a deposit which is to be treated as having always been available by virtue of paragraph 4(2)) is from time to time deposited making the culture available on receipt of the Registrar's certificate authorising the release to the person who is named therein as a person to whom the culture may be made available and who makes a valid request therefor to the authority.

Availability of cultures.

2. (1) Subject to paragraph 3, a request that the Registrar certify a person as a person to whom an international depositary authority may furnish a sample of a micro-organism –

(a) before publication of the application for a patent, to a person who has made a request under section 105(1) in the circumstances mentioned in paragraph 1(3)(*c*); and

(b) at any later time, to any person, shall be made on Patents Form 55 together with the form provided for by the Regulations under the Budapest Treaty.

(2) The Registrar shall send a copy of any form lodged with him under subparagraph (1) and of his certificate authorising the release of the sample –

(a) to the applicant for, or proprietor of, the patent;

(b) to the international depositary authority; and (c) to the person making the request.

(3) A request under sub-paragraph (1) shall comprise, on the part of the person to whom the request relates, undertakings for the benefit of the applicant for, or proprietor of, the patent –

(a) not to make the culture, or any culture derived from it, available to any other person; and

(b) not to use the culture, or any culture derived from it, otherwise than for experimental purposes relating to the subject matter of the invention, and –

(i) subject to sub-paragraph (iii), both undertakings shall have effect during any period before the application for a patent has been withdrawn, has been treated as having been abandoned, has been refused or is treated as having been refused (including any further period allowed under rule 110, 120(1) or (6) but excluding,

where an application is reinstated under either of those rules, the period before it is reinstated);

(ii) if a patent is granted on the application, the undertaking set out in sub-paragraph (a) shall also have effect during any period for which the patent is in force and during the period of 6 months referred to in section 35(3); and

(iii) the undertaking set out in sub-paragraph (*b*) shall not have effect after the date of publication in the journal of a notice that the patent has been granted, and, in this sub-paragraph, references to a culture derived from a deposited culture of a microorganism are references to a culture so derived which exhibits those characteristics of the deposited culture essential for the performance of the invention.

(4) For the purpose of enabling any act specified in section 59 to be done in relation to the culture for the services of the Government, the undertakings specified in subparagraph (3) –

(a) shall not be required from any Government department or person authorised in writing by a Government department for the purposes of this paragraph; and

(b) shall not have effect in relation to any such person who has already given them.

(5) An undertaking given pursuant to sub-paragraph (3) may be varied by way of derogation by agreement between the applicant or proprietor and the person by whom it is given.

(6) Where, in respect of a patent to which the undertaking set out in sub-paragraph (3)(*a*) has effect –

(a) an entry is made in the register under section 55 to the effect that licences are to be available as of right; or

(b) a compulsory licence is granted under section 57, that undertaking shall not have effect to the extent necessary for effect to be given to any such licence.

Availability of cultures to experts.

3. (1) Subject to sub-paragraph (3), where, before the preparations for publication under section 27 of an application for a patent have been completed, the applicant gives notice to the Registrar on Patents Form 56 of his intention that a sample of the microorganism should be made available only to an expert, the provisions of this paragraph shall have effect.

(2) The Registrar –

(a) shall, at the time of publication of the application under section 27, publish a notice in the journal that the provisions of this paragraph have effect; and

(b) notwithstanding paragraph 2, shall not, until the patent is granted or the application has been withdrawn, has been treated as having been abandoned, has been refused or is

treated as having been refused, issue any certificate authorising release of a sample otherwise than under this paragraph.

(3) In the case of an international application for a patent (Brunei Darussalam), the applicant may, for the purpose set out in sub-paragraph (1), give notice in writing to the International Bureau under rule 13 bis 3 of the Regulations under the Patent Co-operation Treaty before the technical preparations for international publication of the application are complete of his intention that a sample of the micro-organism should be made available only to an expert and he shall be treated by the Registrar for the purposes of this paragraph as having complied with the conditions in sub-paragraph (1) and sub-paragraph (2)(*a*) shall not apply.

(4) Any person wishing to have a sample of the micro-organism made available ("the requester") –

(a) shall apply to the Registrar on Patents Form 57 together with the form provided for by the Regulations under the Patent Co-operation Treaty nominating the person ("the expert") to whom he wishes the sample to be made available; and

(b) shall at the same time file undertakings by the expert as set out in paragraph 2 (3) in accordance with the provisions of that paragraph.

(5) The Registrar shall send a copy of Patents Form 57 filed under sub-paragraph (4) to the applicant for the patent and shall specify the period within which the applicant may object, in accordance with sub-paragraph (6), to a sample of the micro-organism being available to the expert.

(6) Unless, within the period specified by the Registrar under sub-paragraph (5) (or within such longer period as the Registrar may, on application made to him within that period, allow), the applicant for the patent sends notice in writing to the Registrar that he objects to a sample of the micro-organism being made available to the expert and gives his reasons for his objection, the Registrar shall send a copy of any form lodged with him under sub-paragraph (4)(*a*) and of his certificate authorising the release of the sample –

(a) to the applicant for the patent;
(b) to the international depositary authority concerned;
(c) to the requester; and
(d) to the expert.

(7) Where, in accordance with sub-paragraph (6), the applicant for the patent sends notice to the Registrar of his objection to the issue of a certificate in favour of the expert, the Registrar –

(a) shall decide, having regard to the knowledge, experience and technical qualifications of the expert and to any other factors he considers relevant, whether to issue his certificate in favour of the expert; and

(b) if he decides to authorise the release of the sample to the expert, shall send to the persons

referred to in sub-paragraph (6) a copy of any form lodged with him under subparagraph (4)(*a*) and of his certificate authorising the release of the sample to the expert.

(8) Before making a decision in accordance with sub-paragraph (7), the Registrar shall afford the applicant and the requester the opportunity of being heard.

(9) If the Registrar decides under sub-paragraph (7) not to issue his certificate in favour of the expert, the requester may, by notice in writing to the Registrar and the applicant, nominate another person as the expert for the purposes of this paragraph; and the Registrar shall give such directions as he may think fit with regard to the subsequent procedure.

(10) Nothing in this paragraph shall affect the rights under section 58 of any Government department or of any person authorised in writing by a Government department.

New deposits.

4. (1) Where the international depositary authority with which a deposit or a new deposit of a culture has been made under this Schedule –

(a) notifies the applicant or proprietor that it –

(i) cannot satisfy a request made in accordance with paragraph 2(1) or 3(4); or

(ii) is not able lawfully, to satisfy such a request, for the culture to be made available;

(b) ceases temporarily or permanently to carry out the functions of an international depositary authority; or

(c) ceases for any reason to conduct its activities as an international depositary authority in an objective and impartial manner, subject to sub-paragraph (3), the applicant or proprietor may, unless the culture has been transferred to another international depositary authority which is able to make it available, make a new deposit of a culture of the micro-organism.

(2) For the purposes of paragraph 1 and this paragraph, the deposit shall be treated as always having been available if, within 3 months of the receipt of such notification or of the international depositary authority ceasing to perform the functions of an international depositary authority or to conduct its activities as such an authority in an objective and impartial manner, the applicant or proprietor –

(a) in a case where the deposit has not already been transferred, makes the new deposit;

(b) furnishes to the international depositary authority with which the new deposit is made a declaration that the culture so deposited is of the same microorganism as was the culture originally deposited; and

(c) requests amendment of the specification under section 31 or 38, as the case may be, so as to indicate the accession number of the transferred or new deposit and, where applicable, the name of the international depositary authority with which the deposit has been made.

(3) The new deposit referred to in sub-paragraph (1) –

(a) shall, subject to sub-paragraph (*b*), be made with the same international depositary authority as was the original deposit; or

(b) in the cases referred to in sub-paragraphs (1)(*a*)(ii), (*b*) and (*c*), shall be made with another international depositary authority which is able to satisfy the request.

Interpretation.

5. In this Schedule –

"Budapest Treaty" means the Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure done at Budapest in 1977; "depositary institution" means an institution which, at all relevant times –

(a) carries out the functions of receiving, accepting and storing microorganisms and the furnishing of samples thereof; and

(b) conducts its affairs in so far as they relate to the carrying out of those functions in an objective and impartial manner;

"international depositary authority" means a depositary institution which has acquired the status of international depositary authority as provided in Article 7 of the Budapest Treaty.

FIFTH SCHEDULE

REMUNERATION OF SCIENTIFIC ADVISERS

1. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order and who attends the proceedings before the Registrar shall be paid –

   (a) a reasonable amount for expenses incurred for transport between his usual place of residence and the place where the proceedings take place; and

   (b) if the scientific adviser is required to be absent overnight from his usual place of residence, a reasonable amount as allowance for meals and accommodation up to a daily maximum of $250.

2. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order shall, apart from the expenses and allowances referred to in paragraph 1, be paid an amount of not less than $650 but not more than $2,000 for each day or part thereof for which he hears the case or works on the report pursuant to an inquiry referred to him under rule 119(1)(*b*).

3. A person appointed as a scientific adviser to sit with the Registrar at the hearing of any proceedings may, apart from the expenses and allowances referred to in paragraph 1, be paid an amount not less than $650 but not more than $2,000 if he is subsequently not required to hear the proceedings with the Registrar.

******

REGISTRAR OF PATENT
BRUNEI DARUSSALAM

PATENTS RULES [S 11/2013]

NEW PATENT APPLICATION

[21] **BN/N/2020/0024** **[22]** **23/12/2020**

[54] **Method of Producing Natural Killer Cells and Composition for Treating Cancer**

[71] **NKMAX CO., LTD. of Healthcare Innovation Park, 6F 172 Dolma-ro, Bundang-gu Seongnam-si Gyeonggi-do 13605, South Korea**

[72] **1. PARK, SANG WOO**
2. KIM, YONG MAN
3. JUNG, JAE SEOB
4. RHEE, YONG-HEE

[74] **Messrs. MARKS & CLERK SINGAPORE LLP of AIP Law, Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 10-2019-0001981 Date: 07 January 2019 Country: Republic of Korea
No. 10-2018-0012938 Date: 01 February 2018 Country: Republic of Korea
No. 10-2018-0012942 Date: 01 February 2018 Country: Republic of Korea
No. 10-2019-0001983 Date: 07 January 2019 Country: Republic of Korea

[86] **PCT/US2019/016076**

[87] **WO/2019/152663**

[51] **A61K 35/17, A61P 31/04, A61P 31/10, A61P 31/12, A61P 33/00, A61P 43/00**

[57] **A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3-/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3-/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.**



FIG. 1B

[21] BN/N/2020/0025 **[22]** 15/04/2020

[54] Chromane Monobactam Compounds for The Treatment of Bacterial Infections

[71] MERCK SHARP & DOHME CORP. of 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States of America

[72]
1. BIFTU, TESFAYE
2. HUANG, XIANHAI
3. LIU, WEIGUO
4. PAN, WEIDONG
5. PARK, MIN
6. PASTERNAK, ALEXANDER
7. SUN, WANYING
8. TANG, HAIFENG
9. ZANG, YI

[74] Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/566,779 Date: 02 October 2017 Country: United States of America

[86] PCT/US2018/053039

[87] WO/2019/070492

[51] A61K 31/427, A61K 31/433, A61K 31/4439

[57] The present invention relates to monobactam compounds of Formula (I) and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

(I)



[21] BN/N/2020/0026 **[22]** 15/04/2020

[54] Anti-Pacap Antibody

[71] ELI LILLY AND COMPANY of Lilly Corporate Center Indianpolis, Indiana 46285, United States of America

[72] 1. BEIDLER, Catherine Brautigam
2. JOHNSON, Michael Parvin
3. PATEL, Chetankumar Natvarlal

[74] Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/565,278 Date: 29 September 2017 Country: United States of America

[86] PCT/US2018/051898

[87] WO/2019/067293

[51] C07K 16/44, C07K 16/18, A61K 39/00

[57] Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and / or migraine.

---

[21] BN/N/2020/0027 **[22]** 15/04/2020

[54] Methods for Gender Determination of Avian Embryos in Unhatched Eggs and Means Thereof

[71] EGGXYT LTD of Keren HaYessod 36 9100760 Jerusalem, Israel

[72] 1. OFFEN, DANIEL

[74] Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/510,921 Date: 25 May 2017 Country: United States of America

[86] PCT/IL2018/050573

[87] WO/2018/216022

[51] A01K 67/027, C12N 9/02, C12N 15/10, C12N 15/90

[57] The present invention relates to methods of fertilization and gender determination

and identification in avian subjects. More specifically, the invention provides non-invasive methods using transgenic avian animals that comprise at least one reporter gene, specifically, RFP, integrated into at least one gender chromosome Z or W. The transgenic avian animals of the invention are used for gender determination and selection of embryos in unhatched avian eggs.

---

[21] **BN/N/2020/0028** **[22]** **15/04/2020**

[54] **A Well in A Geological Structure**

[71] **METROL TECHNOLOGY LIMITED of Unit 24, Kirkhill Place Kirkhill Industrial Estate Dyce Aberdeen Aberdeenshire AB21 0GU**

[72] **1. ROSS, SHAUN COMPTON**
2. JARVIS, LESLIE DAVID

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 1715585.4 Date: 26 September 2017 Country: United Kingdom

[86] **PCT/GB2018/052659**

[87] **WO/2019/063973**

[51] **E21B 47/12, E21B 34/06**

[57] **A well (10) in a geological structure, the well (10) comprising a first casing string (12a) with a second casing string (12b) partially inside, and a third casing string (13c) partially inside the second casing string (12b). A first inter-casing annulus (14a) is defined between the first (12a) and second casing strings (12b), and a second inter-casing annulus (14b) is defined between the second (12b) and third casing strings (12c). A primary fluid flow control device (16a), such as a wirelessly controllable valve, on the second casing provides (12b) fluid communication between the first inter-casing annulus (14a) and the second inter-casing annulus (14b); and a secondary fluid flow control device (16b), such as a second wirelessly controllable valve, on the third casing string (12c) provides fluid communication between the second inter-casing annulus (14b) and a bore of the third casing (14c). In the event of a "blow-out", a kill fluid can then be introduced into an annulus and the fluid flow control devices used to allow the kill fluid to cascade down the well to control it. Accordingly, the time taken to drill a relief well may be mitigated or obviated which can reduce the time and cost to control the well and can mitigate environmental impact of hydrocarbon loss caused by the blow-out.**

---

[21] **BN/N/2020/0029** **[22]** **15/04/2020**

[54] **Heat-Not-Burn Cigarette Having Cavity Container Section**

[71] **NANTONG JIN YUAN NEW MATERIALS CO., LTD. of Floor 8, Building No. 2, No. 388, Yongxing Avenue, Gangzha District Nantong, Jiangsu 226002, China**

[72] **1. TANG, WEI**
2. TANG, RONGCHENG
3. ZHOU, CHENGXI
4. QIN, CHANGFENG
5. LUO, LIANG

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 201710880890.3 Date: 26 September 2017 Country: China

[86] **PCT/CN2017/107271**

[87] **WO/2019/061606**

[51] **A24F 47/00**

[57] **A heat-not-burn cigarette having a cavity container section, comprising a tobacco section (1), a multi-cavity container section (6), and a lip proximity section (4) sequentially and coaxially connected, and an external wrapping material (5) for limiting the tobacco section (1), the multi-cavity container section (6), and the lip proximity section (4). The tobacco section (1) comprises a smoking material; a core material of the tobacco section (1) is wrapped by an aluminum foil composite plug wrap (2) or an oil-proof plug wrap. Due to the material of the multi-cavity container section (6), the cigarette has a good cooling property, such that a user has no sensation of burning during smoking. By providing the multi-cavity container section (6), the cigarette has various flavors, a thick smell, and rich smoke. By providing an aluminum foil composite plug wrap (2) on the tobacco section (1), problems of contamination and deformation of the external wrapping material (5) due to that the core material absorbs moisture from air are reduced.**

---

[21] **BN/N/2020/0030** **[22]** **15/04/2020**

[54] **Btk Inhibitor Compounds**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285, United States of America**

[72] **1. HENRY, KENNETH JAMES, JR.**
2. KHILEVICH, ALBERT
3. ZHOU, CHENGXI
4. KUKLISH, STEVEN, LEE
5. PARTRIDGE, KATHERINE, MARIE
6. QUIMBY, STEVEN, JAMES

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/581,967 Date: 06 November 2017 Country: United States of America

[86] **PCT/US2018/058104**

[87] **WO/2019/089512**

[51] **C07D 401/14, C07D 403/14, A61P 25/00, A61P 37/00, A61P 19/02, A61K 31/506**

[57] **A heat-not-burn cigarette having a cavity container section, comprising a tobacco section (1), a multi-cavity container section (6), and a lip proximity section (4) sequentially and coaxially connected, and an external wrapping material (5) for limiting the tobacco section (1), the multi-cavity container section (6), and the lip proximity section (4). The tobacco section (1) comprises a smoking material; a core material of the tobacco section (1) is wrapped by an aluminum foil composite plug wrap (2) or an oil-proof plug wrap. Due to the material of the multi-cavity container section (6), the cigarette has a good cooling property, such that a user has no sensation of burning during smoking. By providing the multi-cavity container section (6), the cigarette has various flavors, a thick smell, and rich smoke. By providing an aluminum foil composite plug wrap (2) on the tobacco section (1), problems of contamination and deformation of the external wrapping material (5) due to that the core material absorbs moisture from air are reduced.**

---

[21] **BN/N/2020/0030** **[22]** **15/04/2020**

[54] **Btk Inhibitor Compounds**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285, United States of America**

[72] **1. HENRY, KENNETH JAMES, JR.**
2. KHILEVICH, ALBERT
3. ZHOU, CHENGXI
4. KUKLISH, STEVEN, LEE
5. PARTRIDGE, KATHERINE, MARIE
6. QUIMBY, STEVEN, JAMES

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/581,967 Date: 06 November 2017 Country: United States of America

[86] **PCT/US2018/058104**

[87] **WO/2019/089512**

[51] **C07D 401/14, C07D 403/14, A61P 25/00, A61P 37/00, A61P 19/02, A61K 31/506**

[57] **The invention provides BTK Inhibitor compounds, pharmaceutically acceptable salts, pharmaceutical compositions thereof, and methods of using these compounds, salts, or compositions to treat autoimmune diseases such as Rheumatoid Arthritis.**

---

[21] **BN/N/2020/0031** **[22]** **15/04/2020**

[54] **Use Of Amino Acid Supplementation For Improved Muscle Protein Synthesis**

[71] **BIOVENTURES, LLC of 4301 W. Markham Street, #831 Little Rock, Arkansas 72205**

[72] **1. RILEY-VARGAS, REBECCA**
2. BISSEN, SHIRLEY T.
3. DOTY, KATHRYN
4. KREPEL, ALLISON
5. NEALEY, TARA A.
6. ROBERTS, BRETT J.

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/580,861 Date: 02 November 2017 Country: United States of America

[86] **PCT/US2018/058937**

[87] **WO/2019/090061**

[51] **A23L 33/17, A61K 31/198**

[57] **The present invention encompasses an amino acid composition for stimulating muscle protein synthesis. Further, the present disclosure relates generally to the use of an anabolic amino acid composition for the stimulation of muscle protein synthesis. In particular, disclosed are compositions and methods of using the same for the prevention and/or treatment of a loss of any one of muscle mass, muscle strength, muscle function, and physical function, or any combination thereof, in a mammal, especially an adult mammal. Also provided are kits comprising a composition for the stimulation of muscle protein synthesis and, in certain embodiments, instructions for administration.**

---

[21] **BN/N/2020/0032** **[22]** **18/04/2020**

[54] **Condensed Imidazole Derivatives Substituted by Tertiary Hydroxy Groups as Pi3k-Gamma Inhibitors**

[71] **INCYTE CORPORATION of 1801 Augustine Cut-Off Wilmington, Delaware 19803 United States of America**

[72] **1. DOUTY, BRENT**
2. BUESKING, ANDREW W.
3. BURNS, DAVID M.
4. COMBS, ANDREW P.
5. FALAHATPISHEH, NIKOO
6. JALLURI, RAVI KUMAR
7. LEVY, DANIEL
8. POLAM, PADMAJA
9. SHAO, LIXIN
10. SHEPARD, STACEY
11. SHVARTSBART, ARTEM
12. SPARKS, RICHARD B.
13. YUE, EDDY W.

[74] **Messrs. HENRY GOH & CO. SDN. BHD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/574,057 Date: 18 October 2017 Country: United States of America
No. 62/608,897 Date: 21 December 2017 Country: United States of America
No. 62/727,316 Date: 05 September 2018 Country: United States of America

[86] **PCT/US2018/056311**

[87] **WO/2019/090061**

[51] **C07D 487/04, A61P 25/28, A61P 35/00, A61K 31/4985, A61K 31/495**

[57] **This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-y which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.**



(I)

---

[21] **BN/N/2020/0033** **[22]** **18/04/2020**

[54] **A System and Method of Cleaning an Annular Area in A Well**

[71] **HYDRA SYSTEMS AS of Postboks 182, 4098 Tananger, Norway**

[72] **1. MYHRE, MORTEN**
2. LARSEN, ARNE GUNNAR
3. ØSTVOLD, ARNOLD

[74] **Messrs. HENRY GOH & CO. SDN. BHD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 20171650 Date: 17 October 2017 Country: Norway

[86] **PCT/NO2018/050247**

[87] **WO/2019/078728**

[51] **E21B 37/08, E21B 21/00, E21B 33/13, E21B 37/00, E21B 43/114**

[57] **A system and method of cleaning an annular area in a well (2), comprising: - a first pipe body (4) and a surrounding second pipe body (6); - a first annulus (8) containing a clean fluid (10), and a surrounding second annulus (12) containing contaminants (14); - a plurality of sets of holes (22) formed through the pipe bodies (4, 6) and dispersed along a longitudinal section (L), each set of holes (22) comprising holes (22a, 22b) aligned substantially radially; and - a washing tool (26) positioned in the first pipe body (4) and comprising spaced apart flow guides (28a, 28b) configured to enclose of a limited number of sets of holes (22), the flow guides (28a, 28b) cooperating with an inside of the first pipe body (4) to form a confined pressure compartment (30) for the limited number of sets of holes (22) when operational in the well (2).**



Fig. 4

---

[21] **BN/N/2020/0034** **[22]** **27/04/2020**

[54] **Compounds Useful for Inhibiting Cdk7**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America**

[72] **1. COATES, DAVID ANDREW**
2. MONTERO, CARLOS
3. PATEL, BHARVIN KUMAR RAMESCHANDRA
4. REMICK, DAVID MICHAEL
5. YADAV, VIPIN

[74] **Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 17382778.3 Date: 16 November 2017 Country: European Patent Office
No. 18382034.9 Date: 23 January 2018 Country: European Patent Office
No. 18382546.2 Date: 20 July 2018 Country: European Patent Office

[86] **PCT/US2018/060025**

[87] **WO/2019/099298**

[51] **C07D 487/04, A61P 35/00, A61K 31/519**

[57] **The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: (I), or a pharmaceutically acceptable salt thereof.**



(I)

---

[21] **BN/N/2020/0035** **[22]** **27/04/2020**

[54] **Methods Of Using And Compositions Containing Dulaglutide**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America**

[72] **1. COX, DAVID ANDREW**
2. MILICEVIC, ZVONKO
3. THAM, LAI SAN
4. WERNER, ANDREW GORDON
5. WOODWARD, DAVID BRADLEY

[74] **Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law, Unit Nos. 405A-410A 4th**

Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/589,244 Date: 21 November 2017 Country: United States of America

[86] **PCT/US2018/060716**

[87] **WO/2019/103875**

[51] **A61K 38/26, A61P 3/10**

[57] **The present invention relates to methods of using new doses of dulaglutide and compositions containing such higher doses of dulaglutide.**

---

[21] **BN/N/2020/0038** **[22]** **30/04/2020**

[54] **Method of Restraining Migration of Formation Solids in A Wellbore**

[71] **SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. of Carel van Bylandtlaan 30 2596 The Hague Netherlands**

[72] **1. VERBIST, GUY LODE MAGDA MARIA**
2. VAN DER WEGEN, GERARDUS JOHANNES LEONARDUS
3. LANGEDIJK, GIDEON
4. CORNELISSEN, ERIK KERST
5. BLEEKER, PETER JAN
6. HEATHMAN, JAMES FRANK
7. MEAD, CHRISTOPHER JOHN

[74] **Messrs. DREW AND NAPIER LLC of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 17205157.5 Date: 04 December 2017 Country: European Patent Office
No. 62/734,311 Date: 21 September 2018 Country: United States of America

[86] **PCT/US2018/061206**

[87] **WO/2019/112765**

[51] **C09K 8/57, C04B 28/02, C09K 8/504**

[57] **Migration of formation solids in a wellbore is restrained by feeding a slurry, comprising water, a viscosifier, and a concentration of cement clinker particles, into the wellbore, and hydrating the clinker particles in the wellbore. The clinker particles are kept in suspension during the hydrating, and upon completion of the hydrating the hydrated clinker particles form a hardened cement consisting of a permeable structure of interconnected hydrated clinker particles. A layer of degradable lost circulation material (LCM) may be employed to separate the slurry with clinker particles from the formation surrounding the wellbore during hydrating of the clinker**

particles.

---

[21] **BN/N/2020/0047** **[22]** **06/06/2020**

[54] **Compositions Comprising Streptococcus Pneumoniae Polysaccharide-Protein Conjugates and Methods of Use Thereof**

[71] **MERCK SHARP & DOHME CORP. of 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States of America**

[72] **1. SMITH, WILLIAM, J.**
2. MCHUGH, PATRICK
3. WINTERS, MICHAEL ALBERT
4. SKINNER, JULIE, M.
5. HE, JIAN
6. MUSEY, LUWY
7. ABEYGUNAWARDANA, CHITRANANDA
8. CUI, YADONG ADAM
9. KOSINSKI, MICHAEL, J.

[74] **Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/595,388 Date: 06 December 2017 Country: United States of America

[86] **PCT/US2018/063709**

[87] **WO/2019/139692**

[51] **A61K 39/09, A61K 39/385, A61P 31/04, A61K 39/00**

[57] **The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimens that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.**



FIG.31A

---

[21] BN/N/2020/0050 **[22]** 15/06/2020

[54] Incretin Analogs And Uses Thereof

[71] ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285, United States Of America

[72] 1. ALSINA-FERNANDEZ, JORGE
2. COSKUN, TAMER
3. GUO, LILI
4. QU, HONGCHANG

[74] Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/608,613 Date: 21 December 2017 Country: United States of America

[86] PCT/US2018/065663

[87] WO/2019/125938

[51] A61K 38/26, C07K 14/605, A61P 3/00

[57] Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.

---

[21] BN/N/2020/0051 **[22]** 15/06/2020

[54] Incretin Analogs And Uses Thereof

[71] ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285, United States Of America

[72] **1. ALSINA-FERNANDEZ, JORGE**
2. COSKUN, TAMER
3. GUO, LILI
4. QU, HONGCHANG

[74] **Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/608,644 Date: 21 December 2017 Country: United States of America

[86] **PCT/US2018/065605**

[87] **WO/2019/125929**

[51] **A61K 38/26, C07K 14/605, A61P 3/00**

[57] **Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.**

---

[21] **BN/N/2020/0052** **[22]** **18/06/2020**

[54] **Lipid Combinations**

[71] **PHARMALINK INTERNATIONAL LIMITED of Third Floor, 31 C-D Wyndham Street, Central, Hong Kong, China**

[72] **1. HODGSON, CHARLES**
2. MYERS, STEPHEN
3. OLIVER, CHRISTOPHER

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 2017905181 Date: 22 December 2017 Country: Australia

[86] **PCT/IB2018/060482**

[87] **WO/2019/123400**

[51] **A61K 35/612, A61K 35/618, A61P 29/00**

[57] **A combination or composition of mussel lipid and krill oil is disclosed, which is used to treat inflammation or pain. A process for preparing krill oil having a phospholipid content of about 50% or greater is also disclosed.**

[21] BN/N/2020/0055 **[22]** 01/07/2020

[54] Anti-Pd-1 Antibodies and Methods of Treatment

[71] AMGEN INC of One Amgen Center Drive, Thousand Oaks, California 91320-1789, United States of America

[72] 1. ALI, KHALED, M.K.Z.
2. AGRAWAL, NEERAJ JAGDISH
3. KANNAN, GUNASEKARAN
4. FOLTZ, IAN
5. WANG, ZHULUN
6. BATES, DAREN
7. MOCK, MARISSA
8. TAKENAKA, SHUNSUKE

[74] Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/616,733 Date: 22 January 2018 Country: United States of America
No. 62/770,029 Date: 20 November 2018 Country: United States of America

[86] PCT/US2019/013205

[87] WO/2019/140196

[51] C07K 14/54, A61K 47/60, A61K 47/54, C07K 16/28

[57] Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions. Methods of making PD-1 antigen-binding proteins and methods of treating a subject are further provided.

---

[21] BN/N/2020/0056 **[22]** 01/07/2020

[54] A Publicly Accessible Urban Beach Entertainment Complex with A Centerpiece Man-Made Tropical-Style Lagoon and Method for Providing Efficient Utilization of Limited Use Land

[71] CRYSTAL LAGOONS TECHNOLOGIES, INC. of 1209 Orange Street Wilmington, DE 19801

[72] 1. FISCHMANN TORRES, FERNANDO, BENJAMIN

[74] Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/625,182 Date: 01 February 2018 Country: United States of America
No. 62/639,211 Date: 06 March 2018 Country: United States of America
No. 15/990,141 Date: 25 May 2018 Country: United States of America

[86] **PCT/IB2018/001084**

[87] **WO/2019/150159**

[51] **A63G 31/00, E04H 4/00, C02F 103/00, E04H 4/12, C02F 103/42**

[57] **A publicly accessible urban beach entertainment complex is disclosed, with a man-made tropical, pristine-clear lagoon as the centerpiece of the complex, with surrounding entertainment, educational, sports, and commercial facilities, the complex having controlled public access and providing the look and feel of a tropical beach with clear waters and sandy beaches. In addition a method for efficiently utilizing facilities and land that are vacant, underutilized, have limited uses, or that are contiguous to or nearby recreational, educational, sports, or commercial venues is disclosed. The method providing a publicly accessible urban beach entertainment complex with a centerpiece man-made tropical-style pristine- clear lagoon. The method allows for generating revenue and increasing efficiency by pairing vacant sites, underutilized sites, limited use land, or sites that are contiguous to entertainment, educational, sports, and/or commercial venues with urban beach entertainment complexes. The complex preferably has a controlled public access, thereby allowing entrance upon payment of a fee.**

---

[21] **BN/N/2020/0056** **[22]** **01/07/2020**

[54] **A Publicly Accessible Urban Beach Entertainment Complex with A Centerpiece Man-Made Tropical-Style Lagoon and Method for Providing Efficient Utilization of Limited Use Land**

[71] **CRYSTAL LAGOONS TECHNOLOGIES, INC. of 1209 Orange Street Wilmington, DE 19801**

[72] **1. FISCHMANN TORRES, FERNANDO, BENJAMIN**

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/625,182 Date: 01 February 2018 Country: United States of America
No. 62/639,211 Date: 06 March 2018 Country: United States of America
No. 15/990,141 Date: 25 May 2018 Country: United States of America

[86] **PCT/IB2018/001084**

[87] **WO/2019/150159**

[51] **A63G 31/00, C02F 103/00, C02F 103/42, E04H 4/00, E04H 4/12**

[57] **A publicly accessible urban beach entertainment complex is disclosed, with a man-made tropical, pristine-clear lagoon as the centerpiece of the complex, with surrounding entertainment, educational, sports, and commercial facilities, the complex having controlled public access and providing the look and feel of a tropical beach with clear waters and sandy beaches. In addition a method for efficiently utilizing facilities and land that are vacant, underutilized, have limited uses, or that are contiguous to or nearby recreational, educational, sports, or commercial venues is disclosed. The method providing a publicly accessible urban beach entertainment complex with a centerpiece man-made tropical-style pristine- clear lagoon. The method allows for generating revenue and increasing efficiency by pairing vacant sites, underutilized sites, limited use land, or sites that are contiguous to entertainment, educational, sports, and/or commercial venues with urban beach entertainment complexes. The complex preferably has a controlled public access, thereby allowing entrance upon payment of a fee.**

---

[21] **BN/N/2020/0057** **[22]** **09/07/2020**

[54] **A Medicine Dispensing Device**

[71] **UNIVERSITI BRUNEI DARUSSALAM of Tungku Link, Bandar Seri Begawan BE1410 Brunei Darussalam**

[72] **1. MUHAMMAD MU'AZ HAJI IMRAN**
2. CHANDRATILAK DE SILVA LIYANAGE

[57] **The present invention discloses a device for dispensing medicine of different shape/size/nature integrated with a monitoring mechanism. The device for dispensing a medicine comprising a storage mechanism having a storage box capable of storing at least one medicine, said storage box is customizable to store medicines of different sizes and shapes, and a dispensing mechanism coupled to the storage mechanism, the dispensing mechanism having a rack and pinion assembly capable to dispense the medicine from the storage box to a storage tray or a platform in response to input received on from an input interface of the device.**

---

[21] **BN/N/2020/0058** **[22]** **28/07/2020**

[54] **Contraceptive Composition with Reduced Cardiovascular Effects**

[71] **ESTETRA SPRL of Rue Saint-Georges, 5 4000 Liege, Belgium**

[72] **1. JOST, MAUD**
2. RAUSIN, GLWADYS

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 18155571.5 Date: 07 February 2018 Country: European Patent Office

No. 18160586.6 Date: 07 March 2018 Country: European Patent Office

[86] **PCT/EP2019/052980**

[87] **WO/2019/154899**

[51] **A61K 31/565, A61P 15/18**

[57] **The present invention relates to a contraceptive method with reduced cardiovascular effects, such as reduced thromboembolism risk, such as reduced venous thromboembolism (VTE) risk and reduced aortic thromboembolism (ATE) risk. The method of the invention comprises administering to a female mammal an effective amount of an estetrol component in combination with a progestogenic component. The method enjoys a favourable profile for thromboembolism compared to currently available methods which employs contraceptives from the so-called second, third or fourth generation.**

---

[21] **BN/N/2020/0059** **[22]** **30/07/2020**

[54] **Methods of Testosterone Therapy**

[71] **AYTU BIOSCIENCE, INC. of Inverness Parkway, Suite 206, Englewood, Colorado 80112, United States of America**
ACERUS BIOPHARMA INC. of 2486 Dunwin Drive Mississauga, Ontario L5L 1J9, Canada

[72] **1. WESTFIELD, GERWIN**
2. ZWIERKO, MARGAUX
3. RAMASAMY, RANJITH
4. BRYSON, NATHAN

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/625,653 Date: 02 February 2018 Country: United States of America
No. 62/756,976 Date: 07 November 2018 Country: United States of America

[86] **PCT/US2019/016373**

[87] **WO/2019/152854**

[51] **A61K 31/568, A61M 5/20, A61M 5/30**

[57] **Methods and systems for preventing or reducing side effects of testosterone replacement therapy (TRT) by administering a testosterone formulation multiple times per day are disclosed. The methods of the present invention enable men who cannot tolerate previous TRT regimens, e.g. because they wish to attempt to conceive or are at risk of developing cardiovascular side effects, to receive TRT treatment.**



Fig. 4

---

[21] **BN/N/2020/0060** **[22]** **03/08/2020**

[54] **Systems And Methods For Gravel Packing Wells**

[71] **HALLIBURTON ENERGY SERVICES, INC. of 3000 N. Sam Houston Parkway E., Houston, Texas 77032, United States of America**

[72] **1. FROSELL, THOMAS JULES**
2. COFFIN, MAXIME PM
3. LEONG, MAN YEE

[74] **Messrs. HENRY GOH & CO SDN BHD of AIP Law Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/644,975 Date: 19 March 2018 Country: United States of America

[86] **PCT/US2019/018577**

[87] **WO/2019/182706**

[51] **E21B 43/04, E21B 43/08**

[57] **A well screen system includes upstream and downstream screen assemblies arranged along an axis. The assemblies each have first and second transport tubes. A first packing tube is connected to the first transport tube by first adapter and has an uppermost nozzle axially spaced from the first adapter by a first effective packing tube length. A second packing tube is connected to the second transport tube by a second adapter and has an uppermost nozzle axially spaced from the second adapter by a second effective packing tube length different than the first effective packing tube length. The downstream screen assembly second transport tube is connected to the upstream screen assembly first transport tube to alternate the effective packing tube lengths of packing tube uppermost nozzles along the screen system. Methods of making well screen systems and methods of gravel packing well screen systems are also disclosed.**



FIG. 2

---

[21] BN/N/2020/0061 **[22]** 03/08/2020

[54] Composition of Multivalent Nitrate Salts and Their Applications as Drilling and Completion Fluids in Oil and Gas, Geothermal, And Coal Based Methane

[71] HENDRA BUDIMAN of Discovery Lumina DL F-21, Rt 001 Rw 020, Kel. Parigi, Kec. Pondok Aren, Tangerang Selatan, Banten, Indonesia

[72] 1. HENDRA BUDIMAN

[74] Messrs. DREW & NAPIER LLC of AIP Law Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. P00201910651 Date: 19 November 2019 Country: Indonesia

[57] This invention is related to the composition of multivalent nitrate salts blend with an SG (Specific Gravity) of 1.70, which is higher than those of each nitrate salt component. Furthermore, the multivalent nitrate salts is modified, in order to minimize the corrosion rate and to optimize performance at High Temperature High Pressure (HTHP) well condition.
The multivalent nitrate salts blend, according to this invention can be used an product alternative to KCl, NaCI, CaCL2, KBr, NaBr, CaBr2, Na-Formate, or K-Formate, that are commonly used as a drill-in fluids, killing fluids, completion fluids, workover fluids, packer fluids in the oil, and gas, geothermal, and coal based methane industries.

---

[21] BN/N/2020/0062 **[22]** 03/08/2020

[54] Process for The Preparation of a Nitric Oxide Donating Prostaglandin Analogue

[71] NICOX S.A. of Drakkar 2 - Bat D, 2405 Route des Dolines, 06560 CS10313 - SOPHIA ANTIPOLIS – VALBONNE, France

[72] 1. ALMIRANTE, NICOLETTA

[74] Messrs. MARKS & CLERK SINGAPORE LLP of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]

No. 18157888.1 Date: 21 February 2018 Country: European Patent Office

[86] **PCT/EP2019/053455**

[87] **WO/2019/162149**

[51] **C07C 405/00, C07C 291/02, C07C 201/02**

[57] **The present invention relates to a process for preparing the hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester of formula (I). In accordance with the present invention, the compound (I) can be efficiently prepared with high purity by coupling bimatoprost in a boronate protected form with 6-(nitrooxy)hexanoyl chloride and removing the boronate protecting group. The 6-(nitrooxy)hexanoyl chloride intermediate is prepared by ring-opening reaction of 2-caprolactone and subsequent nitration of the 6-hydroxyhexanoic acid potassium salt with a mixture of HNO3 and H2SO4 in dichloromethane.**



(I)

---

[21] **BN/N/2020/0063** **[22]** **03/08/2020**

[54] **Method of Producing Natural Killer Cells and Composition for Treating Cancer**

[71] **NKMAX CO., LTD. of Healthcare Innovation Park, 6F 172 Dalmo-ro, Bundang-gu Seongnam-si Gyeonggi-do 13605, Republic of Korea**

[72] **1. PARK, SANG WOO**
2. KIM, YONG MAN
3. JUNG, JAE SEOB
4. RHEE, YONG-HEE

[74] **Messrs. MARKS & CLERK SINGAPORE LLP of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 10-2018-0012938 Date: 01 February 2018 Country: Republic of Korea
No. 10-2018-0012942 Date: 01 February 2018 Country: Republic of Korea
No. 10-2019-0001981 Date: 07 January 2019 Country: Republic of Korea
No. 10-2019-0001983 Date: 07 January 2019 Country: Republic of Korea

[86] **PCT/US2019/016076**

[87] **WO/2019/152663**

[51] **A61K 35/17, A61P 31/04, A61P 31/10, A61P 31/12, A61P 33/00, A61P 43/00**

[57] **A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3-/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3-/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.**



FIG. 1B

---

[21] **BN/N/2020/0064** **[22]** **12/08/2020**

[54] **Arginase Inhibitors and Methods of Use Thereof**

[71] **ASTRAZENECA AB of 151 85 Södertälje, Sweden**

[72] **1. MLYNARSKI, SCOTT NATHAN**
2. GREBE, TYLER
3. KAWATKAR, SAMEER
4. FINLAY, MAURICE RAYMOND VERSCHOYLE
5. SIMPSON, IAIN
6. WANG, JIANYAN
7. COOK, STEVE
8. WU, DEDONG

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/631,659 Date: 17 February 2018 Country: United States of America
No. 62/671,576 Date: 15 May 2018 Country: United States of America
No. 62/721,113 Date: 22 August 2018 Country: United States of America
No. 62/778,002 Date: 11 December 2018 Country: United States of America

[86] **PCT/IB2019/051236**

[87] **WO/2019/159120**

[51] **A61P 29/00, C07F 5/02, A61K 31/69, A61P 35/00**

[57] **Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase, wherein R1 is -NHR1a; R1a is -H or -C(O)CH(R1b)NHR1c; and R1b is selected from -H, -(C1-C4) alkyl and CH2OR1d and R1cis -H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or -CH3.**



(Ia)

---

[21] **BN/N/2020/0065** **[22]** **19/08/2020**

[54] **Granular Composition, Method for Producing Granular Composition, And Method for Improving Elution Property of Granular Composition**

[71] **NIPPON SHINYAKU CO., LTD. of 14, Kisshoin Nishinosho Monguchicho, Minami-Ku, Kyoto-Shi, Kyoto 6018550, Japan**

[72] **1. TANAKA TOSHINORI**
2. YAMADA RIE

[74] **Messrs. MARKS & CLERK SINGAPORE LLP of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 2018-029093 Date: 21 February 2018 Country: Japan

[86] **PCT/JP2019/006317**

[87] **WO/2019/163822**

[51] **A61K 31/4965, A61K 9/14, A61K 9/16, A61K 9/20, A61K 9/48, A61K 47/26, A61K 47/36, A61P 7/00, A61P 7/02, A61P 9/08, A61P 11/08, A61P 43/00**

[57] **Provided is a method for producing a granular composition which is improved in the elution of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyl- oxy}-N-(methylsulfonyl)acetamide. The method for producing the granular composition includes a compression molding step of compression-molding a mixture prepared**

by mixing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyl- oxy}-N-(methylsulfonyl)acetamide with at least one excipient selected from the group consisting of a sugar alcohol, a starch and a sugar to produce a compression-molded product.



---

[21] **BN/N/2020/0066** **[22]** **24/08/2020**

[54] **Working Medium Characteristic Difference Power Generation System and Working Medium Characteristic Difference Power Generation Method in Which Said Power Generation System Is Used**

[71] **TAKAITSU KOBAYASHI of 3-16-33, Nekozane, Urayasu-shi,Chiba 2790004, Japan**

[72] **1. KOBAYASHI TAKAITSU**

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 2018-036840 Date: 01 March 2018 Country: Japan

[86] **PCT/JP2019/004410**

[87] **WO/2019/167588**

[51] **F01K 25/10, H02K 7/18, H02K 35/02**

[57] **Provided are a power generation system and a power generation method in which natural heat energy can be used as a heat source, and in which power can be generated while loss of heat energy is greatly minimized. A first heat exchanger 1A, a first heat engine 2A, and a first power generator 3A are provided on a first working medium line L1 through which a first working medium W1 is channeled; a second heat exchanger 1B, a third working medium supply means 5 that supplies a third working medium W3, a mixing means 6 that mixes a second working medium W2 and the third working medium W3, a second heat engine 2B, and a second power generator 3B are provided on a second working medium line L2 through which the second working medium W2 is channeled; a third heat exchanger 1C is provided to both a side of the first working medium line L1 downstream of the first heat engine 2A and a side of the second working medium line L2 downstream of the second heat engine 2B; and a third working medium discharge means 10 for discharging the third working medium W3 is provided to**

the third heat exchanger 1C.



---

[21] BN/N/2020/0067 **[22]** 27/08/2020

[54] Treatment and Prevention of Pre-Eclampsia

[71] PHARMING INTELLECTUAL PROPERTY B.V. of Darwinweg 24, 2333 Cr Leiden, Netherlands

[72] 1. DE VRIES, SIJMEN
2. GIANNETTI, BRUNO

[74] Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 18159064.7 Date: 28 February 2018 Country: European Patent Office

[86] PCT/EP2019/055001

[87] WO/2019/166556

[51] A61K 38/57, A61P 9/10

[57] The present invention relates to the field of medicine, specifically to the prevention and treatment of pre-eclampsia

---

[21] BN/N/2020/0068 **[22]** 31/08/2020

[54] Microencapsulated Products, Clear Solutions Thereof, And Methods of Making

[71] 463IP PARTNERS, LLC of 3133 Orchard Vista Drive, SE Grand Rapids, Michigan 49546-7071, United States of America

[72] 1. GROCHOSKI, GREGORY THOMAS

[74] Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/637,258 Date: 01 March 2018 Country: United States of America

[86] **PCT/US2019/020107**

[87] **WO/2019/169167**

[51] **A23L 2/52**

[57] **Provided herein are methods for producing formulations for incorporation into clear beverages. A variety of solutes may be microencapsulated to provide a formulation that results in a clear solution upon addition to water. Microencapsulation may be achieved by, for example, spray drying. Also provided herein are microencapsulated products and solutions of microencapsulated products in water.**

---

[21] **BN/N/2020/0069** **[22]** **31/08/2020**

[54] **Improved Elevated Structure-Mounted Lighting System**

[71] **C&M OILFIELD RENTALS, LLC of 519 Circle Drive Cody, Wyoming 82414, United States of America**

[72] **1. ALLISON, JOSHUA C.**
2. HAALAND, JOSH
3. IVANOFF, JESSICA

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 16/009,032 Date: 14 June 2018 Country: United States of America
No. 62/643,663 Date: 15 March 2018 Country: United States of America

[86] **PCT/US2018/042795**

[87] **WO/2019/177653**

[51] **F21S 8/08, F21S 9/04, F21V 21/116, F21V 21/00, F21V 21/22, F21V 21/30**

[57] **An improved elevated structure-mounted lighting system is disclosed. The lighting system may be used on drilling rigs, or with other applications, including for drilling, production, refineries, frac sites, construction, and other industrial applications that may use tower/mast type equipment. The improved elevated structure-mounted lighting system may accommodate any style or design of crown section of a drilling rig and may be mounted on a pole or independent mount system.**



FIG. 3

---

[21] **BN/N/2020/0070** **[22]** **02/09/2020**

[54] **Pd-1 Agonist Antibodies and Uses Thereof**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285, United States of America**

[72] **1. CHAI, QING**
2. FENG, YIQING
3. NEWBURN, KRISTIN PAIGE
4. TRUHLAR, STEPHANIE MARIE
5. VERDINO, PETRA
6. YACHI, PIA PAULIINA

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No.62/637,643 Date: 02 March 2018 Country: United States of America

[86] **PCT/US2019/019076**

[87] **WO/2019/168745**

[51] **C07K 16/28, A61P 37/06, A61K 39/00**

[57] **The present invention relates to anti-human PD-1 agonist antibodies, and uses thereof for treating autoimmune disorders such as rheumatoid arthritis or for decreasing rejection of transplanted cells and/or tissues.**

---

[21] **BN/N/2020/0071** **[22]** **02/09/2020**

[54] **Cd73 Inhibitors**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285, United States of America**

[72] **1. DALLY, ROBERT DEAN**
2. GARCIA PAREDES, MARIA CRISTINA
3. HEINZ, LAWRENCE JOSEPH II
4. HOWELL, JENNIFER MARIE
5. NJOROGE, FRANK GEORGE
6. WANG, YAN
7. ZHAO, GENSHI

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/636,978 Date: 01 March 2018 Country: United States of America
No. 62/775,553 Date: 05 December 2018 Country: United States of America

[86] **PCT/US2019/019074**

[87] **WO/2019/168744**

[51] **C07D 403/04, A61P 35/00, A61K 31/513**

[57] **The present invention provides 5-[5]-[2-cycloa Ikyl]-6-pyridazin-3-yl]- IH-pyrimidine-2,4-dione compounds, or pharmaceutically acceptable salts thereof, that inhibit the activity of CD73 and are useful in treating cancer. (Formula (I))**

---

[21] **BN/N/2020/0072** **[22]** **02/09/2020**

[54] **Therapeutic Uses Of Glp1r Agonists**

[71] **VTV THERAPEUTICS LLC of 4170 Mendenhall Oaks Pkwy High Point, North Carolina 27265, United States of America**

[72] **1. FREEMAN, JENNIFER L.R.**
2. VALCARCE LOPEZ, MARIA CARMEN

[74] **Messrs. DREW & NAPIER LLC of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/668,384 Date: 08 May 2018 Country: United States of America

[86] **PCT/US2019/030110**

[87] **WO/2019/217165**

[51] **A61K 31/4741, A61K 31/538, A61K 45/06, A61K 31/155, A61P 3/04, A61P 9/12, A61P 3/10**

[57] **Methods of using glucagon-like peptide 1 receptor (GLP1R) agonists are generally disclosed herein. In certain aspects, the disclosure provides methods of treating type 2 diabetes that include administering a GLP1R agonist according to certain dosage regimens. In certain other aspects, the disclosure provides methods of treating obesity that include administering a GLP1R agonist according to certain dosage regimens. In certain other aspects, the disclosure provides methods of lowering glycated hemoglobin (for example, lowering HbA1c) that include administering a GLP1R agonist according to certain dosage regimens. Compositions containing GLP1R agonists and their manufacture, for example, for use as a medicament are also disclosed herein.**



FIGURE 1

---

[21] **BN/N/2020/0073** **[22]** **07/09/2020**

[54] **Amino Acid Compounds and Methods Of Use**

[71] **PLIANT THERAPEUTICS, INC. of 260 Littlefield Avenue, South San Francisco, California 94080, United States of America**

[72]
1. CHA, JACOB
2. DONG, CHENGGUO
3. HOM, TIMOTHY
4. JIANG, LAN
5. LEFTHERIS, KATERINA
6. LI, HUI
7. MORGANS JR., DAVID J.
8. MUNOZ, MANUEL
9. REILLY, MAUREEN
10. ZHENG, YAJUN

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/639,988 Date: 07 March 2018 Country: United States of America
No. 62/690,933 Date: 27 June 2018 Country: United States of America

[86] PCT/US2019/021243

[87] WO/2019/173653

[51] A61K 31/4375, C07D 401/12

[57] The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).



---

[21] BN/N/2020/0074 **[22]** 07/09/2020

[54] In-Situ Process to Produce Synthesis Gas from Underground Hydrocarbon Reservoirs

[71] PROTON TECHNOLOGIES CANADA INC. of 1310, 700 - 9th Avenue SW, South Tower, Calgary, Alberta T2P 3V4, Canada

[72] 1. STREM, GRANT D.
2. GATES, IAN D.
3. WANG, JINGYI

[74] Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/639,184 Date: 06 March 2018 Country: United States of America

[86] PCT/CA2019/050271

[87] WO/2019/169492

[51] E21B 43/295, E21B 43/24

[57] A petroleum reservoir is treated with heat to induce gasification, water-gas shift, and/or aquathermolysis reactions to generate synthesis gas comprising hydrogen gas. The synthesis gas is produced to the surface using one or more production wells.



FIG. 1A

---

[21] **BN/N/2020/0075** **[22]** **19/09/2020**

[54] **System and Method for Compressed Air Energy Storage**

[71] **CLEANTECH GEOMECHANICS INC. of 1011 9th Avenue South East, Suite 208 Calgary, Alberta T2G 0H7, Canada**

[72] **1. BILAK, ROMAN A.**
2. DUSSEAULT, MAURICE B.

[74] **Messrs. ZAID IBRAHIM & CO. of Units 6 & 8, 1st Floor, Block C, Shakirin Complex, Kiulap, Bandar Seri Begawan, BE1518 Brunei Darussalam**

[31][32][33]
No. 62/644,696 Date: 19 March 2018 Country: United States of America

[86] **PCT/CA2019/050331**

[87] **WO/2019/178679**

[51] **B65G 5/00, E21F 17/16**

[57] **Storage vessel, system and method for storing compressed gas are provided. A storage vessel for storing compressed gas comprises a wellbore provided in the subsurface; a casing placed within the wellbore and cemented to the formation, the casing defining a volumetric space within the wellbore for storing the compressed gas; and at least one flow regulator sealed at a top end of the casing for selectively injecting the compressed gas into the space or discharging the compressed gas from the space, wherein the wellbore has a volumetric capacity of at least 20m3, and wherein the compressed gas has a pressure of at least 5 MPa.**



---

[21] BN/N/2020/0076 **[22]** 30/09/2020

[54] Methods of Treating Ulcerative Colitis

[71] ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285, United States of America

[72]
1. CANAVAN, JAMES BENEDICT
2. FRIEDRICH, STUART WILLIAM
3. KRUEGER, KATHRYN ANN
4. MILCH, CATHERINE
5. TUTTLE, JAY LAWRENCE

[74] Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/650,314 Date: 30 March 2018 Country: United States of America

[86] PCT/US2019/024633

[87] WO/2019/191464

[51] A61K 39/395

[57] The present invention generally relates to the treatment of ulcerative colitis with an anti-IL-23pl9 antibody, in particular dosage regimens for the treatment of the disease.



Abbreviations: PI = projection interval; Bio Naive = biologic-naive, Bio Experienced = biologic-experienced

Note: Projection intervals are based on simulation of 500 replicated trials with an N = 500 each for biologic-naive and biologic-experienced patients. Vertical dashed lines represent the median expected Week 12 concentrations for fixed IV doses administered Q4W

Figure 5: Model-simulated change in modified Mayo score at Week 12 versus Week 12 concentration of mirikizumab

---

[21] **BN/N/2020/0078** **[22]** **06/10/2020**

[54] **Growth Differentiation Factor 15 Agonist Compounds and Methods of Using the Same**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285, United States of America**

[72] **1. GONCIARZ, MALGORZATA DONATA**
2. OBUNGU, VICTOR H.
3. PICKARD, RICHARD TODD

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/653,759 Date: 06 April 2018 Country: United States of America

[86] **PCT/US2019/024756**

[87] **WO/2019/195091**

[51] **C07K 14/495**

[57] **Compounds are provided herein that induce weight loss and that treat diabetes, dyslipidemia, NASH and/or obesity. Also provided are pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions, where such compounds act as GDF15 agonists with extended time of action and other advantageous properties.**

---

[21] BN/N/2020/0079 **[22]** 06/10/2020

[54] Growth Differentiation Factor 15 Fusion Proteins

[71] AMGEN INC. of One Amgen Center Drive Thousand Oaks, California 91320-1799, United States of America

[72] 1. XIONG, YUMEI
2. WALKER, KENNETH WILLIAM
3. VENIANT ELLISON, MURIELLE MARIE

[74] Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/655,108 Date: 09 April 2018 Country: United States of America

[86] PCT/US2019/026369

[87] WO/2019/199685

[51] A61K 38/00, C07K 14/475, A61K 38/18

[57] GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.

---

[21] BN/N/2020/0080 **[22]** 10/10/2020

[54] Chimeric Receptors to Dll3 And Methods of Use Thereof

[71] AMGEN INC. of One Amgen Center Drive Thousand Oaks, California 91320-1799, United States of America
KITE PHARMA, INC. of 2400 Broadway Santa Monica, California 90404, United States of America

[72] 1. GIFFIN, MICHAEL JOHN
2. THOMAS, MELISSA
3. MURAWSKY, CHRISTOPHER
4. CASE, RYAN BENJAMIN
5. WU, LAWREN
6. WILTZIUS, JED
7. RODRIGUEZ, RUBEN ALVAREZ
8. FENG, JUN

[74] Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/655,725 Date: 10 April 2018 Country: United States of America

[86] **PCT/US2019/026840**

[87] **WO/2019/200007**

[51] **A61P 35/00, C07K 16/28, C07K 16/30**

[57] **Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.**

FIG. 6



---

[21] **BN/N/2020/0081** **[22]** **10/10/2020**

[54] **Pyrazo-Tetrahydroisoquinoline Derivatives as Dopamine D1 Receptor Positive Modulators**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285, United States of America**

[72] **1. COATES, DAVID ANDREW**
2. HAO, JUNLIANG
3. HILLIARD, DARRYL WAYNE

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/660,622 Date: 20 April 2018 Country: United States of America

[86] PCT/US2019/027842

[87] WO/2019/204418

[51] C07D 405/14, C07D 401/04, A61P 25/16, A61P 25/28

[57] **The invention provides certain (phenyl)-(pyrazol)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one compounds of formula I as D1 positive allosteric modulators (PAMs), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I, or a pharmaceutically acceptable salt thereof, to treat certain symptoms of Parkinson's disease, schizophrenia, ADHD or Alzheimer's disease.**



(I)

---

[21] BN/N/2020/0083 **[22]** 10/10/2020

[54] Compounds and Their Uses for Alleviating Menopause-Associated Symptoms

[71] ESTETRA SPRL of Rue Saint-Georges, 5 400 Liège, Belgium

[72] 1. TAZIAUX, MELANIE
2. RAUSIN, GLWADYS
3. JOST, MAUD
4. MAWET, MARIE

[74] Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 18168234.5 Date: 19 April 2018 Country: European Patent Office
No. 18174985.4 Date: 30 May 2018 Country: European Patent Office
No. 19150421.6 Date: 04 January 2019 Country: European Patent Office

[86] PCT/EP2019/060221

[87] WO/2019/202142

[51] A61K 31/565, A61K 31/55, A61K 31/57, A61K 31/585, A61P 5/30

[57] **The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units,for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at a specific daily dose, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.**

---

[21] **BN/N/2020/0084** **[22]** **19/10/2020**

[54] **Compounds and Their Uses for Alleviating Menopause-Associated Symptoms**

[71] **ESTETRA SPRL of Rue Saint-Georges, 5 400 Liège, Belgium**

[72] **1. TAZIAUX, MELANIE**
2. RAUSIN, GLWADYS
3. JOST, MAUD
4. MAWET, MARIE

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 18168336.8 Date: 19 April 2018 Country: European Patent Office
No. 18174982.1 Date: 30 May 2018 Country: European Patent Office
No. 19150423.2 Date: 04 January 2019 Country: European Patent Office

[86] **PCT/EP2019/060220**

[87] **WO/2019/202141**

[51] **A61K 31/565, A61K 31/55, A61K 31/57, A61K 31/585, A61P 5/30**

[57] **The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at a specific daily dose, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.**

---

[21] **BN/N/2020/0085** **[22]** **24/10/2020**

[54] **Control Device for Massager and Method Therefor**

[71] **CERAGEM CO., LTD. of 10, Jeongja 1-gil, Seonggeo-eup, Seobuk-gu, Cheonan-si,, Chungcheongnam-do 31045, Republic of Korea**

[72] **1. HAN, SANG CHEOL**
2. LEE, DONG MYOUNG
3. KIM, KI SUNG
4. KIM, SANG HEE

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 10-2018-0048419 Date: 26 April 2018 Country: Republic of Korea

[86] **PCT/KR2019/003415**

[87] **WO/2019/208935**

[51] **A61H 15/02, A61H 1/00, A61H 15/00, A61H 7/00**

[57] **A control device for a massager and a method therefor are provided. A control device for a massager according to an embodiment of the present invention comprises: a setting unit for setting a massage mode; and a control unit for controlling the moving speed of an operation module for performing massage, so as to adjust at least one of the massage intensity and the operation time of a corresponding massage pattern according to a user's body shape and the massage mode set by the setting unit.**



---

[21] **BN/N/2020/0086** **[22]** **24/10/2020**

[54] **Molecular Adjuvant**

[71] **ADC THERAPEUTICS SA of Biopôle Route de la Corniche 3B 1066 Epalinges, Switzerland**

[72] **1. VAN BERKEL, PATRICK HENDRIKUS CORNELIS**
2. FEINGOLD, JAY MARSHALL
3. WUERTHNER, JENS
4. ADAMS, JAMES

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei**

Darussalam

[31][32][33]
No. 1808507.6 Date: 23 May 2018 Country: United Kingdom
No. 1813067.4 Date: 10 August 2018 Country: United Kingdom
No. 1818152.9 Date: 07 November 2018 Country: United Kingdom

[86] **PCT/EP2019/063262**

[87] **WO/2019/224275**

[51] **A61K 47/68, A61P 35/00, C07K 16/28**

[57] **The present disclosure relates to therapies for the treatment of a disorders characterized by a disorder-associated antigen (DAA); vaccination methods are disclosed. In particular, the disclosure describes anti-CD25 ADC molecular adjuvants for use in inducing or enhancing a subject's immune response against a DAA, allowing for treatment of the disorder characterized by the DAA. Also disclosed are dosage regiments for the treatment of solid tumours with an AThe present disclosure relates to the treatment of pathological conditions, such as cancer, with anti-CD25 ADCs.**

---

[21] **BN/N/2020/0087** **[22]** **24/10/2020**

[54] **Tubular Threaded Connection**

[71] **VALLOUREC OIL & GAS FRANCE of 54 rue Anatole France, 59620 Aulnoye-Aymeries, France**
NIPPON STEEL CORPORATION of 6-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo, 100-8071, Japan

[72] **1. DELPRAT, OLIVIER**
2. CASALONGA, AXEL
3. ZAPALOWICZ, FRANCIS
4. DOSSMANN, GÉRARD
5. MARTIN-CHARBONNEAU, VIRGINIE
6. LE ROY, GWENNHAËL
7. THON, JULIEN
8. LECOEUR, JEAN-BAPTISTE

[74] **Messrs. HENRY GOH & CO. SDN. BHD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 18305640.7 Date: 25 May 2018 Country: European Patent Office

[86] **PCT/EP2019/063437**

[87] **WO/2019/224345**

[51] **E21B 17/042, F16L 15/00**

[57] **Threaded tubular connection (10) comprising a tubular female end (20) extending from a main body (21) of a first tubular member (22), and a tubular male end (30) extending from a main body (31) of a second tubular member (32), such that the tubular male end (30) comprises a first machined inner surface (68) close to the male free end (35) and a second machined inner cylindrical surface (70) above a threaded portion of the male end such that a second inner diameter (JIP2) of the second machined inner cylindrical surface (70) is smaller than a first inner diameter (JIP) of the first machined inner surface (68).**



Fig. 4

---

[21] **BN/N/2020/0088** **[22]** **24/10/2020**

[54] **Threaded Tubular Connection for Casing**

[71] **VALLOUREC OIL & GAS FRANCE of 54 Rue Anatole France, 59620-Aymeries, France**
NIPPON STEEL CORPORATION of 6-1, Marunouchi 2-Chome, Chiyoda-Ku, Tokyo, 100-8071, Japan

[72] **1. FOULOGNE, ANTHONY**
2. MARTIN, PIERRE

[74] **Messrs. HENRY GOH & CO. SDN. BHD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 18305641.5 Date: 25 May 2018 Country: European Patent Office

[86] **PCT/EP2019/063434**

[87] **WO/2019/224343**

[51] **E21B 17/042, F16L 15/00**

[57] **Threaded tubular connection (10) comprising a box member (20) comprising a female external thread (26), a female internal thread (29) and a female intermediate sealing surface (27) between the female external thread and the**

female internal thread, and pin member (30) comprising corresponding male external thread (36), male internal thread (39) and a male intermediate sealing surface (37), such that male threads interlock by thread engagement with female threads, and intermediate sealing surfaces (27, 37) are forming an intermediate metal-to-metal seal when the threaded tubular connection is made up, wherein the box member (20) comprises a minimal outer diameter (JOBmin) at the intermediate metal-to-metal seal location, the minimal outer diameter (JOBmin) being smaller than respectively an external and an internal outer diameter (JOBe; JOBi) respectively being located above the female external thread and the female internal thread.



Fig. 1

---

[21] BN/N/2020/0089 **[22]** 24/10/2020

[54] Tubular Threaded Connection

[71] VALLOUREC OIL & GAS FRANCE of 54 Rue Anatole France, 59620-Aymeries, France
NIPPON STEEL CORPORATION of 6-1, Marunouchi 2-Chome, Chiyoda-Ku, Tokyo, 100-8071, Japan

[72] 1. BRIANE, BENOÎT
2. FOTHERGILL, ALAN
3. FOULOGNE, ANTHONY
4. MARTIN, PIERRE

[74] Messrs. HENRY GOH & CO. SDN. BHD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 18305639.9 Date: 25 May 2018 Country: European Patent Office

[86] PCT/EP2019/063436

[87] WO/2019/224344

[51] E21B 17/042, F16L 15/00

[57] Threaded tubular connection (10) comprising a tubular female end (20) extending from a main body (21) of a first tubular member (22), and a tubular male end (30) extending from a main body (31) of a second tubular member (32), such that the tubular female end (20) comprises a machined outer cylindrical surface (58) close to the female free end (25) having a first outer diameter (JOB) and a second

machined outer cylindrical surface (60) above a threaded portion of the female end, a second outer diameter (JOB2) of the second outer cylindrical surface being bigger than the first outer diameter (JOB).



Fig. 1

---

[21] BN/N/2020/0090 **[22]** 31/10/2020

[54] Spiropiperidine Allosteric Modulators of Nicotinic Acetylcholine Receptors

[71] MERCK SHARP & DOHME CORP of 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States of America

[72]
1. CROWLEY, BRENDAN, M.
2. CAMPBELL, BRIAN, T.
3. CHOBANIAN, HARRY, R.
4. FELLS, JAMES, I.
5. GUIADEEN, DEODIAL, G.
6. GRESHOCK, THOMAS, J.
7. LEAVITT, KENNETH, J.
8. RADA, VANESSA, L.
9. BELL, IAN, M.

[74] Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/665,091 Date: 01 May 2018 Country: United States of America

[86] PCT/US2019/029561

[87] WO/2019/212927

[51] C07D 413/14, C07D 413/04, C07D 417/04, C07D 417/14, A61P 25/00, A61K 31/438, C07D 401/04, C07D 471/04, C07D 471/08, C07D 487/04, C07D 513/04, A61K 31/439, A61K 31/444, A61K 31/501, A61K 31/506

[57] The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I).



(I).

---

[21] BN/N/2020/0093 **[22]** 02/11/2020

[54] Rip1 Inhibitory Compounds and Methods for Making and Using the Same

[71] RIGEL PHARMACEUTICALS, INC. of 1180 Veterans Boulevard South San Fransisco, California 94080, United States of America

[72]
1. DARWISH, IHAB
2. YU, JIAXIN
3. CHEN, YAN
4. MASUDA, ESTEBAN
5. TAYLOR, VANESSA

[74] Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/666,452 Date: 03 May 2018 Country: United States of America

[86] PCT/US2019/030473

[87] WO/2019/213445

[51] C07D 413/14, C07D 413/12, A61P 37/02, A61P 29/00, A61K 31/553

[57] Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to inhibit a RIP1 kinase in vivo or ex vivo, and also may treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

---

[21] BN/N/2020/0094 **[22]** 02/11/2020

[54] **Rip1 Inhibitory Compounds and Methods for Making and Using the Same**

[71] **RIGEL PHARMACEUTICALS, INC. of 1180 Veterans Boulevard South San Fransisco, California 94080, United States of America**

[72] **1. MASUDA, ESTEBAN**
2. SHAW, SIMON
3. TAYLOR, VANESSA
4. BHAMIDIPATI, SOMASEKHAR

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/666,462 Date: 03 May 2018 Country: United States of America

[86] **PCT/US2019/030476**

[87] **WO/2019/213447**

[51] **C07D 413/14, C07D 413/12, A61P 37/02, A61P 29/00, A61K 31/553**

[57] **Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.**

---

[21] **BN/N/2020/0095** **[22]** **07/11/2020**

[54] **Azabenzimidazole Compounds And Pharmaceutical**

[71] **NIPPON SHINYAKU CO., LTD. of 14, Kisshoin Nishinosho Monguchicho, Minami-ku, Kyoto-shi Kyoto 6018550, Japan**

[72] **1. OIKAWA KOUYA**
2. HIRAI SHO
3. WAKITA KAZUHIKO
4. FUJIBAYASHI AKIKO

[74] **Messrs. AIP LAW of Unit 9 & 10, 2nd floor,Block C, Kiarong Complex, Lebuhraya Sultan Hassanal Bolkiah BE 1318 Brunei Darussalam**

[31][32][33]
No. 2018-086867 Date: 08 May 2018 Country: Japan

[86] **PCT/JP2019/018201**

[87] **WO/2019/216294**

[51] **C07D 471/04, A61K 31/437, A61K 31/444, A61K 31/4545, A61K 31/46, A61K 31/496, A61K 31/497, A61K 31/551, A61P 3/10, A61P 13/02, A61P 13/10, A61P 27/06, A61P 43/00, C07D 519/00**

[57] **The purpose of the present invention is to provide compounds having an M3 PAM action. Examples of the present invention include azabenzimidazole compounds represented, for example, by formula [I], and pharmacologically acceptable salts thereof. These compounds have M3 PAM activity. In addition, because these compounds have M3 PAM activity, these compounds are useful as agents for the prevention or treatment of dysuria and/or urine storage disorder in underactive bladder, hypotonic bladder, acontractile bladder, detrusor hypoactivity, and neurogenic bladder.**



[1]

---

[21] **BN/N/2020/0096** **[22]** **07/11/2020**

[54] **Tetracyclic Heteroaryl Compounds**

[71] **ASTRAZENECA AB of 151 85 Sodertalje, Sweden**

[72] **1. KETTLE, JASON, GRANT**
2. BAGAL, SHARANJEET, KAUR
3. EATHERTON, ANDREW, JOHN
4. FILLERY, SHAUN, MICHAEL
5. ROBB, GRAEME, RICHARD
6. LAMONT, SCOTT, GIBSON
7. KEMMITT, PAUL, DAVID
8. GOLDBERG, FREDERICK, WOOLF

[74] **Messrs. AIP LAW of Unit 9 & 10, 2nd floor,Block C, Kiarong Complex, Lebuhraya Sultan Hassanal Bolkiah BE 1318 Brunei Darussalam**

[31][32][33]
No. 62/668,321 Date: 08 May 2018 Country: United States of America
No. 62/754,814 Date: 02 November 2018 Country: United States of America

[86] **PCT/EP2019/061754**

[87] **WO/2019/215203**

[51] **C07D 498/14, A61K 31/55, A61P 35/00**

[57] **The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.**



---

[21] BN/N/2020/0097 **[22]** 07/11/2020

[54] 1, 3, 4, 5-Tetrahydro-2h-Pyrido[4,3-B]Indole Derivatives For The Treatment, Alleviation Or Prevention Of Disorders Associated With Tau Aggregates Like Alzheimer's Disease

[71] AC IMMUNE SA of EPFL Innovation Park, Building B1015, Lausanne, Switzerland

[72] 1. NAMPALLY, SREENIVASACHARY
2. GABELLIERI, EMANUELE
3. MOLETTE, JÉRÔME

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 18150422.6 Date: 05 January 2018 Country: Euporean Patent Office
No. 18175852.5 Date: 04 June 2018 Country: Euporean Patent Office

[86] PCT/EP2019/050180

[87] WO/2019/134978

[51] C07D 471/04, A61K 31/437, A61P 25/28

[57] The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

---

[21] BN/N/2020/0098 **[22]** 07/11/2020

[54] Pinning Tool For Pinning A Tubular Structure

[71] SMART INSTALLATIONS AS of Postboks 8, 4098 Tananger, Norway

[72] 1. BIRKELAND, Petter

[74] **Messrs. HENRY GOH & CO SDN BHD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 201880560 Date: 23 April 2018 Country: Norway

[86] **PCT/US2018/028213**

[87] **WO/2018/200289**

[51] **B25B 27/02, B30B 12/00, E21B 19/16**

[57] **It is described a pinning tool (1) for pinning a tubular structure (8) by pressing a pin (4) through a sidewall (80) of the tubular structure (8). The pinning tool (1) comprises: - a tool body (2) configured for receiving the tubular structure (8); - an actuator (5) mounted on the tool body (2), the actuator (5) being provided with a piston rod (52), wherein the actuator (5) is configured for displacing the piston rod (52) in a translational movement; - a pin adaptor (7) releasably coupled to the piston rod (52) of the actuator (5) and being configured for receiving and releasably holding the pin (4) to be pressed through and remain in the sidewall (80) of the tubular structure (8), and - a reaction member (3) for fixing a relative position between the tool body (2) and the tubular structure (8) during pinning, wherein the translational movement of the piston rod (52) causes displacement of the pin adaptor (7), thereby pressing, in operational use, the pin (4) through the sidewall (80) of the tubular structure (8).**



Fig. 1

---

[21] **BN/N/2020/0099** **[22]** **11/11/2020**

[54] **Tetrahydro-Imidazo[4,5-C]Pyridine Derivatives As Pd-L1 Immunomodulators**

[71] **INCYTE CORPORATION of 1801 Augustine Cut-Off Wilmington Delaware 19803 United States of America**

[72] **1. WU, LIANGXING**
2. XIAO, KAIJIONG
3. YAO, WENQING

[74] **Messrs. HENRY GOH & CO SDN BHD c/o AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/670,249 Date: 11 May 2018 Country: United States of America
No. 62/688,164 Date: 21 June 2018 Country: United States of America

[86] **PCT/US2019/031728**

[87] **WO/2019/217821**

[51] **C07D 471/04, A61P 35/00, A61P 37/00, A61P 31/437**

[57] **Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.**



---

[21] **BN/N/2020/0100** **[22]** **14/11/2020**

[54] **Synthetic Modeling With Noise Simulation**

[71] **SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.of Carel van Bylandtlaan 30 NL-2596 The Hague, Netherlands**

[72] **1. GRIFFITH, DONALD PAUL**
2. ZAMANIAN, SAM AHMAD
3. POTTER, RUSSELL DAVID
4. VIAL-AUSSAVY, ANTOINE VICTOR APPLOLINAIRE

[74] **Messrs. DREW & NAPIER LLC c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/679,206 Date: 01 June 2018 Country: United States of America

[86] **PCT/US2019/027708**

[87] **WO/2019/231573**

[51] **G01V 1/28, G01V 1/30, G06N 3/02, G06N 3/08, G01V 99/00**

[57] **A method for producing a synthetic model for training a backpropagation-enabled process for identifying subsurface features, includes generating noise-free synthetic subsurface models with realizations of subsurface features. The noise-free synthetic subsurface models are generated by introducing a model variation selected from geologically realistic features simulating the outcome of a geologic process, simulations of geologic processes, and combinations thereof. Labels are applied to one or more of the subsurface features in one or more of the synthetic subsurface models. A simulation of a noise source is applied to a copy of one or more of the noise-free synthetic subsurface models to produce a noise-augmented copy. The labels and the corresponding synthetic subsurface models are imported into the backpropagation-enabled process for training.**



FIG. 2

---

[21] **BN/N/2020/101** **[22]** **14/11/2020**

[54] **Synthetic Modeling**

[71] **SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.of Carel van Bylandtlaan 30 NL-2596 The Hague, Netherlands**

[72] **1. GRIFFITH, DONALD PAUL**
2. ZAMANIAN, SAM AHMAD
3. POTTER, RUSSELL DAVID
4. VIAL-AUSSAVY, ANTOINE VICTOR APPLOLINAIRE

[74] **Messrs. DREW & NAPIER LLC c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/679,183 Date: 01 June 2018 Country: United States of America

[86] **PCT/US2019/027703**

[87] **WO/2019/231572**

[51] **G01V 1/30, G01V 99/00, G06N 3/02**

[57] **A method for producing a synthetic model for training a backpropagation-enabled process for identifying subsurface features, includes generating synthetic subsurface models with realizations of subsurface features. The synthetic subsurface models are generated by introducing at least three distinct model variations selected from geologically realistic features simulating the outcome of a geologic process, simulations of geologic processes, simulations of noise sources, and combinations thereof. Labels are applied to one or more of the subsurface features in one or more of the synthetic subsurface models. The labels and the corresponding synthetic subsurface models are imported into the backpropagation-enabled process for training.**



FIG. 2

---

[21] **BN/N/2020/0102** **[22]** **14/11/2020**

[54] **Multiple Zone Integrated Intelligent Well Completion**

[71] **HALLIBURTON ENERGY SERVICES, INC. of 10200 Bellaire Boulevard Houston, Texas 77072 United States of America**

[72] **1. TIPS, TIMOTHY R.**
2. RICHARD, WILLIAM M.

[74] **Messrs. SPRUSON & FERGUSON PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/522,559 Date: 20 June 2017 Country: United States of America

[86] **PCT/US2012/051557**

[87] **WO/2014/057216**

[51] **E21B 43/08, E21B 43/10**

[57] **A system for use with a well having multiple zones can include multiple well screens which filter fluid flowing between a completion string and respective ones of the zones, at least one optical waveguide which senses at least one property of the fluid as it flows between the completion string and at least one of the zones, multiple flow**

control devices which variably restrict flow of the fluid through respective ones of the well screens, and multiple pressure sensors which sense pressure of the fluid which flows through respective ones of the well screens. A completion string for use in a subterranean well can include at least one well screen, at least one flow control device which selectively prevents and permits substantially unrestricted flow through the well screen, and at least one other flow control device which is remotely operable, and which variably restricts flow through the well screen.



FIG. 1

---

[21] BN/N/2020/0103 **[22]** 19/11/2020

[54] Modulators Of Apol1 Expression

[71] IONIS PHARMACEUTICALS, INC. of 2855 Gazelle Court, Carlsbad CA 92010, United States of America

[72] 1. FREIER, SUSAN M

[74] Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/674,865 Date: 22 May 2018 Country: United States of America

[86] PCT/US2019/033244

[87] WO/2019/226611

[51] A61K 48/00, C07H 21/02

[57] The present embodiments provide methods, compounds, and compositions useful for inhibiting APOL1 expression, which may be useful for treating, preventing, or ameliorating a disease associated with APOL1.

---

[21] BN/N/2020/0104 **[22]** 21/11/2020

[54] Selective Treg Stimulator Rur20kd-Il-2 And Related Compositions

[71] NEKTAR THERAPEUTICS of 455 Mission Bay Boulevard South, Suite 100, San Francisco, California 94158, United States of America

[72] 1. KIRK, PETER BENEDICT
2. LANGOWSKI, JOHN L
3. ZALEVSKY, JONATHAN

[74] Messrs. SPRUSON & FERGUSON PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/674,244 Date: 21 May 2018 Country: United States of America

[86] PCT/ US2019/033100

[87] WO/2019/226538

[51] A61K 47/60, A61P 37/00

[57] The instant disclosure provides selective Treg stimulator compositions, including RUR20kD-IL-2 and related compositions, and methods of using these compositions, for example, for treating autoimmune diseases, and/or other conditions responsive to therapy that is effective to provide a selective increase in numbers and activation of regulatory T cells over effector T cells.



FIGURE 17A



FIGURE 17B

---

[21] BN/N/2020/0105 **[22]** 25/11/2020

[54] Composition Comprising Antisense Oligonucleotide And Use Thereof For Treatment Of Duchenne Muscular Dystrophy

[71] NIPPON SHINYAKU CO., LTD. of K14, Kisshoin Nishinosho Monguchicho,

Minami-ku, Kyoto-shi, Kyoto 601-8550 Japan

[72] **1. UNO, TOMONORI**
2. NATSUKAWA, TAKASHI
3. EGAWA, YOUICHI
4. SATOU, YOUHEI

[74] **Messrs. HENRY GOH & CO SDN BHD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/690,270 Date: 26 June 2018 Country: United States of America
No. 62/739,386 Date: 01 October 2018 Country: United States of America

[86] **PCT/JP2019/026393**

[87] **WO/2020/004675**

[51] **A61K 31/7088, A61K 48/00, A61P 21/00, A61P 21/04, C12N 15/113, C12N 15/12**

[57] **The present invention relates to a composition containing an antisense oligonucleotide and a use thereof for the treatment of Duchenne muscular dystrophy. The present invention, specifically, relates to the composition effective for the treatment of Duchenne muscular dystrophy when administered at a treatment dose, and a use thereof.**



AA Increase of dystrophin protein from the baseline (% to normal)

---

[21] **BN/N/2020/0106** **[22]** **25/11/2020**

[54] **Application Container**

[71] **SATO PHARMACEUTICAL CO., LTD. Of 5-27, MOTOAKASAKA 1-CHOME, MINATO-KU, TOKYO 1070051, Japan**
VALLOUREC OIL AND GAS FRANCE of 54 rue Anatole France, Aulnoye-Aymeries 59620, France

[72] **1. SAKATA KOTA**

[74] **Messrs. CCW PARTNERSHIP of Unit 9 & 10, 2nd floor, Block C, Kiarong Complex, Lebuhraya Sultan Hassanal Bolkiah BE 1318 Brunei Darussalam**

[31][32][33]

No. 2018-105125 Date: 31 May 2018 Country: Japan
No. 2018-135943 Date: 19 July 2018 Country: Japan

[86] **PCT/JP2019/020799**

[87] **WO/2019/230619**

[51] **B65D 47/42, B65D 83/00**

[57] **The present invention is provided with a container body (2), an inner plug member (20), and an impregnation material (30). The inner plug member (20) is provided with: an impregnation-member-accommodating part (21); and a valve-body-accommodating part (22) having a valve seat (22a) on the impregnation-member-accommodating-part (21) side and a valve body support part (22b) on the container-body (2) side, there being a valve body (22c) movably installed between the valve seat (22a) and the valve body support part (22b). In a state in which the valve body (22c) is supported by the valve body support part (22b), a communication groove (50) that forms a gap is formed between the valve body (22c) and the valve-body-accommodating part (22).**



---

[21] **BN/N/2020/0107** **[22]** **01/12/2020**

[54] **Benzenesulfonamide Compounds And Their Use As Therapeutic Agents**

[71] **XENON PHARMACEUTICALS INC. of 200-3650 Gilmore Way Burnaby, british Columbia V5G 4W8, Canada**

[72]
1. FOCKEN, THILO
2. BURFORD, KRISTEN NICOLE
3. LOFSTRAND, VERNER ALEXANDER
4. WILSON, MICHAEL SCOTT
5. ZENOVA, ALLA YUREVNA

[74] **Messrs. SPRUSON & FERGUSON PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/684,436 Date: 13 June 2018 Country: United States of America

[86] **PCT/US2019/037011**

[87] **WO/2019/241533**

[51] **C07D 487/08, C07D 277/52, A61K 31/407, A61P 25/08**

[57] **This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels ($Na_v1.6$), such as epilepsy and/or epileptic seizure disorders.**

---

[21] **BN/N/2020/0108** **[22]** **03/12/2020**

[54] **Multiple Zone Integrated Intelligent Well Completion**

[71] **ONCOIMMUNE, INC. of 9430 Key West Avenue Suite 113 Rockville, Maryland 20850 United States of America**

[72] **1. LIU, YANG**
2. ZHENG, PAN
3. DEVENPORT, MARTIN

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/680,218 Date: 04 June 2018 Country: United States of America
No. 62/739,719 Date: 01 October 2018 Country: United States of America
No. 62/739,742 Date: 01 October 2018 Country: United States of America

[86] **PCT/US2019/035200**

[87] **WO/2019/236472**

[51] **A61P 37/06, C07K 07/00**

[57] **The present invention relates to the use of a CD24 protein for preventing or treating Graft versus Host Disease and mucositis.**

---

[21] **BN/N/2020/0110** **[22]** **05/12/2020**

[54] **Aquatic Farming In Intermodal Containers**

[71] **TEMASEK LIFE SCIENCES LABORATORY LIMITED of National University of Singapore, 1 Research Link, Singapore 117604, Singapore**

[72] **1. GOH, CHIN HENG**

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 10201804724U Date: 04 June 2018 Country: Singapore

[86] **PCT/SG2019/050286**

[87] **WO/2019/236006**

[51] **A01K 63/00**

[57] **The present invention generally relates to an aquatic farming system (200) comprising one or more stacked levels of an array of one or more aquatic farming modules (100). Each aquatic farming module (100) comprises an intermodal container (102) comprising a pair of opposing side walls (104) and a pair of opposing end entrances (106), and a housing structure (110) disposed in the intermodal container (102) and extending between the side walls (104) thereof. The aquatic farming module (100) further comprises a set of access doors (130) disposed at one or both end entrances (106) of the intermodal container (100), the access doors (130) actuatable planarly for selectively opening/closing the respective end entrances (106). Selective opening/closing of the end entrances (106) of the intermodal containers (102) in each stacked level facilitates user accessibility to the housing structures (110) in said stacked level for farming aquatic organisms.**



Figure 1

---

[21] **BN/N/2020/0112** **[22]** **15/12/2020**

[54] **Purinone Compounds And Their Use In Treating Cancer**

[71] **ASTRAZENECA AB of 151 85 Södertälje, Sweden**
CANCER RESEARCH TECHNOLOGY LIMITED of Angel Building, 407 St John Street, London EC I V 4AD, United Kingdom

[72] **1. FINLAY, MAURICE, RAYMOND, VERSCHOYLE**
2. GOLDBERG, FREDERICK, WOOLF
3. HOWARD, MARTIN, RICHARD
4. TING, ATTILLA, KUAN, TSUEI

[74] **Messrs. AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha**

Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/685,325 Date: 15 June 2018 Country: United States of America

[86] **PCT/EP2019/065686**

[87] **WO/2019/238929**

[51] **C07D 473/32, A61K 31/522, A61P 35/00**

[57] **The specification generally relates to compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, where R^1, A^1, A^2 and A^3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.**



(I)

---

[21] **BN/N/2020/0113** **[22]** **17/12/2020**

[54] **Pcsk9 Antagonist Compounds**

[71] **MERCK SHARP & DOHME CORP. of 10200 Bellaire Boulevard Houston, Texas 77072 United States of America**

[72]
1. WOOD, HAROLD, B.
2. JOSIEN, HUBERT, B.
3. TUCKER, THOMAS, JOSEPH
4. KEREKES, ANGELA, DAWN
5. TONG, LING
6. WALJI, ABBAS, M.
7. NAIR, ANILKUMAR, G.
8. DING, FA-XIANG
9. BIANCHI, ELISABETTA
10. BRANCA, DANILA
11. WU, CHENGWEI
12. XIONG, YUSHENG
13. HA, SOOKHEE, NICOLE
14. LIU, JIAN
15. BOGA, SOBHANA, BABU

[74] **Messrs. SPRUSON & FERGUSON PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/687,913 Date: 21 June 2018 Country: United States of America

[86] **PCT/US2019/038155**

[87] **WO/2019/246349**

[51] **C07K 7/06, A61K 38/00, C12N 7/64**

[57] **Disclosed are compounds of Formula I, or a salt thereof: where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.**



(I)

---

[21] **BN/N/2020/0114** **[22]** **21/12/2020**

[54] **GIP/GLP1 Agonist Compositions**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285 United States of America**

[72] **1. CORVARI, VINCENT JOHN**
2. MINIE, CHRISTOPHER SEARS
3. MISHRA, DINESH SHYANDEO
4. QIAN, KEN KANGYI

[74] **Messrs. SPRUSON & FERGUSON PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/688,632 Date: 22 June 2018 Country: United States of America

[86] **PCT/US2019/037146**

[87] **WO/2019/245893**

[51] **A61K 47/02, A61K 47/10, A61K 38/00, A61K 38/16, A61P 3/10**

[57] **A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.**

---

[21] **BN/N/2020/0115** **[22]** **23/12/2020**

[54] **Method Of Treating Or Ameliorating Metabolic Disorders Using Binding Proteins For Gastric Inhibitory Peptide Receptor (Gipr) In Combination With Glp-1 Agonists**

[71] **AMGEN INC. of 10200 Bellaire Boulevard Houston, Texas 77072 United States of America**

[72]
1. DONGHUI SHI
2. DONGHUI SHI
3. DAVID J. LLOYD
4. JINGHONG WANG
5. GLENN N. SIVITS, JR.
6. MURIELLE M. VENIANT-ELLISON
7. RENEE KOMOROWSKI
8. NEERAJ AGRAWAL
9. DARREN L. BATES
10. BRANDON C. P. CLAVETTE
11. IAN N. FOLTZ
12. SHU-YIN HO
13. CHRISTOPHER MURAWSKY
14. XIAOSHAN MIN
15. ZHULUN WANG

[74] **Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. BN/N/2018/006 Date: 12 February 2019 Country: Brunei Darussalam
No. 62/337,799 Date: 17 May 2016 Country: United States of America
No. 62/387,486 Date: 23 December 2015 Country: United States of America
No. 62/420,415 Date: 10 November 2016 Country: United States of America

---

[21] **BN/N/2020/0116** **[22]** **24/12/2020**

[54] **Ectonucleotidase Inhibitors And Methods Of Use Thereof**

[71] **CALITHERA BIOSCIENCES, INC. of 343 Oyster Point Boulevard, Suite 200, South San Francisco, Ca 94080, United States of America**

[72] **1. CHEN, LIJING**
2. BILLEDEAU, ROLAND, JOSEPH
3. LI, JIM

[74] **Messrs. DREW & NAPIER LLC c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/688,225 Date: 21 June 2018 Country: United States of America
No. 62/827,505 Date: 01 April 2019 Country: United States of America

[86] **PCT/US2019/038245**

[87] **WO/2019/246403**

[51] **C07F 9/02, A61K 31/517, A61K 31/675, A61K 31/7076, A61K 31/706, A61K 31/7064, C07F 9/6561, C07H 19/14, C07H 19/16, C07H 19/20, C07H 19/23**

[57] **The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.**

---

[21] **BN/N/2020/0117** **[22]** **24/12/2020**

[54] **Combination Therapy**

[71] **ADC THERAPEUTICS SA of Biopole route de la Corniche 1066 Epalinges, Switzerland**
MEDIMMUNE LIMITED Of Milstein Building Granta Park Cambridge Cambridgeshire CB21 6GH, United Kingdom

[72] **1. VAN BERKEL, PATRICIUS HENDRIKUS CORNELIS**
2. ZAMMARCHI, FRANCESCA
3. HARTLEY, JOHN

[74] **Messrs. SPRUSON & FERGUSON PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 1811364.7 Date: 11 July 2018 Country: United Kingdom

[86] **PCT/EP2019/068287**

[87] **WO/2020/011724**

[51] **A61K 31/5517, A61K 31/7068, A61K 47/68, A61P 35/00**

[57] **The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an anti-CD25 ADC and**

Gemcitabine.

---

[21] **BN/N/2020/0118** **[22]** **24/12/2020**

[54] **Anti-Steap1 Antigen-Binding Protein**

[71] **AMGEN INC. of One Amgen Center Drive Thousand Oaks, CA 91320-1799 United States of America**
XENCOR, INC of 111 West Lemon Avenue Monrovia, CA 91016 United States of America

[72] **1. NOLAN-STEVAUX, OLIVIER**
2. LI, CONG
3. MURAWSKY, CHRISTOPHER, M.
4. ALBA, BENJAMIN, M.
5. AGRAMAL, NEERAJ JAGDISH
6. GRAHAM, KEVIN
7. STEVENS, JENNITTE, LEANN
8. MOORE, GREGORY

[74] **Messrs. SPRUSON & FERGUSON PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/693,216 Date: 02 July 2019 Country: United States of America
No. 62/800,259 Date: 01 February 2019 Country: United States of America

[86] **PCT/US2019/040296**

[87] **WO/2020/010079**

[51] **A61K 39/12, C07K 16/18, A61K 39/00, A61K 35/00**

[57] **The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.**

---

[21] **BN/N/2020/0119** **[22]** **28/12/2020**

[54] **Modified Y Type Molecular Sieve, Catalytic Cracking Catalyst Having Same, And Preparation Method Therefor And Application Thereof**

[71] **CHINA PETROLEUM & CHEMICAL CORPORATION of 22 Chaoyangmen North Street, Chaoyang District, Beijing 100728, China**
RESEARCH INSTITUTE OF PETROLEUM PROCESSING, SINOPEC of 18 Xueyuan Road, Haidian District, Beijing 100083, China

[72] **1. YUAN, SHUAI**
2. ZHOU, LINGPING

3. TIAN, HUIPING
4. SHA, HAO
5. CHEN, ZHENYU
6. ZHANG, WEILIN

[74] Messrs. HENRY GOH & CO SDN BHD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 201810714296.1 Date: 29 June 2018 Country: China
No. 201810715238.0 Date: 29 June 2018 Country: China

[86] PCT/CN2019/093279

[87] WO/2020/001540

[51] B01J 29/08, B01J 35/10, C10G 11/05

[57] A modified Y type molecular sieve, and a preparation method therefor and an application thereof. The calcium content of the modified Y type molecular sieve is about 0.3-4 wt% in terms of calcium oxide; the rare earth content is about 2.7 wt% in terms of rare earth oxide; the sodium content is not more than about 0.5 wt% in terms of sodium oxide; the total pore volume is about 0.33-0.39 mL/g, wherein the pore volume of secondary pores having a pore diameter of 2-100 nm occupies about 10-25% of the total pore volume; the lattice constant is about 2.440-2.455 nm; the content of non-framework aluminum occupies no higher than about 20% of the total aluminum content; the lattice collapse temperature is not less than about 1050°C; moreover, the ratio of B acid content to L acid content is no less than about 2.30 in the total acid content measured using a pyridine adsorption infrared method at the temperature of 200°C. The modified Y type molecular sieve and a catalytic cracking catalyst having same have higher heavy oil conversion activity and lower coke selectivity during heavy oil fluid catalytic cracking and can obtain a higher gasoline yield and an isomeric C4 yield, and the obtained gasoline has a higher isohydrocarbon content

---

[21] BN/N/2020/0120 [22] 28/12/2020

[54] Modified Y-Type Molecular Sieve, Catalytic Cracking Catalyst Comprising The Same, Its Preparation And Application Thereof

[71] CHINA PETROLEUM & CHEMICAL CORPORATION of 22 Chaoyangmen North Street, Chaoyang District, Beijing 100728, China
RESEARCH INSTITUTE OF PETROLEUM PROCESSING, SINOPEC of 18 Xueyuan Road, Haidian District, Beijing 100083, China

[72] 1. YUAN, SHUAI
2. ZHOU, LINGPING
3. TIAN, HUIPING
4. CHEN, ZHENYU
5. ZHANG, WEILIN

6. SHA, HAO

[74] **Messrs. HENRY GOH & CO SDN BHD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 201810713533.2 Date: 29 June 2018 Country: China
No. 201810713603.4 Date: 29 June 2018 Country: China
No. 201810714440.1 Date: 29 June 2018 Country: China
No. 201810715455.X Date: 29 June 2018 Country: China

[86] **PCT/CN2019/093250**

[87] **WO/2020/001531**

[51] **B01J 29/08, B01J 35/10, C10G 11/05**

[57] **Disclosed is a modified Y-type molecular sieve having high stability, and the preparation and the use thereof. On a dry basis and using the weight of the modified Y-type molecular sieve as a reference, the modified metal content of the modified Y-type molecular sieve is approximately 0.5-6.3 wt% calculated in terms of a modified metal oxide, and the sodium content thereof is not more than approximately 0.5 wt% calculated in terms of sodium oxide, wherein the modified metal is magnesium and/or calcium. The non-skeleton aluminium percentage content of the modified Y-type molecular sieve is not higher than approximately 20% with respect to the total content of aluminum; the total pore volume thereof is approximately 0.33-0.39 mL/g, wherein the percentage of the pore volume of secondary pores with a pore diameter of 2-100 nm is approximately 10%-25% with respect to the total pore volume; the lattice constant thereof is approximately 2.440-2.455 nm; and the lattice collapsing temperature thereof is not lower than approximately 1040ºC. Moreover, the ratio of the amount of the B acid to that of the L acid in the total acid amount determined at 200ºC using a pyridine adsorption infrared method is not less than approximately 2.30. When used for the catalytic cracking of a heavy oil, the modified Y-type molecular sieve and a catalyst containing same have a lower coke selectivity, and can result in a higher gasoline yield and liquefied gas yield, and the resulting gasoline has a higher isomeric hydrocarbon content.**

---

[21] **BN/N/2021/0001** **[22]** **04/01/2021**

[54] **Ophthalmic Compositions Containing A Nitric Oxide Releasing Prostamide**

[71] **NICOX S.A. of Drakkar 2 - Bât D 2405 Route Des Dolines 06560 Cs 10313 - Sophia Antipolis – Valbonne France**

[72] **1. PILOTAZ, FRÉDÉRIC**
2. WEINER, ALAN L.
3. DO, MARINA
4. SALDO, JULIEN

[74] **Messrs. MARKS & CLERK SINGAPORE LLP c/o AIP Law of Unit Nos. 405A-410A**

4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 18290082.9 Date: 12 July 2018 Country: European Patent Office

[86] **PCT/EP2019/068511**

[87] **WO/2020/011845**

[51] **A61K 9/00, A61K 47/14, A61K 9/08, A61K 31/5575, A61P 27/06**

[57] **The present invention provides aqueous ophthalmic compositions in the form of solution comprising hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and macrogol 15 hydroxystearate as the only solubilizing agent, and a method for their preparation.**

---

[21] **BN/N/2021/0002** **[22]** **04/01/2021**

[54] **Fused Pyrazine Derivatives As A2a / A2b Inhibitors**

[71] **INCYTE CORPORATION of 1801 Augustine Cut-Off, Wilmington, Delaware 19803 United States of America**

[72]
1. HOANG, GIA
2. WANG, XIAOZHAO
3. CARLSEN, PETER NIELS
4. GAN, PEI
5. LI, YONG
6. QI, CHAO
7. WU, LIANGXING
8. YAO, WENQING
9. YU, ZHIYONG
10. ZHU, WENYU

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/694,138 Date: 05 July 2018 Country: United States of America
No. 62/755,845 Date: 05 November 2018 Country: United States of America

[86] **PCT/US2019/040496**

[87] **WO/2020/010197**

[51] **C07D 487/04, C07D 519/00, A61P 9/00, A61P 25/28, A61P 29/00, A61P 35/00, A61K 31/4985**

[57] **This application relates to compounds of Formula (I) or pharmaceutically acceptable**

salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.



(I).

---

[21] BN/N/2021/0003 **[22]** 07/01/2021

[54] System And Method For Vehicle-Side Control Of A Multi-Pile Charging Session

[71] MINE MOBILITY RESEARCH CO.LTD. of 89 Aia Capital Center Building 16thfloor, Ratchadaphisek Raod, Dindaeng, Bangkok 10400 Thailand

[72]
1. SOMPHOTE AHUNAI
2. PAN WEN WU
3. LIU GANG
4. DENG XIAO MENG
5. CHENG HANG HANG
6. LI JIAN HUA
7. LUO XIAN KAI
8. ZHANG SI YUAN

[74] Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 2001005629 Date: 28 September 2020 Country: Thailand

---

[21] BN/N/2021/0004 **[22]** 13/01/2021

[54] Selective Estrogen Receptor Degraders

[71] ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285 United States of America

[72]
1. COHEN, JEFFREY DANIEL
2. SALL, DANIEL JON

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]

No. 62/697,100 Date: 12 July 2018 Country: United States of America
No. 62/825,172 Date: 28 March 2019 Country: United States of America

[86] **PCT/US2019/041342**

[87] **WO/2020/014440**

[51] **C07D 491/052, A61K 31/436, A61P 35/00**

[57] **Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts, pharmaceutical compositions, uses, and methods of use thereof are provided.**



---

[21] **BN/N/2021/0005** **[22]** **13/01/2021**

[54] **Selective Estrogen Receptor Degraders**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285 United States of America**

[72] **1. BASTIAN, JOLIE ANNE**
2. COHEN, JEFFREY DANIEL
3. RUBIO, ALMUDENA
4. SALL, DANIEL JON

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/697,100 Date: 12 July 2018 Country: United States of America

[86] **PCT/US2019/041334**

[87] **WO/2020/014435**

[51] **C07D 491/052, A61K 31/436, A61P 35/00**

[57] **Novel selective estrogen receptor degraders (SERDs) according to the formula:, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R^1 or R^2 is independently selected from Cl, F, -CF_3, or -CH_3, and the other is hydrogen, and methods for their use are provided.**



---

[21] **BN/N/2021/0006** **[22]** **14/01/2021**

[54] **Methods Of Using A GIP/GLP1 Co-Agonist For Therapy**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285 United States of America**

[72] **1. BENSON, CHARLES T.**
2. AAUPT, AXEL
3. THOMAS, MELISSA KAY
4. URVA, SHWETA

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/702,061 Date: 23 July 2018 Country: United States of America
No. 62/730,565 Date: 13 September 2018 Country: United States of America
No. 62/740,619 Date: 03 October 2018 Country: United States of America

[86] **PCT/US2019/042817**

[87] **WO/2020/023382**

[51] **A61P 1/16, A61K 38/16, A61P 3/04, A61P 3/10, A61P 9/10, A61P 13/12**

[57] **The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and/or treating dyslipidemia.**

---

[21] **BN/N/2021/0007** **[22]** **14/01/2021**

[54] **HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS**

[71] **XENON PHARMACEUTICALS INC of 200 - 3650 Gilmore Way Burnaby, British Columbia V5G 4W8 Canada**

[72] **1. FOCKEN, THILO**
2. ANDREZ, JEAN-CHRISTOPHE
3. BURFORD, KRISTEN NICOLE
4. DEHNHARDT, CHRISTOPH MARTIN
5. GRIMWOOD, MICHAEL EDWARD
6. JIA, QI
7. LOFSTRAND, VERNER ALEXANDER
8. WILSON, MICHAEL SCOTT
9. ZENOVA, ALLA YUREVNA
10. WESOLOWSKI, STEVEN SIGMUND
11. SUN, SHAOYI

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/725,956 Date: 31 August 2018 Country: United States of America

[86] **PCT/US2019/048917**

[87] **WO/2020/047323**

[51] **C07D 213/76, C07D 401/14, C07D 409/12, C07D 413/12, C07D 417/12, C07D 417/14, C07D 471/04, C07D 487/08, A61K 31/4439, A61P 25/00**

[57] **This invention is directed to pyridine- and thiophene-sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/ or epileptic seizure disorders.**

---

[21] **BN/N/2021/0008** **[22]** **16/01/2021**

[54] **An Enclosure For Conducting Hot Works**

[71] **RAJESH PANTHAVOOR, CHANDANAM PARAMBATHU of House No 9, Simpang 39-81, Pandan 7, Kuala Belait Brunei Darussalam**

[72] **1. RAJESH PANTHAVOOR, CHANDANAM PARAMBATHU**

[31][32][33]
No. BN/N/2018/0061 Date: 23 June 2018 Country: Brunei Darussalam

[86] **PCT/BN2019/050001**

[87] **WO/2020/028959**

[51] **B23K 13/06, B23K 26/12, B23K 37/00, F16P 1/06**

[57] **The present invention relates to a compact hot work enclosure (10) that allows quick installation and is intended to carry out minor hot works safely in a potentially flammable gas environment. In particular, it allows the hot works to be carried out by technicians outside the enclosure by inserting their hand(s) through a glove section (22). Visibility is ensured by large view panel(s) (16) which consists of large transparent window(s) made up of high impact resistant fire retardant materials. Other panels of the enclosure are made from high temperature resistant materials. Positive pressure will be maintained in the enclosure using air supply from a blower or an inert gas supply from a cylinder. The enclosure components can be transported in handbags and can be assembled and de-assembled quickly.**



Fig 1

---

[21] **BN/N/2021/0010** **[22]** **18/01/2021**

[54] **Chimeric Receptors To StEAP1 And Methods Of Use Thereof**

[71] **AMGEN INC of One Amgen Center Drive Thousand Oaks, California 91320-1799 United States of America**

[72] **1. NOLAN-STEVAUX, OLIVIER**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/700,463 Date: 18 July 2018 Country: United States of America

[86] **PCT/US2019/042245**

[87] **WO/2020/018695**

[51] **C07K 16/30, A61K 39/00, C07K 14/725, A61P 35/00**

[57] **Antigen binding molecules, chimeric receptors, and engineered immune cells to STEAP1 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the STEAP1 antigen binding molecules and engineered immune cells.**

---

[21] **BN/N/2021/0011** **[22]** **18/01/2021**

[54] **Methods Of Treating HFpEf Employing Dapagliflozin And Compositions Comprising The Same**

[71] **ASTRAZENECA AB of 151 85 Sodertalje Sweden**

[72] **1. LANGKILDE, ANNA, MARIA**

[74] **Messrs. AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/700,463 Date: 19 July 2018 Country: United States of America

[86] **PCT/EP2019/069323**

[87] **WO/2020/016335**

[51] **A61K 31/70, A61P 9/00, A61P 9/04**

[57] **Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed.**



FIG. 1

---

[21] **BN/N/2021/0013** **[22]** **20/01/2021**

[54] **GIP/GLP1 Co-Agonist Compounds**

[71] **ELI LILLY AND COMPANY of Lilly Corrporate Center Indianpolis, Indiana 46285 United States of America**

[72] **1. ABRAHAM, MILATA MARY**
2. ABURUB, AKTHAM
3. ALSINA-FERNANDEZ, JORGE
4. BROWN, ROBERT ANDREW
5. CABRERA, OVER
6. COSKUN, TAMER
7. CUMMINS, ROBERT CHADWICK
8. DATTA-MANNAN, AMITA
9. ELSAYED, MOHAMED ELSAYED HAMED
10. LAI, XIANYIN
11. PATEL, PHENIL JAYANTILAL
12. QU, HONGCHANG
13. SLOOP, KYLE WYNN
14. TRAN, THI THANH HUYEN
15. WALLIS, JAMES LINCOLN
16. WILLARD, FRANCIS STAFFORD

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/702,072 Date: 23 July 2018 Country: United States of America
No. 62/730,563 Date: 13 September 2018 Country: United States of America
No. 62/740,596 Date: 03 October 2018 Country: United States of America

[86] **PCT/US2019/042822**

[87] **WO/2020/023386**

[51] **C07K 14/605, A61K 38/00, A61K 38/26, A61P 3/04, A61P 3/10, C07K 14/575**

[57] **The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIF) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus ("T2DM"). Also, the compounds may be useful in the treatment of obesity.**

---

[21] **BN/N/2021/0014** **[22]** **20/01/2021**

[54] **Method Of Using A GIP/GLP1 Co-Agonist For Diabetes**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285 United States of America**

[72] **1. ALSINA-FERNANDEZ, JORGE**
2. CABRERA, OVER
3. COSKUN, TAMER

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/702,180 Date: 23 July 2018 Country: United States of America
No. 62/730,562 Date: 13 September 2018 Country: United States of America
No. 62/740,640 Date: 03 October 2018 Country: United States of America

[86] **PCT/US2019/042824**

[87] **WO/2020/023388**

[51] **A61K 38/26, A61P 3/10**

[57] **The present invention provides methods of treating type 2 diabetes (T2D) using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 10:1 GIP to GLP-1. Furthermore, the present invention provides methods of treating T2D using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 5:1 GIP to GLP-1. Also, the present invention provides methods of inducing T2D remission using a novel dosing regimen of a GIP:GLP-1 Peptide. The present invention also provides methods of treating obesity using a novel dosing regimen of a GIP:GLP-1 Peptide.**

---

[21] **BN/N/2021/0015** **[22]** **02/02/2021**

[54] **Antibody Constructs For CLDN18.2 And CD3**

[71] **AMGEN RESEARCH (MUNICH) GMBH of Staffelseestrasse 2 81477 Munich Germany**
AMGEN INC. of One Amgen Center Drive Thousand Oaks, California 91320-1799 United States of America

[72] **1. DAHLHOFF, CHRISTOPH**
2. BLUEMEL, CLAUDIA
3. BROZY, JOHANNES
4. RAUM, TOBIAS
5. NAHRWOLD, ELISABETH
6. ARVEDSON, TARA
7. CHEN, IRWIN
8. ROSS, SANDRA
9. BAILIS, JULIE

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/714,366 Date: 03 August 2018 Country: United States of America

[86] **PCT/EP2019/070886**

[87] **WO/2020/025792**

[51] **A61K 39/395, A61P 35/00, C07K 16/28, C07K 16/30, A61K 39/00**

[57] **The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.**

---

[21] **BN/N/2021/0016** **[22]** **08/02/2021**

[54] **Combination Therapy**

[71] **ADC THERAPEUTICS SA of Biopole route de la Corniche 3b Epalinges 1066 Switzerland**
MEDLMMUNE LIMITED of Milstein Building Granta Park Cambridge Cambridgeshire CB21 6GH United Kingdom

[72] **1. ZAMMARCHI, FRANCESCA**
2. BERTONI, FRANCESCO

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 1814207.5 Date: 31 August 2018 Country: United Kingdom
No. 1908225.4 Date: 10 June 2019 Country: United Kingdom

[86] **PCT/EP2019/073212**

[87] **WO/2020/001531**

[51] **A61K 31/635, A61K 45/06, A61K 47/68, A61P 35/00**

[57] **The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an anti-CD19 Antibody Drug Conjugate (anti-CD19 ADC) and an anti-BCL-2 agent.**

---

[21] **BN/N/2021/0017** **[22]** **11/02/2021**

[54] **Dendrimer Formulations**

[71] **ASTRAZENECA AB of SE-151-85 Sodertälje Sweden**

[72] **1. GELLERT, PAUL**
2. HILL, KATHRYN
3. STOREY, RICHARD

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/719,319 Date: 17 August 2018 Country: United States of America

[86] **PCT/IB2019/056924**

[87] **WO/2020/035815**

[51] **A61P 35/00, A61K 47/56, A61K 47/60, A61K 49/12, A61K 49/14, B82Y 5/00, C07D 211/22, C08G 83/00, A61K 31/445, C08G 69/10**

[57] **Disclosed are pharmaceutical compositions comprising a lyophilized compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, and methods of using the same for treating cancer.**



---

[21] **BN/N/2021/0018** **[22]** **20/02/2021**

[54] **Chronic Nightly Dosing Of Lasmiditan For Migraine Prevention**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center, Indianapolis, Indiana 46285 United States of America**

[72] **1. CONLEY, ROBERT RUSSELL**
2. DAVAR, GUDARZ
3. JOHNSON, KIRK WILLIS

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/726,585 Date: 04 September 2018 Country: United States of America

[86] **PCT/US2019/049340**

[87] **WO/2020/051137**

[51] **A61K 31/444, A61P 25/06**

[57] **The present invention relates to chronic nightly use of lasmiditan for the prevention of migraine, particularly therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment or prevention regimens.**



Figure 1

---

[21] **BN/N/2021/0019** **[22]** **24/02/2021**

[54] **CD200R Agonist Antibodies And Uses Thereof**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center, Indianapolis, Indiana 46285 United States of America**

[72] **1. DEMAREST, STEPHEN JOHN**
2. KOESTER, ANJA
3. MEHTA, PAYAL
4. POTTER, SCOTT CHARLES
5. RUIZ, DIANA ISABEL
6. WITCHER, DERRICK RYAN
7. WU, XIUFENG

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/731,204 Date: 14 September 2018 Country: United States of America

[86] **PCT/US2019/050511**

[87] **WO/2020/055943**

[51] **A61P 37/06, A61P 37/08, C07K 16/28, A61K 39/395, A61K 39/00**

[57] **The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.**

---

[21] **BN/N/2021/0020** **[22]** **24/02/2021**

[54] **2,6-Diamino Pyridine Compounds**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center, Indianapolis, Indiana 46285 United States of America**

[72] **1. DURHAM, TIMOTHY BARRETT**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 62/726,520 Date: 04 September 2018 Country: United States of America

[86] **PCT/US2019/048788**

[87] **WO/2020/051058**

[51] **A61K 31/4439, C07D 210/00, A61P 3/10, A61P 9/04**

[57] **The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.**



Formula I

****

REGISTRAR OF PATENT
BRUNEI DARUSSALAM

PATENTS RULES [S 11/2013]

PATENT RENEWAL APPLICATION

Patent No.:	**BN/N/2017/0080**
Date of Grant:	**30 June, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC**
Title of Invention:	**Outflow Control Device For Creating A Packer**

Patent No.:	**BN/N/2017/0086**
Date of Grant:	**5 June, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title of Invention:	**Completion System For Gravel Packing With Zonal Isolation**

Patent No.:	**BN/N/2017/0104**
Date of Grant:	**1 July, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ELI LILLY AND COMPANY** **AUDION THERAPEUTICS**
Title of Invention:	**Notch Pathway Signaling Inhibitor Compounds**

Patent No.:	**BN/N/2018/0007**
Date of Grant:	**29 August, 2016**
Annuity:	**5th Year**

Applicant(s) / Proprietor(s): **MEDRX CO. LTD.**

Title of Invention: **Transdermally Absorptive Composition**

Patent No.: **RE/R/2012/0041**

Date of Grant: **9 June, 2005**

Annuity: **16th Year**

Applicant(s) / Proprietor(s): **WARNER-LAMBERT COMPANY LLC**

Title of Invention: **Preparation Of Pregabalin And Related Compounds**

Patent No.: **RE/R/2013/0025**

Date of Grant: **31 May, 2012**

Annuity: **9th Year**

Applicant(s) / Proprietor(s): **DEBIOPHARM INTERNATIONAL SA**

Title of Invention: **Slow Release Pharmaceutical Composition Made Of Microparticles**

Patent No.: **RE/R/2014/0011**

Date of Grant: **28 June, 2013**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **SINGAPORE AIRLINES LIMITED**

Title of Invention: **Aircraft Seating And Seating Arrangements**

Patent No.: **RE/R/2014/0020**

Date of Grant: **28 June, 2013**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **INCYTE CORPORATION**

Title of Invention: **Azetidine And Cyclobutane Derivatives As Jak Inihibitors**

Patent No.: **RE/R/2014/0043**

Date of Grant: **2 June, 2014**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **INDUSTRIAL GALVANIZERS CORPORATION PTY LTD**

Title of Invention: **Improved Road Barrier**

Patent No.: **RE/R/2014/0068**

Date of Grant: **4 June, 2014**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **ROYALTY PHARMA COLLECTION TRUST**

Title of Invention: **Treatment of Type 2 Diabetes With a Combination of DPIV Inhibitor and Metformin or Thiazolidinedione**

Patent No.: **RE/R/2015/0064**

Date of Grant: **24 June, 2015**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **MERUS N.V.**

Title of Invention: **Antibody Producing Non-Human Mammals**

Patent No.: **RE/R/2016/0020**

Date of Grant: **22 June, 2015**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **REGENERON PHARMACEUTICALS, INC**

Title of Invention: **Stabilized Formulations Containing Anti-NGF Antibodies**

Patent No.:	**RE/R/2016/0034**
Date of Grant:	**05 July, 2015**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ESTEVE PHARMACEUTICALS, S.A.**
Title of Invention:	**Pharmaceutical Compositions Of Co-Crystals Of Tramadol And Coxibs**

Patent No.:	**RE/R/2017/0012**
Date of Grant:	**22 June, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Coated Tablet Formulation And Method**

Patent No.:	**RE/R/2017/0027**
Date of Grant:	**15 June, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**SUMITOMO METAL INDUSTRIES, LTD.** **VALLOUREC MANNESMANN OIL & GAS FRANCE**
Title of Invention:	**Threaded Connection Comprising At Least One Threaded Element With An End Lip For A Metal Tube**

Patent No.:	**RP/R/2007/0045**
Date of Grant:	**30 April, 2007**
Annuity:	**15th Year**
Applicant(s) / Proprietor(s):	**NOVARTIS AG**
Title of Invention:	**Substituted 3,5-Diphenyl -1,2,4-Triazoles And Their Use As Pharmaceutical Metal Chelators**

Patent No.:	**RP/R/2008/0067**
Date of Grant:	**29 June, 2007**
Annuity:	**14th Year**
Applicant(s) / Proprietor(s):	**SUMITOMO METAL INDUSTRIES, LTD. VALLOUREC MANNESMANN OIL & GAS FRANCE**
Title of Invention:	**A Premium Threaded Turbular Connection Comprising At Least One Threaded Element With An End Lip**

Patent No.:	**BN/N/2015/0002**
Date of Grant:	**05 July, 2013**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**SINGAPORE AIRLINES LIMITED**
Title of Invention:	**A Method And Device For Controlling A Display Device**

Patent No.:	**RE/R/2012/0040**
Date of Grant:	**16 June, 2005**
Annuity:	**15th Year**
Applicant(s) / Proprietor(s):	**RONALD NEVILLE LANGFORD**
Title of Invention:	**Authenticating Images Identified By A Software Application**

Patent No.:	**RE/R/2012/0061**
Date of Grant:	**29 July, 2011**
Annuity:	**10th Year (paid july 2020)**
Applicant(s) / Proprietor(s):	**HELSINN HEALTHCARE SA**
Title Of Invention:	**Liquid Pharmaceutical Formulations Of Palonosetron**

Patent No.:	**RE/R/2013/0007**
Date of Grant:	**04 June, 2010**
Annuity:	**11th Year**
Applicant(s) / Proprietor(s):	**OPULENT ELECTRONICS INTERNATIONAL PTE LTD**
Title Of Invention:	**Device And Method For Driving Leds**

Patent No.:	**RE/R/2013/0059**
Date of Grant:	**31 July, 2012**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**PIERRE FABRE MEDICAMENT**
Title Of Invention:	**Novel Antibodies Inhibiting C-Met Dimerization, And Uses Thereof**

Patent No.:	**RE/R/2013/0091**
Date of Grant:	**12 July, 2002**
Annuity:	**19th Year**
Applicant(s) / Proprietor(s):	**DOLBY LABORATORIES LICENSING CORPORATION**
Title Of Invention:	**Method And System For Improving Compressed Image Chroma Information**

Patent No.:	**RE/R/2014/0044**
Date of Grant:	**31 July, 2013**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**ONE SMART STAR LIMITED**
Title Of Invention:	**Communicating With Business Customers**

Patent No.: RE/R/2015/0023

Date of Grant: 31 July, 2014

Annuity: 7th Year

Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.

Title Of Invention: Treatment Fluids Comprising Relative Permeability Modifiers And Methods Of Use

---

Patent No.: RE/R/2015/0030

Date of Grant: 26 February, 2004

Annuity: 7th Year

Applicant(s) / Proprietor(s): SUGEN, INC.

Title Of Invention: Aminoheteroaryl Compounds As Protein Kinase Inhibitors

---

Patent No.: RE/R/2015/0047

Date of Grant: 31 July, 2014

Annuity: 7th Year

Applicant(s) / Proprietor(s): OIL STATES INTERNATIONAL

Title Of Invention: Two-Element Tandem Flexible Joint

Patent No.: RE/R/2016/0011

Date of Grant: 17 June, 2015

Annuity: 6th Year

Applicant(s) / Proprietor(s): WYETH HOLDINGS LLC

Title Of Invention: Anti-Tumor Activity Of Temsirolimus In Papillary Renal Cell Cancer

---

Patent No.: RE/R/2016/0012

Date of Grant: 08 July, 2015

Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**WYETH HOLDINGS LLC**
Title Of Invention:	**Calicheamicin Derivative-Carrier Conjugates**

Patent No.:	**RE/R/2017/0037**
Date of Grant:	**27 July 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**WYETH HOLDINGS LLC**
Title Of Invention:	**Calicheamicin Derivative-Carrier Conjugates**

Patent No.:	**BN/N/2015/0047**
Date of Grant:	**20 February, 2013**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title Of Invention:	**Securing Connections In Alternate Path Well Screens**

Patent No.:	**BN/N/2016/0026**
Date of Grant:	**9 February, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**OPULENT ELECTRONICS INTERNATIONAL PTE LTD**
Title Of Invention:	**Device And Method For Providing Regulated Current To An Electrical Load**

Patent No.:	**BN/N/2016/0056**
Date of Grant:	**10 February, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**SKY URBAN IP PTE LTD**

Title Of Invention:	**Rotatable Rack System**

Patent No.:	**RE/R/2015/0016**
Date of Grant:	**26 February, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**UCB PHARMA GMBH**
Title Of Invention:	**New Chirla Intermediate, Process For Producing The Same And Its Use In The Manufacture Of Telterodine, Fesoterodine, Or The Active Metabolite Thereof**

Patent No.:	**RE/R/2017/0003**
Date of Grant:	**03 February, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**MERIDIAN MEDICAL TECHNOLOGIES, INC.**
Title Of Invention:	**Automatic Injector**

Patent No.:	**RE/R/2017/0006**
Date of Grant:	**15 February, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**MERCK SHARP & DOHME CORP.**
Title Of Invention:	**Crystalline Form Of R)-3-(4-(2-(2-Methyltetrazol-5-Yl)Pyridin-5-Yl)-3-Fluorophenyl)-5-Hydroxymethyl Oxazolidin-2-One Dihydrogen Phosphate**

Patent No.:	**RP/R/2010/0014**
Date of Grant:	**15 February, 2020**
Annuity:	**20th Year**
Applicant(s) / Proprietor(s):	**PHARMACIA & UPJOHN COMPANY LLC SUGEN INC.**

Title Of Invention:	**Pyyrole Substituted 2-Indolinone Protein Kinase Inhibitors**

Patent No.:	**BN/N/2015/0085**
Date of Grant:	**15 February, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**LABORATORIOS MENARINI SA**
Title Of Invention:	**Pharmaceutical Compositions Containing Dexketoprofen And Tramadol**

Patent No.:	**BN/N/2015/0085**
Date of Grant:	**15 February, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**LABORATORIOS MENARINI SA**
Title Of Invention:	**Pharmaceutical Compositions Containing Dexketoprofen And Tramadol**

Patent No.:	**BN/N/2015/0085**
Date of Grant:	**15 February, 2016**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**LABORATORIOS MENARINI SA**
Title Of Invention:	**Pharmaceutical Compositions Containing Dexketoprofen And Tramadol**

Patent No.:	**BN/N/2015/0108**
Date of Grant:	**28 March, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.** **SUMITOMO DAINIPPON PHARMA CO., LTD.**

Title Of Invention:	**WT1-Antigen Peptide Conjugate Vaccine**

Patent No.:	**BN/N/2016/0076**
Date of Grant:	**27 March, 2019**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**AMOREPACIFIC CORPORATION**
Title of Invention:	**Cosmetic Composition For Skin Moisturizing Containing Minerals And Quinoa Extract**

Patent No.:	**BN/N/2018/0081**
Date of Grant:	**27 November, 2019**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**NICHIBAN CO. LTD.**
Title of Invention:	**Stamp Type Coating-Film Transfer Tool**

Patent No.:	**RE/R/2013/0053**
Date of Grant:	**29 July, 2013**
Annuity:	**16th Year**
Applicant(s) / Proprietor(s):	**BETH ISRAEL DEACONESS MEDICAL CENTER**
Title of Invention:	**Methods Of Diagnosing And Treating Pre-Eclampsia Or Eclampsia**

Patent No.:	**RE/R/2014/0006**
Date of Grant:	**8 January, 2014**
Annuity:	**18th Year**
Applicant(s) / Proprietor(s):	**SUGEN, INC.**
Title of Invention:	**Aminoheteroaryl Compounds As Protein Kinase Inhibitors**

Patent No.:	**RE/R/2014/0031**
Date of Grant:	**24 February, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**ELI LILLY AND COMPANY**
Title of Invention:	**Protein Kinase Inhibitors**

Patent No.:	**RP/R/2006/0010**
Date of Grant:	**22 February, 2006**
Annuity:	**16th Year**
Applicant(s) / Proprietor(s):	**MSD ITALIA S.R.L.**
Title of Invention:	**N-Substituted Hydroxtpyrimidinone Carboxamide Inhibitors Of Hiv Integrase**

Patent No.:	**RP/R/2008/0041**
Date of Grant:	**29 February, 2008**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**RICHTER GEDEON NYRT.**
Title of Invention:	**(Thio) Carbamoyl-Cyclohexane Derivatives As D3/D2 Receptor Antagonists**

Patent No.:	**BN/N/2015/0098**
Date of Grant:	**21 June, 2016**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**SHODA SHOYU CO., LTD.** **SOY & WORLD INC.**
Title of Invention:	**Process For Manufacturing Soybean Paste, And Soybean Paste**

Patent No.:	**BN/N/2017/0026**
Date of Grant:	**30 November, 2019**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ELI LILLY AND COMPANY**
Title of Invention:	**Aurora A Kinase Inhibitor**

Patent No.:	**BN/N/2017/0037**
Date of Grant:	**30 November, 2019**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**MERCK SHARP & DOHME CORP.**
Title of Invention:	**Insulin Receptor Partial Agonists**

Patent No.:	**RE/R/2014/0059**
Date of Grant:	**30 April, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**UNIDENSE TECHNOLOGY GMBH**
Title of Invention:	**Catalyst Loading System**

Patent No.:	**RE/R/2016/0035**
Date of Grant:	**2 March, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**IMMUNOGEN, INC.**
Title of Invention:	**Cytotoxic Benzodiazepine Derivatives**

Patent No.:	**BN/N/2014/0084**
Date of Grant:	**11 September, 2014**

Annuity: 8th Year

Applicant(s) / Proprietor(s): PURAPIPE HOLDING LTD.

Title of Invention: Multilayer Pipeline In A Polymer Material, Device For Manufacture Of The Multilayer Pipeline And A Method For Manufacturing The Multilayer Pipeline

---

Patent No.: BN/N/2017/0019

Date of Grant: 27 November, 2019

Annuity: 5th Year

Applicant(s) / Proprietor(s): Eli Lilly and Company

Title of Invention: Treatment Of Androgen Deprivation Therapy Associated Symptoms

---

Patent No.: BN/N/2018/0067

Date of Grant: 20 December, 2018

Annuity: 5th Year

Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION and VALLOUREC OIL AND GAS FRANCE

Title of Invention: Threaded Joint For Steel Pipes

Patent No.: RE/R/2012/0054

Date of Grant: 2 November, 2012

Annuity: 9th Year

Applicant(s) / Proprietor(s): Billion King International Limited

Title of Invention: A Method For The Preparation Of A Heat Stable Oxygen Carrier-Containing Pharmaceutical Composition

---

Patent No.: RE/R/2012/0055

Date of Grant: 19 November, 2012

Annuity:	**18th Year**
Applicant(s) / Proprietor(s):	**ARRAY BIOPHARMA, INC**
Title of Invention:	**N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors**

Patent No.:	**RE/R/2015/0038**
Date of Grant:	**11 March, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**ALMIRALL S.A.**
Title of Invention:	**Combinations comprising antimuscarinic agents and beta-adrenergic agonists**

Patent No.:	**RE/R/2017/0002**
Date of Grant:	**15 March, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**PHARMAESSENTIA CORP.**
Title of Invention:	**Peptide-Polymer Conjugates**

Patent No.:	**RE/R/2015/0053**
Date of Grant:	**25 February, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**GILEAD SCIENCES, INC.**
Title of Invention:	**Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same**

Patent No.:	**BN/N/2016/0069**
Date of Grant:	**9 October, 2017**
Annuity:	**6th Year**

Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL CORPORATION VALLOUREC OIL AND GAS FRANCE**
Title of Invention:	**Solid Lubricant Coating Composition, Threaded Joint For Pipes Comprising Solid Lubricant Coating Formed Using Said Composition, And Production Method For Said Threaded Joint For Pipes**

Patent No.:	**RE/R/2016/0005**
Date of Grant:	**3 March, 2016**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**CRYSTAL LAGOONS (CURACAO) B.V.**
Title of Invention:	**Method And System For The Sustainable Cooling Of Industrial Processes**

Patent No.:	**BN/N/2016/0070**
Date of Grant:	**24 August, 2017**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**CHUA, BOON PEN**
Title of Invention:	**A Method Of Priming A Drainage Apparatus For Siphoning Liquid, And A Drainage Apparatus**

Patent No.:	**RE/R/2016/0025**
Date of Grant:	**31 March, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL CORPORATION VALLOUREC OIL AND GAS FRANCE**
Title of Invention:	**Tubular Threaded Joint Having Improved High Torque Performance**

Patent No.:	**RP/R/2007/0039**

Date of Grant:	**30 March, 2007**
Annuity:	**14th Year**
Applicant(s) / Proprietor(s):	**VALLOUREC MANNESMANN OIL & GAS FRANCE SUMITOMO METAL INDUSTRIES, LTD.**
Title of Invention:	**Threaded Joint For Pipes**

Patent No.:	**RE/R/2012/0036**
Date of Grant:	**16 May, 2012**
Annuity:	**11th Year**
Applicant(s) / Proprietor(s):	**HIGH SEALED AND COUPLED "HSC" FZCO**
Title of Invention:	**An Improved Seal Between Pipes**

Patent No.:	**RE/R/2012/0059**
Date of Grant:	**31 May, 2012**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**GILEAD PHARMASSET LLC**
Title of Invention:	**Nucleoside Phosphoramidate Prodrugs**

Patent No.:	**BN/N/2015/0114**
Date of Grant:	**4 September, 2017**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**HUWE INC.**
Title of Invention:	**Hammer Union Wrench**

Patent No.:	**RE/R/2014/0008**
Date of Grant:	**11 April, 2013**
Annuity:	**8th Year**

Applicant(s) / Proprietor(s):	**EWOOTEC CO., LTD**
Title of Invention:	**Apparatus And Method For Detecting Location Of Underground Facility**

Patent No.:	**RE/R/2015/0017**
Date of Grant:	**23 March, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**WYETH HOLDINGS LLC**
Title of Invention:	**Substituted 3-Cyanoquinolines As Protein Tyrosine Kinases Inhibitors**

Patent No.:	**RE/R/2016/0002**
Date of Grant:	**11 March, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**MERCH CANADA INC**
Title of Invention:	**Non-Necleoside Reverse Transcriptase Inhibitors**

Patent No.:	**RE/R/2016/0007**
Date of Grant:	**11 March, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**REGENERON PHARMACEUTICALS, INC.**
Title of Invention:	**High Affinity Human Antibodies To Pcsk9**

Patent No.:	**RP/R/2008/0058**
Date of Grant:	**12 April, 2001**
Annuity:	**20th Year**
Applicant(s) / Proprietor(s):	**JAGOTEC AG**

Title of Invention: **Ropinirole-Containing Hydrophilic/Liphilic Polymeric Magtrix Dosage Formulation**

Patent No.: **BN/N/2014/0087**

Date of Grant: **11 March, 2013**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **AZMI, MOIN UZZAMAN**

Title of Invention: **Wash Basin With Foot Washing Facility**

Patent No.: **BN/N/2017/0102**

Date of Grant: **09 June, 2015**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **MUN SIONG ENGINEERING LIMITED**

Title of Invention: **Viewing Method After Cleaning Pipeline And Viewing Apparatus Thereof**

Patent No.: **RE/R/2012/0004**

Date of Grant: **29 April, 2011**

Annuity: **10th Year**

Applicant(s) / Proprietor(s): **VALLOUREC MANNESMANN OIL & GAS FRANCE**
SUMITOMO METAL INDUSTRIES LTD

Title of Invention: **Threaded Joint For Steel Pipes**

Patent No.: **RE/R/2014/0001**

Date of Grant: **24 May, 2012**

Annuity: **9th Year**

Applicant(s) / Proprietor(s): **UNITED PIPELINES ASIA PACIFIC PTE LIMITED**

Title of Invention: **Austenitic Stainless Steel**

Patent No.:	**RE/R/2014/0023**
Date of Grant:	**17 April, 2008**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**UNITED KINGDOM RESEARCH AND INNOVATION**
Title of Invention:	**Antibodies Against Il-25**

Patent No.:	**RE/R/2015/0026**
Date of Grant:	**14 May, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**WYETH LLC**
Title of Invention:	**Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles**

Patent No.:	**RE/R/2016/0027**
Date of Grant:	**25 April, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**CRYSTAL LAGOONS (CURACAO) B.V.**
Title of Invention:	**Method And System For Treating Water Used For Industrial Purposes**

Patent No.:	**RE/R/2014/0024**
Date of Grant:	**31 May, 2001**
Annuity:	**20th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**New Crystalline Form Of A Triazolo (4,5-D) Pyrimidine Compound**

Patent No.: **RP/R/2006/0006**

Date of Grant: **02 May, 2003**

Annuity: **18th Year**

Applicant(s) / Proprietor(s): **ASTRAZENECA AB**

Title of Invention: **Novel Form Of S-Omeprazole**

Patent No.: **RP/R/2007/0030**

Date of Grant: **30 April, 2007**

Annuity: **14th Year**

Applicant(s) / Proprietor(s): **SANOFI-AVENTIS**

Title of Invention: **Polymorphic Clopidogrel Hydrogegensulphate Form**

Patent No.: **RP/R/2008/0073**

Date of Grant: **30 April, 2008**

Annuity: **13th Year**

Applicant(s) / Proprietor(s): **JANSSEN ALZHEIMER IMMUNOTHERAPY**

Title of Invention: **Prevention And Treatment Of Amyloidogenic Disease**

Patent No.: **BN/N/2014/0092**

Date of Grant: **21 May, 2013**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **NIPPON STEEL & SUMITOMO METAL CORPORATION**
VALLOUREC OIL AND GAS FRANCE

Title of Invention: **Tubular Threaded Joint Having Improved High-Torque Makeup Properties**

Patent No.: **BN/N/2014/0114**

Date of Grant: 07 June, 2013

Annuity: 8th Year

Applicant(s) / Proprietor(s): BERTHOLD SICHERT GMBH

Title of Invention: Underground Switch Cabinet For Electric Installation

---

Patent No.: BN/N/2016/0082

Date of Grant: 23 April, 2015

Annuity: 6th Year

Applicant(s) / Proprietor(s): MEIER SANITECH PTE LTD

Title of Invention: A Sanitary Valve Device And Assembly

Patent No.: BN/N/2016/0084

Date of Grant: 16 April, 2015

Annuity: 6th Year

Applicant(s) / Proprietor(s): DAICEL CORPORATION

Title of Invention: Flange Fastening Skill Determination Apparatus And Flange Fastening Skill Determination Program

---

Patent No.: RE/R/2012/0031

Date of Grant: 02 April, 2009

Annuity: 12th Year

Applicant(s) / Proprietor(s): MERCK SHARP & DOHME CORP

Title of Invention: Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists

---

Patent No.: RE/R/2013/0061

Date of Grant: 20 July, 2011

Annuity: 10th Year

Applicant(s) / Proprietor(s):	**SHOWCASE INC.**
Title of Invention:	**Web Display Program Conversion System, Web Display Program Conversion Method And Program For Converting Web Display Program**

Patent No.:	**RE/R/2013/0069**
Date of Grant:	**17 April, 2008**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**ERKE ERKE ARASTIRMALARI VE MÜHENDISLIK A.S.**
Title of Invention:	**Gear Device And Method For Providing A Rotary Motor**

Patent No.:	**RE/R/2013/0072**
Date of Grant:	**16 April, 2008**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**GLAXO GROUP LIMITED**
Title of Invention:	**Tricyclic Nitrogen Containing Compounds As Antibacterial Agents**

Patent No.:	**RE/R/2014/0013**
Date of Grant:	**04 April, 2008**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**VALLOUREC MANNESMANN OIL & GAS FRANCE**
Title of Invention:	**Lubricating Composition With An Adaptable Coefficient Of Friction, For A Threded Element Of A Component Of A Tubular Threaded Joint**

Patent No.:	**RE/R/2015/0024**
Date of Grant:	**13 April, 2015**

Annuity: 6th Year

Applicant(s) / Proprietor(s): HELSINN HEALTHCARE SA

Title of Invention: Compositions For Treating Centrally Mediated Nausea And Vomiting

---

Patent No.: RE/R/2016/0015

Date of Grant: 19 May, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s): BAVARIAN NORDIC A/S

Title of Invention: Use Of A Modified Poxvirus For The Rapid Induction Of Immunity Against A Poxvirus Or Other Infectious Agents

---

Patent No.: RE/R/2017/0007

Date of Grant: 15 April, 2016

Annuity: 5th Year

Applicant(s) / Proprietor(s): MERCK SHARP & DOHME CORP.

Title of Invention: Treating Allergic And Inflammatory Conditions

---

Patent No.: RP/R/2010/0009

Date of Grant: 30 April, 2009

Annuity: 12th Year

Applicant(s) / Proprietor(s): KHOO TIAN
O-STABLE PANEL SDN. BHD.

Title of Invention: Vertical Construction Joints

Patent No.: BN/N/2014/0091

Date of Grant: 02 May, 2013

Annuity: 8th Year

Applicant(s) / Proprietor(s): ELI LILLY AND COMPANY

Title of Invention: Pyrazole Compounds As Sglt1 Inhibitors

Patent No.: BN/N/2014/0115

Date of Grant: 16 April, 2013

Annuity: 8th Year

Applicant(s) / Proprietor(s): ELI LILLY AND COMPANY

Title of Invention: Anti-Baff-Anti-Il17 Bispecific Antibodies

---

Patent No.: BN/N/2016/0080

Date of Grant: 13 April, 2015

Annuity: 6th Year

Applicant(s) / Proprietor(s): THERMTECH HOLDING AS

Title of Invention: Method Of Treating A Material

Patent No.: RE/R/2013/0026

Date of Grant: 31 March, 2006

Annuity: 15th Year

Applicant(s) / Proprietor(s): WYETH LLC

Title of Invention: Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition

---

Patent No.: RE/R/2013/0076

Date of Grant: 31 March, 2009

Annuity: 12th Year

Applicant(s) / Proprietor(s): HYDROBALL TECHNICS HOLDINGS PTE LTD

Title of Invention: Cleaning System For Cleaning Tubing

Patent No.: RE/R/2014/0028

Date of Grant: 22 April, 2010

Annuity: 11th Year

Applicant(s) / Proprietor(s): F.HOFFMAN-LA ROCHE AG

Title of Invention: Methods For Improving Pharmacokinetics

Patent No.: RE/R/2015/0014

Date of Grant: 14 May, 2014

Annuity: 7th Year

Applicant(s) / Proprietor(s): TOTAL S.A.

Title of Invention: Pipe For Transporting A Fluid Containing A Hydrocarbon, And Method For Producing Such A Line

---

Patent No.: RE/R/2015/0031

Date of Grant: 30 April, 2014

Annuity: 7th Year

Applicant(s) / Proprietor(s): ACCELERON PHARMA INC.

Title of Invention: ANTI-ACTIVIN A Or B Antibodies And Use Thereof For Promoting Bone Growth

---

Patent No.: RE/R/2015/0032

Date of Grant: 21 May, 2014

Annuity: 7th Year

Applicant(s) / Proprietor(s): MERIDIAN MEDICAL TECHNOLOGIES

Title of Invention: **Automatic injector**

Patent No.: **RE/R/2015/0039**

Date of Grant: **08 April, 2015**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **ALMIRALL S.A.**

Title of Invention: **Combinations comprising antimuscarinic agents and beta-adrenergic agonists**

Patent No.: **RE/R/2015/0040**

Date of Grant: **28 May, 2014**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **ACCELERON PHARMA, INC.**

Title of Invention: **Variants derived from ActRIIB and uses therefor**

Patent No.: **RE/R/2016/0014**

Date of Grant: **17 April, 2015**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA**

Title of Invention: **Methods And Systems For Phylogenetic Analysis**

Patent No.: **RE/R/2016/0032**

Date of Grant: **23 March, 2016**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **MERCK SHARP & DOHME CORP.**

Title of Invention: **Inhibitors of Hepatitis C Virus Replication**

Patent No.:	**RE/R/2017/0004**
Date of Grant:	**16 March, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**TOTAL S.A.**
Title of Invention:	**Heating Cover For A Device For Transporting A Fluid Containing A Hydrocarbon**

Patent No.:	**RE/R/2017/0005**
Date of Grant:	**29 January, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**LABORATORIOS DEL DR. ESTEVE, S.A**
Title of Invention:	**Co-Crystals Of Tramadol And Coxibs**

Patent No.:	**RE/R/2017/0009**
Date of Grant:	**30 March, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**MERIDIAN MEDICAL TECHNOLOGIES, INC.**
Title of Invention:	**Needle Assemblies for Wet/Dry Automatic Injectors**

Patent No.:	**RE/R/2017/0014**
Date of Grant:	**15 April, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**SCYNEXIS. INC.**
Title of Invention:	**Antifungal Agents**

Patent No.:	**RE/R/2017/0015**
Date of Grant:	**04 April, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**GILEAD SCIENCES, INC.**
Title of Invention:	**Modulators Of Pharmacokinetic Properties Of Therapeutics**

Patent No.:	**RE/R/2017/0017**
Date of Grant:	**15 April, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC**
Title of Invention:	**Extending Lines Through And Preventing Extrusion Of, Seal Elements Of Packer Assemblies**

Patent No.:	**RE/R/2017/0020**
Date of Grant:	**10 May, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**GILEAD SCIENCES, INC. (US)** **JAPAN TOBACCO, INC.**
Title of Invention:	**Methods For Improving The Pharmacokinetics Of Hiv Integrase Inhibitors**

Patent No.:	**RP/R/2006/0012**
Date of Grant:	**22 March, 2006**
Annuity:	**15th Year**
Applicant(s) / Proprietor(s):	**MERCK SHARPE & DOHME CORP.**
Title of Invention:	**Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inihibitors For The Treatment Or Prevention Of**

Diabetes

Patent No.:	**RP/R/2007/0057**
Date of Grant:	**04 May, 2005**
Annuity:	**16th Year**
Applicant(s) / Proprietor(s):	**ARENA PHARMACEUTICALS, INC.**
Title of Invention:	**5ht2c Receptor Modulators**

Patent No.:	**RP/R/2010/0008**
Date of Grant:	**30 April, 2007**
Annuity:	**14th Year**
Applicant(s) / Proprietor(s):	**ELI LILLY AND COMPANY**
Title of Invention:	**Diaryl Ethers As Opioid Receptor Antagonist**

Patent No.:	**BN/N/2014/0104**
Date of Grant:	**24 June, 2013**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL CORPORATION** **VALLOUREC OIL & GAS FRANCE**
Title of Invention:	**Electroplating Device**

Patent No.:	**RE/R/2014/0016**
Date of Grant:	**30 April, 2013**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**UNITED STATES GYPSUM COMPANY**
Title of Invention:	**High Starch Light Weight Gypsium Wallboard**

Patent No.:	**RE/R/2015/0033**
Date of Grant:	**25 June, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Pyrrolo [2, 3 -D] Pyrimidin Derivatives As Protein Kinase B Inhibitors**

Patent No.:	**RE/R/2016/0010**
Date of Grant:	**15 June, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**SUMITOMO METAL INDUSTRIES LTD.** **VALLOUREC MANNESMANN OIL & GAS FRANCE**
Title of Invention:	**Threaded Joint For Steel Pipes**

Patent No.:	**RE/R/2016/0036**
Date of Grant:	**13 May, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**DOLBY INTERNATIONAL AB** **DOLBY LABORATORIES LICENSING CORPORATION**
Title of Invention:	**Audio Decoder And Decoding Method Using Efficient Downmixing**

Patent No.:	**RE/R/2017/0010**
Date of Grant:	**15 June, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**SUMITOMO METAL INDUSTRIES, LTD.** **VALLOUREC MANNESMANN OIL & GAS FRANCE**

Title of Invention: **Photocurable Composition Suitable For Rust Prevention Of A Threaded Joint For Steel Pipes**

Patent No.: **RP/R/2005/0023**

Date of Grant: **21 May, 2002**

Annuity: **19th Year**

Applicant(s) / Proprietor(s): **ASTRAZENECA AB**

Title of Invention: **Formulation**

Patent No.: **RP/R/2009/0020**

Date of Grant: **16 June, 2005**

Annuity: **16th Year**

Applicant(s) / Proprietor(s): **CHAMPION TECHNOLOGIES, INC**

Title of Invention: **Low Dosage Naphthenate Inhibitors**

Patent No.: **RE/R/2015/0029**

Date of Grant: **11 June, 2014**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **PFIZER PRODUCTS INC.**

Title of Invention: **Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases**

Patent No.: **RE/R/2015/0054**

Date of Grant: **16 June, 2015**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **GILEAD SCIENCES, INC.**

Title of Invention: **Modulators Of Pharmacokinetic Properties Of**

Therapeutics

Patent No.:	**RP/R/2007/0017**
Date of Grant:	**26 July, 2006**
Annuity:	**15th Year**
Applicant(s) / Proprietor(s):	**TWISTER B.V.**
Title of Invention:	**Cyclonic Fluid Separator With Vortex Generator In Inlet Section**

Patent No.:	**RE/R/2014/0005**
Date of Grant:	**2 October, 2013**
Annuity:	**18th Year**
Applicant(s) / Proprietor(s):	**TAKEDA PHARMACEUTICAL COMPANY LIMITED**
Title of Invention:	**Solid Preparation**

Patent No.:	**RE/R/2016/0049**
Date of Grant:	**20 October, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**JANSSEN SCIENCES IRELAND UC**
Title of Invention:	**Aqueous Suspensions of TMC278**

Patent No.:	**RP/R/2009/0017**
Date of Grant:	**31 October, 2007**
Annuity:	**14th Year**
Applicant(s) / Proprietor(s):	**JANSSEN ALZHEIMER IMMUNOTHERAPY**
Title of Invention:	**Prevention And Treatment Of Amyloidogenic Disease**

Patent No.:	**RP/R/2009/0021**
Date of Grant:	**08 October, 2008**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**
Title of Invention:	**Borehole Imaging**

Patent No.:	**RP/R/2009/0037**
Date of Grant:	**07 October, 2009**
Annuity:	**12th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B. V**
Title of Invention:	**Method For Optimising The Production Of A Cluster Of Wells**

Patent No.:	**BN/N/2016/0045**
Date of Grant:	**12 November, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**CRYSTAL LAGOONS (CURACAO) B.V.**
Title Of Invention:	**Suctioning Device For Large Artificial Water Bodies**

Patent No.:	**BN/N/2017/0035**
Date of Grant:	**09 November, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**MEDIMMUNE LIMITED**
Title Of Invention:	**Binding Molecules Specific For Cd73 And Uses Thereof**

Patent No.:	**BN/N/2017/0082**

Date of Grant:	**5 August, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**CS CONSTRUCTION & GEOTECHNIC PTE LTD**
Title Of Invention:	**System And Method For Securing, Moving And Placing A Pile Or Heavy Elongated Object**

Patent No.:	**RE/R/2012/0022**
Date of Grant:	**13 September, 2006**
Annuity:	**15th Year**
Applicant(s) / Proprietor(s):	**TAKEDA PHARMACEUTICAL COMPANY LIMITED**
Title Of Invention:	**Dipeptidyl Peptidase Inhibitors For Treating Diabetes**

Patent No.:	**RE/R/2012/0029**
Date of Grant:	**30 November, 2009**
Annuity:	**12th Year**
Applicant(s) / Proprietor(s):	**PEAK WELL SYSTEMS PTY LTD**
Title Of Invention:	**A Retrievable Downhole Tool And Running Tool**

Patent No.:	**RE/R/2013/0092**
Date of Grant:	**13 September, 2006**
Annuity:	**15th Year**
Applicant(s) / Proprietor(s):	**TAKEDA PHARMACEUTICAL COMPANY LIMITED**
Title Of Invention:	**Administration Of Dipeptidyl Peptidase Inhibitors**

Patent No.:	**RE/R/2014/0067**
Date of Grant:	**20 November, 2013**
Annuity:	**8th Year**

Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title Of Invention:	**Pyrimidine Sulphonamide Derivatives As Chemokine Receptor Modulators**

Patent No.:	**RP/R/2005/0001**
Date of Grant:	**31 October, 2002**
Annuity:	**19th Year**
Applicant(s) / Proprietor(s):	**JANSSEN PHARMACEUTICA N.V.**
Title Of Invention:	**Aqueous Risperidone Formulations**

Patent No.:	**BN/N/2015/0010**
Date of Grant:	**11 September, 2013**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL CORPORATION** **VALLOUREC OIL AND GAS FRANCE**
Title Of Invention:	**Threaded Joint For Steel Pipe**

Patent No.:	**BN/N/2018/0008**
Date of Grant:	**31 July, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**AKESO BIOPHARMA, INC.**
Title Of Invention:	**An Anti-Ctla4 Monoclonal Antibody Or Antigen Binding Fragment Thereof, A Pharmaceutical Composition And Use**

Patent No.:	**BN/N/2018/0018**
Date of Grant:	**15 September, 2016**
Annuity:	**5th Year**

Applicant(s) / Proprietor(s): **ASTRAZENECA AB**

Title of Invention: **8-[6-[3-(Amino)Propoxy]-3-Pyridyl]-1 -Isopropyl-Imidazo[4,5-C]Quinolin-2-One Derivatives As Selective Modulators Of Ataxia Telangiectasia Mutated (Atm) Kinase For The Treatment Of Cancer**

Patent No.: **RE/R/2013/0058**

Date of Grant: **28 September, 2012**

Annuity: **9th Year**

Applicant(s) / Proprietor(s): **FIRST GAIN INTERNATIONAL LIMITED**

Title Of Invention: **A Method For The Preparation Of A High-Temperature Stable Oxygen-Carrier-Containing Pharmaceutical Composition And The Use Thereof**

Patent No.: **RE/R/2015/0070**

Date of Grant: **12 August, 2015**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **ALMIRALL, S.A.**

Title Of Invention: **Inhalation Composition Containing Aclidinium For Treatment Of Chronic Obstructive Pulmonary Disease**

Patent No.: **RE/R/2016/0045**

Date of Grant: **25 November, 2015**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **MERIDIAN MEDICAL TECHNOLOGIES, INC.**

Title Of Invention: **Automatic Injector With Needle Cover**

Patent No.: **RE/R/2017/0057**

Date of Grant: **02 November, 2016**

Annuity: **5th Year**

Applicant(s) / Proprietor(s):	**PFIZER INC.**
Title Of Invention:	**Benzimidazole Derivatives**

Patent No.:	**RP/R/2009/0038**
Date of Grant:	**17 September, 2002**
Annuity:	**19th Year**
Applicant(s) / Proprietor(s):	**BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED COMPANY**
Title Of Invention:	**Lactam-Containing Compounds And Derivatives Thereof As Factor XA Inhibitors**

Patent No.:	**BN/N/2014/0004**
Date of Grant:	**25 July, 2012**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title Of Invention:	**2 - (2, 4, 5 - Substituted -Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer**

Patent No.:	**BN/N/2016/0085**
Date of Grant:	**16 June, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL CORPORATION** **VALLOUREC OIL & GAS FRANCE**
Title Of Invention:	**Threaded Joint For Steel Pipes**

Patent No.:	**BN/N/2016/0086**
Date of Grant:	**05 May, 2015**
Annuity:	**6th Year**

Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title Of Invention:	**Imidazo[4,5-C]QUINOLIN-2-ONE Compounds And Their Use In Treating Cancer**

Patent No.:	**BN/N/2017/0002**
Date of Grant:	**24 July, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title Of Invention:	**[1,2,4] Triazolo [4,3-B] Pyridazines For Use In The Treatment Of Proliferative Diseases**

Patent No.:	**BN/N/2017/0093**
Date of Grant:	**03 May, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title Of Invention:	**Pyrazole Derivatives Useful As 5-Lipoxygenase Activating Protein (Flap) Inhibitors**

Patent No.:	**RE/R/2016/0019**
Date of Grant:	**07 June, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**THERACOS SUB, LLC**
Title Of Invention:	**Crystalline Form of Benzylbenzene SGLT2 Inhibitor**

Application No.:	**RE/R/2016/0022**
Date of Grant:	**15 July, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**SUMITOMO METAL INDUSTRIES, LTD**

	VALLOUREC MANNESMANN OIL & GAS FRANCE
Title of Invention:	**Threaded Joint For Steel Pipes**

Application No.:	**RE/R/2016/0024**
Date of Grant:	**8 July, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**HUTCHISON MEDIPHARMA LIMITED**
Title of Invention:	**Certain Triazolopyrazines, Compositions Thereof And Methods Of Use Therefor**

Application No.:	**RE/R/2017/0021**
Date of Grant:	**28 May, 2010**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**PEARL THERAPEUTICS, INC.**
Title of Invention:	**Compositions For Respiratory Delivery Of Active Agents And Associated Methods And Systems**

Application No.:	**RE/R/2017/0022**
Date of Grant:	**6 July, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**PEARL THERAPEUTICS, INC.**
Title of Invention:	**Respiratory Delivery Of Active Agents**

Application No.:	**RE/R/2017/0023**
Date of Grant:	**6 July, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**PEARL THERAPEUTICS, INC.**
Title of Invention:	**Compositions For Pulmonary Delivery Of Long-Acting**

Muscarinic Antagonists And Long-Acting B2 Adrenergic Receptor Agonists And Associated Methods And Systems

---

Application No.:	**RE/R/2017/0030**
Date of Grant:	**8 July, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**GILEAD SCIENCES, INC. JAPAN TOBACCO, INC.**
Title of Invention:	**Methods For Improving The Pharmacokinetics Of Hiv Intergrase Inhibitors**

Application No.:	**RE/R/2017/0031**
Date of Grant:	**20 July, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**KUDOS PHARMACEUTICALS LIMITED**
Title of Invention:	**Pharmaceutical Formulation 514**

Application No.:	**BN/N/2015/0004**
Date of Grant:	**4 September, 2017**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B. V**
Title of Invention:	**Process For Producing And Separating Oil**

Application No.:	**BN/N/2016/0004**
Date of Grant:	**1 February, 2016**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**LIQWD, INC.**
Title of Invention:	**Methods For Fixing Hair And Skin**

Application No.:	**RE/R/2015/0034**
Date of Grant:	**13 August, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**BIOGEN MA INC.**
Title of Invention:	**Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof**

Application No.:	**RE/R/2015/0045**
Date of Grant:	**13 August, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Morpholino Pyrimidines And Their Use In Therapy**

Application No.:	**RE/R/2016/0026**
Date of Grant:	**19 August, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**GILEAD PHARMASSET LLC**
Title of Invention:	**Antiviral Compounds**

Application No.:	**RE/R/2016/0029**
Date of Grant:	**10 July 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**SKYONIC CORPORATION**
Title of Invention:	**Carbon Dioxide Sequestrations Involving Two-Salt-Based Thermolytic Processes**

Application No.: RP/R/2004/0028

Date of Grant: 19 July, 2004

Annuity: 18th Year

Applicant(s) / Proprietor(s): SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.

Title of Invention: Method For Transporting And Installing An Expandable Steel Tubular

---

Application No.: RP/R/2011/0051

Date of Grant: 5 December, 2011

Annuity: 10th Year

Applicant(s) / Proprietor(s): SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B. V.

Title of Invention: Marine Time Lapse Seismic Surveying

Application No.: BN/N/2016/0020

Date of Grant: 18 August, 2018

Annuity: 8th Year

Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.

Title of Invention: Gravel Packing Apparatus Having Optimized Fluid Handling

---

Application No.: BN/N/2017/0070

Date of Grant: 8 August, 2018

Annuity: 6th Year

Applicant(s) / Proprietor(s): HERNÁNDEZ MIRAMONTES, JORGE ANTONIO

Title of Invention: Mixture Of Carboxylic Acids For Treating Patients With Kidney Failure

---

Application No.:	**BN/N/2018/0055**
Date of Grant:	**11 June, 2018**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Isoindole Compounds**

Application No.:	**RE/R/2013/0087**
Date of Grant:	**15 November, 2012**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**OXFORD BIODYNAMICS LIMITED**
Title of Invention:	**Methods Of Detecting Long Range Chromosomal Interactions**

Application No.:	**RE/R/2015/0051**
Date of Grant:	**19 November, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**WYETH LLC**
Title of Invention:	**Processes For The Convergent Synthesis Of Calicheamicin Derivatives**

Application No.:	**RE/R/2015/0062**
Date of Grant:	**26 November, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**NEWRON PHARMACEUTICALS S.P.A.**
Title of Invention:	**Process For The Production Of 2- [4 - (3- And 2- Flu0r0benzyl0xy) Benzylamin0] Propan Amides**

Application No.:	**RE/R/2016/0043**

Date of Grant: 4 November, 2015

Annuity: 6th Year

Applicant(s) / Proprietor(s): MERIDIAN MEDICAL TECHNOLOGIES, INC.

Title of Invention: Drug Delivery System With A Small Amount Of A Therapeutic Agent

---

Application No.: RE/R/2016/0044

Date of Grant: 22 November, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s): ELI LILLY AND COMPANY

Title of Invention: Anti-N3pglu Amyloid Beta Peptide Antibodies And Uses Thereof

---

Application No.: RE/R/2017/0001

Date of Grant: 25 January, 2017

Annuity: 5th Year

Applicant(s) / Proprietor(s): ALMIRALL S.A.

Title of Invention: New Cyclohexylamine Derivatives Having Beta2 Adrenergic Agonist And M3 Muscarinic Antagonist Activities

---

Application No.: RE/R/2017/0048

Date of Grant: 2 November, 2016

Annuity: 5th Year

Applicant(s) / Proprietor(s): MSD K.K.

Title of Invention: Dihydropyrazolopyrimidinone Derivative

Application No.: RE/R/2017/0058

Date of Grant: 15 November, 2016

Annuity: 5th Year

Applicant(s) / Proprietor(s): PETROLIAM NASIONAL BERHAD (PETRONAS)

Title of Invention: Water Curable Resin Formulations

Application No.: RP/R/2008/0072

Date of Grant: 15 October, 2008

Annuity: 17th Year

Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: Dipeptidyl Peptidase Inhibitors

Application No.: RP/R/2011/0009

Date of Grant: 30 June, 2010

Annuity: 15th Year

Applicant(s) / Proprietor(s): ERKE ERKE ARASTIRMALARI VE MUHENDISLIK A.S.

Title of Invention: Gyroscopic Apparatus

Application No.: BN/N/2014/0025

Date of Grant: 24 March, 2014

Annuity: 9th Year

Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION
VALLOUREC OIL AND GAS FRANCE

Title of Invention: Tubular Threaded Joint Having Improved High Torque Performance

---

Application No.: BN/N/2014/0046

Date of Grant: 28 August, 2012

Annuity: 9th Year

Applicant(s) / Proprietor(s):	**CCP TECHNOLOGY GMBH**
Title of Invention:	**Process And System For Conversion Of Carbon Dioxide To Carbon Monoxide**

Patent No.:	**BN/N/2014/0048**
Date of Grant:	**20 December, 2012**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**CCP TECHNOLOGY GMBH**
Title of Invention:	**Process And System For Generating Synthesis Gas**

Patent No.:	**BN/N/2017/0044**
Date of Grant:	**30 November, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**1-[2-(Aminomethyl)Benzyl]-2-Thioxo-1,2,3,5-Tetrahydro-4h-Pyrrolo[3,2-D]Pyrimidin-4-Ones As Inhibitors Of Myeloperoxidase**

Patent No.:	**RE/R/2013/0020**
Date of Grant:	**22 December, 2004**
Annuity:	**17th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Maleate Salts Of A Quinazoline Derivative Useful As An Antiangiogenic Agent**

Patent No.:	**RE/R/2013/0023**
Date of Grant:	**22 December, 2006**
Annuity:	**15th Year**

Applicant(s) / Proprietor(s): **ARIAD PHARMACEUTICALS, INC.**

Title of Invention: **Bicyclic Heteroaryl Compounds**

Patent No.: **RE/R/2013/0041**

Date of Grant: **18 December, 2007**

Annuity: **14th Year**

Applicant(s) / Proprietor(s): **TAKEDA PHARMACEUTICAL COMPANY LIMITED**

Title of Invention: **MAPK/ERK Kinase Inhibitors**

Patent No.: **RE/R/2013/0086**

Date of Grant: **30 November, 2011**

Annuity: **10th Year**

Applicant(s) / Proprietor(s): **JANSSEN PHARMACEUTICA N.V**

Title of Invention: **Processes For The Preparation Of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidinyl]Amino]Benzonitrile**

Patent No.: **RE/R/2014/0017**

Date of Grant: **15 November, 2013**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **SUMITOMO METAL INDUSTRIES LTD.**
VALLOUREC MANNESMANN OIL & GAS FRANCE

Title of Invention: **Threaded Joint For Steel Pipes**

Patent No.: **RE/R/2015/0055**

Date of Grant: **10 December, 2014**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **PFIZER INC.**

Title of Invention:	**Dioxa-Bicyclo[3.2.1]Octane-2,3,4-Triol Derivatives**

Patent No.:	**RE/R/2015/0066**
Date of Grant:	**31 December, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**ARDEA BIOSCIENCES, INC.**
Title Of Invention:	**Thioacetate Compounds,Compositions And Methods Of Use**

Patent No.:	**RE/R/2015/0069**
Date of Grant:	**23 December, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**GILEAD BIOLOGICS, INC.**
Title Of Invention:	**Antibodies That Bind To Lysyl Oxidase-Like 2(Loxl2) And Methods Of Use Therefor**

Patent No.:	**RE/R/2016/0007**
Date of Grant:	**15 December, 2009**
Annuity:	**12th Year**
Applicant(s) / Proprietor(s):	**REGENERON PHARMACEUTICALS, INC.**
Title Of Invention:	**High Affinity Human Antibodies To PCSK9**

Patent No.:	**RE/R/2016/0017**
Date of Grant:	**16 December, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB** **NEKTAR THERAPEUTICS**
Title Of Invention:	**Crystalline Naloxol-PEG Conjugate**

Patent No.:	**RE/R/2016/0028**
Date of Grant:	**15 December, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**SUMITOMO METAL INDUSTRIES, LTD. VALLOUREC MANNESMANN OIL & GAS FRANCE**
Title Of Invention:	**Threaded Joint For Pipes Having A Lubricating Coating**

Patent No.:	**RE/R/2016/0033**
Date of Grant:	**29 December, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**INCYTE HOLDINGS CORPORATION**
Title Of Invention:	**Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1h-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile**

Patent No.:	**RE/R/2017/0008**
Date of Grant:	**07 December, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**GILEAD SCIENCES, INC.**
Title Of Invention:	**Method of Preparing An Inhibitor Of Cytochrome P450 Monooxygenase, And Intermediates Involved**

Patent No.:	**RE/R/2017/0016**
Date of Grant:	**15 November, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL CORPORATION VALLOUREC MANNESMANN OIL & GAS FRANCE**

Title Of Invention: **Tubular Threaded Joint Having Improved Low Temperature Performance**

Patent No.: **RE/R/2017/0061**

Date of Grant: **28 December, 2016**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **VERTEX PHARMACEUTICALS INCORPORATED**

Title Of Invention: **Heterocyclic Modulators Of Atp-Binding Cassette Transporters**

Patent No.: **RP/R/2008/0023**

Date of Grant: **28 December, 2005**

Annuity: **16th Year**

Applicant(s) / Proprietor(s): **BAVARIAN NORDIC A/S**

Title Of Invention: **Modified Vaccinia Ankara Virus Variant**

Patent No.: **RP/R/2008/0043**

Date of Grant: **30 December, 2005**

Annuity: **16th Year**

Applicant(s) / Proprietor(s): **JANSSEN PHARMACEUTICA N.V.**

Title of Invention: **HIV Replication Inhibiting Pyrimidines**

Patent No.: **RP/R/2009/0015**

Date of Grant: **31 December, 2007**

Annuity: **14th Year**

Applicant(s) / Proprietor(s): **JANSSEN ALZHEIMER IMMUNOTHERAPY**

Title Of Invention: **Prevention And Treatment Of Amyloidogenic Disease**

Patent No.:	**RP/R/2009/0039**
Date of Grant:	**17 December, 2008**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**
Title Of Invention:	**Method For Expanding A Steel Tubing And Well With Such As Tubing**

Patent No.:	**RP/R/2010/0012**
Date of Grant:	**19 November, 2008**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**NOVARTIS AG**
Title Of Invention:	**Inhibitors Of Tyrosine Kinases**

Patent No.:	**RP/R/2011/0011**
Date of Grant:	**31 December, 2010**
Annuity:	**12th Year**
Applicant(s) / Proprietor(s):	**PANASONIC INTELLECTUAL PROPERTY CORPORATION OF AMERICA**
Title Of Invention:	**Coding Method, Decoding Method, Coding Apparatus, Decoding Apparatus, Program, And Integrated Circuit**

Patent No.:	**RP/R/2011/0015**
Date of Grant:	**19 January, 2009**
Annuity:	**12th Year**
Applicant(s) / Proprietor(s):	**PANASONIC INTELLECTUAL PROPERTY CORPORATION OF AMERICA**
Title Of Invention:	**Coding Method, Decoding Method, Coding Apparatus, Decoding Apparatus, Program, And Integrated Circuit**

Patent No.:	**BN/N/2015/0017**
Date of Grant:	**26 September, 2012**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title Of Invention:	**Single Trip Multi-Zone Completion Systems And Methods**

Patent No.:	**BN/N/2015/0021**
Date of Grant:	**26 September, 2012**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title Of Invention:	**Tubing Conveyed Multiple Zone Integrated Intelligent Well Completion**

Patent No.:	**BN/N/2015/0027**
Date of Grant:	**26 September, 2012**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title Of Invention:	**Completion Assembly And Methods For Use Thereof**

Patent No.:	**BN/N/2015/0030**
Date of Grant:	**26 September, 2012**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title Of Invention:	**Single Trip Multi-Zone Completion Systems And Methods**

Patent No.:	**BN/N/2016/0028**

Date of Grant:	**10 October, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**BERLIN-CHEMIE AG**
Title Of Invention:	**Conjugated Antibodies Against Ly75 For The Treatment Of Cancer**

Patent No.:	**BN/N/2016/0088**
Date of Grant:	**19 June, 2014**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL CORPORATION VALLOUREC OIL AND GAS FRANCE**
Title Of Invention:	**Threaded Coupling For Steel Piping**

Patent No.:	**RE/R/2012/0035**
Date of Grant:	**30 June, 2011**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**BOEHRINGER INGELHEIM INTERNATIONAL GMBH**
Title Of Invention:	**DPP IV Inhibitor Formulations**

Patent No.:	**RE/R/2012/0060**
Date of Grant:	**29 November, 2017**
Annuity:	**16th Year**
Applicant(s) / Proprietor(s):	**PFIZER, INC.**
Title Of Invention:	**Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors**

Patent No.:	**RE/R/2013/0017**
Date of Grant:	**31 July, 2009**

Annuity: 12th Year

Applicant(s) / Proprietor(s): THOMSON LICENSING S. A.

Title Of Invention: Method For Representing Animated Menu Buttons

---

Patent No.: RE/R/2013/0033

Date of Grant: 29 August, 2012

Annuity: 9th Year

Applicant(s) / Proprietor(s): MERCK SHARP & DOHME CORP.
MSD ITALIA S.R.L.

Title Of Invention: Macrocyclic Quinoxaline Compounds As HCY NS3 Protease Inhibitors

---

Patent No.: RE/R/2013/0062

Date of Grant: 24 August, 2007

Annuity: 14th Year

Applicant(s) / Proprietor(s): PURDUE PHARMA L.P.

Title Of Invention: Tamper Resistent Oral Pharmaceutical Dosage Forms Comprising An Opioid Analgesic

---

Patent No.: RE/R/2013/0065

Date of Grant: 17 August, 2006

Annuity: 15th Year

Applicant(s) / Proprietor(s): ARRAY BIOPHARMA, INC.

Title Of Invention: 8-Substituted Benzoazepines As Toll-Like Receptor Modulators

---

Patent No.: RE/R/2013/0067

Date of Grant: 29 August, 2008

Annuity: 13th Year

Applicant(s) / Proprietor(s): **PURDUE PHARMA L.P.**

Title Of Invention: **Substituted-Quinoxaline-Type-Piperidine Compounds And The Uses Thereof**

Patent No.: **RE/R/2013/0081**

Date of Grant: **28 September, 2012**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **HOUSING AND DEVELOPMENT BOARD**

Title Of Invention: **A Plant Tray**

Patent No.: **RE/R/2013/0088**

Date of Grant: **14 August, 2005**

Annuity: **16th Year**

Applicant(s) / Proprietor(s): **PFIZER INC**

Title Of Invention: **Pyrazole-Substituted Aminoheteroaryl Compounds As Protein Kinase Inhibitors**

Patent No.: **RE/R/2014/0051**

Date of Grant: **30 August, 2013**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **ELI LILLY AND COMPANY**

Title Of Invention: **Amidophenoxyindazoles Useful As Inhibitors Of C-Met**

Patent No.: **RE/R/2014/0055**

Date of Grant: **30 September, 2011**

Annuity: **10th Year**

Applicant(s) / Proprietor(s): **NOVARTIS AG**

Title Of Invention: **Combination Of Glycopyrrolate And Beta2 Adrenoceptor Agonists**

Patent No.: **RE/R/2015/0013**

Date of Grant: **20 August, 2014**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **TOTAL S.A.**

Title Of Invention: **Line For Transporting A Fluid Containing A Hyrdocarbon, And Method For Producing Such A Line**

Patent No.: **RE/R/2015/0036**

Date of Grant: **27 August, 2014**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **PFIZER PRODUCTS INC.**

Title Of Invention: **Bicyclic [3.1.0] Heteroaryl Amides As Type I Glycine Transport Inhibitors**

Patent No.: **RE/R/2016/0030**

Date of Grant: **13 July, 2015**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **METROL TECHNOLOGY LIMITED**

Title Of Invention: **A Safety Mechanism For A Well, A Well Comprising The Safety Mechanism, And Related Methods**

Patent No.: **RE/R/2017/0039**

Date of Grant: **17 August, 2016**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **PFIZER INC.**

Title of Invention: **N1-Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors**

Patent No.: **RE/R/2017/0040**

Date of Grant: **24 August, 2016**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **MERIDIAN MEDICAL TECHNOLOGIES, INC**

Title of Invention: **Drug Delivery Device**

Patent No.: **RP/R/2004/0001**

Date of Grant: **10 September, 2003**

Annuity: **18th Year**

Applicant(s) / Proprietor(s): **MERCK CANADA INC.**

Title of Invention: **Substituted Pyridines As Selective Cyclooxygenase-2 Inhibitors**

Patent No.: **RP/R/2007/0060**

Date of Grant: **12 September, 2007**

Annuity: **14th Year**

Applicant(s) / Proprietor(s): **MERCK SHARP & DOHME CORP.**

Title of Invention: **Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor**

Patent No.: **RP/R/2009/0035**

Date of Grant: **23 June, 2000**

Annuity: **21th Year**

Applicant(s) / Proprietor(s): **GENENTECH, INC.**

Title of Invention:	**Humanized Anti-Erbb2 Antibodies And Treatment With Anti-Erbb2 Antibodies**

Patent No.:	**RP/R/2011/0008**
Date of Grant:	**11 September, 2002**
Annuity:	**19th Year**
Applicant(s) / Proprietor(s):	**GLAXO GROUP LIMITED**
Title of Invention:	**Phenethanolamine Derivatives For Treatment Of Respiratory Diseases**

Patent No.:	**RP/R/2011/0029**
Date of Grant:	**15 June, 2011**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**BOEHRINGER INGELHEIM INTERNATIONAL GMBH**
Title of Invention:	**Uses Of Dpp-Iv Inhibitors**

Patent No.:	**BN/N/2016/0033**
Date of Grant:	**28 October, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**ELI LILLY AND COMPANY**
Title of Invention:	**Glucopyranosyl-Substituted Indole-Urea Derivatives And Their Use As Sglt Inhibitors**

Patent No.:	**RE/R/2012/0062**
Date of Grant:	**23 October, 2006**
Annuity:	**15th Year**

Applicant(s) / Proprietor(s):	**ABBOTT LABORATORIES**
Title of Invention:	**Infant Formulas Containing Docosahexaenoic Acid And Lutein**

Patent No.:	**RE/R/2013/0011**
Date of Grant:	**13 October, 2010**
Annuity:	**11th Year**
Applicant(s) / Proprietor(s):	**PFIZER IRELAND PHARMACEUTICALS**
Title of Invention:	**Novel Heterocyclic Compounds Which Are Active As Inhibitors Of Beta+Lactamases**

Patent No.:	**RE/R/2013/0022**
Date of Grant:	**14 November, 2012**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**KANON LOADING EQUIPMENT B.V**
Title of Invention:	**Coupling Device For A Marine Loading Arm**

Patent No.:	**RE/R/2014/0004**
Date of Grant:	**10 September, 2007**
Annuity:	**14th Year**
Applicant(s) / Proprietor(s):	**MEBIOL INC.**
Title of Invention:	**Plant Cultivation System**

Patent No.:	**RE/R/2015/0057**
Date of Grant:	**14 October, 2014**

Annuity: 7th Year

Applicant(s) / Proprietor(s): PFIZER ANTI-INFECTIVES AB

Title of Invention: Compositions And Methods For Treating Bacterial Infections Using Ceftaroline

---

Patent No.: RE/R/2016/0004

Date of Grant: 15 October, 2015

Annuity: 6th Year

Applicant(s) / Proprietor(s): PFIZER INC

Title of Invention: Dioxa-Bicyclo[3.2.1]Octane-2,3,4-Triol Derivatives

---

Patent No.: RP/R/2005/0004

Date of Grant: 15 November, 2001

Annuity: 20th Year

Applicant(s) / Proprietor(s): ENI S. P. A

Title of Invention: Method For Centralising A Tight Fitting Casing In A Borehole

---

Patent No.: RP/R/2007/0004

Date of Grant: 09 May, 2001

Annuity: 20th Year

Applicant(s) / Proprietor(s): PFIZER LIMITED

Title of Invention: Triazolyl Tropane Derivatives As Ccr5 Modulators

---

Patent No.: RP/R/2011/0048

Date of Grant: 5 October, 2011

Annuity: 10th Year

Applicant(s) / Proprietor(s): MERCK SHARP AND DOHME CORP.

Title of Invention: Polycyclic Indazole Derivatives That Are Erk Inhibitors

---

Patent No.: RE/R/2016/0039

Date of Grant: 27 July, 2016

Annuity: 5th Year

Applicant(s) / Proprietor(s): NOVARTIS AG

Title of Invention: Treatment Of Solid Kidney Tumours With A Rapamycin Derivative

---

Patent No.: RP/R/2011/0025

Date of Grant: 30 July, 2010

Annuity: 11th Year

Applicant(s) / Proprietor(s): SUMITOMO METAL INDUSTRIES, LTD.
VALLOUREC MANNESMANN OIL & GAS FRANCE

Title of Invention: Lubricating Coating Composition Suitable For Lubrication Of A Threaded Joint

---

Patent No.: BN/N/2016/0005

Date of Grant: 04 August, 2014

Annuity: 7th Year

Applicant(s) / Proprietor(s): PAUL STEVEN KOURIS

Title of Invention: An Assembly For Generating Electricity

Patent No.: BN/N/2016/0006

Date of Grant: 05 August, 2014

Annuity: 7th Year

Applicant(s) / Proprietor(s): CHIYODA CORPORATION

Title of Invention: Hydrogen Supply System And Hydrogen Supply Method

---

Patent No.: BN/N/2018/0011

Date of Grant: 12 August, 2016

Annuity: 5th Year

Applicant(s) / Proprietor(s): ICTB GLOBAL CO., LTD.

Title of Invention: Method For Hair Shaping Treatment That Is Hair Straightening Treatment Or Permanent Waving Treatment, And Hair Treating Liquid For Hair Shaping Treatment

---

Patent No.: RE/R/2012/0049

Date of Grant: 29 August, 2006

Annuity: 15th Year

Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: 1 - Heterocyclylsulfonyl, 2 - Aminomethyl, 5 - (Hetero -) Aryl Substituted 1 - H - Pyrrole Derivatives As Acid Secretion Inhibitors

---

Patent No.: RE/R/2017/0026

Date of Grant: 30 August, 2016

Annuity: 5th Year

Applicant(s) / Proprietor(s): GLAXOSMITHKLINE LLC

Title of Invention: Novel Phamaceutical Composition

Patent No.:	**RP/R/2003/0016**
Date of Grant:	**18 September, 2002**
Annuity:	**19th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**
Title of Invention:	**Method For Drilling And Completing A Hydrocarbon Production Well**

Patent No.:	**RP/R/2005/0006**
Date of Grant:	**01 September, 2004**
Annuity:	**17th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**
Title of Invention:	**Method For Annular Sealing**

Patent No.:	**RP/R/2007/0028**
Date of Grant:	**23 August, 2002**
Annuity:	**19th Year**
Applicant(s) / Proprietor(s):	**SATOSHI SAWAMURA**
Title of Invention:	**Transparent Silicone Film-Forming Composition And Method For Curing Same**

Patent No.:	**RP/R/2011/0030**
Date of Grant:	**23 September, 2004**
Annuity:	**17th Year**

Applicant(s) / Proprietor(s): **TASLY PHARMACEUTICAL GROUP CO., LTD.**

Title of Invention: **Pharmaceutical Composition For The Treatment Of Cardiovascular And Cerebrovascular Diseases**

Patent No.: **RP/R/2011/0041**

Date of Grant: **29 August, 2006**

Annuity: **15th Year**

Applicant(s) / Proprietor(s): **TAKEDA PHARMACEUTICAL COMPANY LIMITED**

Title of Invention: **1-Heterocyclylsulfonyl, 2-Aminomethyl, 5- (Hetero-) Aryl Substituted 1-H-Pyrrole Derivatives As Acid Secretion Inhibitors**

Patent No.: **BN/N/2015/0130**

Date of Grant: **08 August, 2013**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **SAFWAY SERVICES, LLC**

Title of Invention: **Access Structure Integration Assembly And Integrated Access Systems And Methods Of Using The Same**

Patent No.: **RE/R/2017/0041**

Date of Grant: **24 August, 2016**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **IMMUNOGEN, INC.**

Title of Invention: **Folate Receptor 1 Antibodies And Immunoconjugates And Uses Thereof**

Patent No.: **RP/R/2010/0041**

Date of Grant: **5 August, 2009**

Annuity: 12th Year

Applicant(s) / Proprietor(s): MERCK SHARP & DOHME CORP.

Title of Invention: Pharmaceutical Composition Containing Proton Pump Inhibitors

---

Patent No.: BN/N/2017/0013

Date of Grant: 11 September, 2014

Annuity: 7th Year

Applicant(s) / Proprietor(s): ICTB GLOBAL CO., LTD.

Title of Invention: Hair Coloring Agent And Hair Dyeing Method

---

Patent No.: RE/R/2012/0006

Date of Grant: 15 September, 2011

Annuity: 10th Year

Applicant(s) / Proprietor(s): BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Title of Invention: Polymorphs

Patent No.: RE/R/2016/0040

Date of Grant: 16 September, 2015

Annuity: 6th Year

Applicant(s) / Proprietor(s): ACCELERON PHARMA INC.

Title of Invention: Activin-Actrii Antagonists And Uses For Increasing Red Blood Cell Levels

---

Patent No.: RP/R/2011/0047

Date of Grant: 01 September, 2006

Annuity: 15th Year

Applicant(s) / Proprietor(s): PFIZER LIMITED

Title of Invention: Carboxamide Derivatives As Muscarinic Receptor Antagonists

---

Patent No.: RP/R/2011/0044

Date of Grant: 25 September, 2006

Annuity: 15th Year

Applicant(s) / Proprietor(s): ASTEX PHARMACEUTICALS, INC.

Title of Invention: Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein

---

Patent No.: BN/N/2018/0017

Date of Grant: 15 September, 2016

Annuity: 5th Year

Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION
VALLOUREC OIL AND GAS FRANCE

Title of Invention: Composition, Threaded Joint For Pipes Including Solid Lubricant Coating Formed From The Composition, And Method For Producing The Threaded Joint For Pipes

---

Patent No.: RE/R/2012/0018

Date of Grant: 18 October, 2006

Annuity: 15th Year

Applicant(s) / Proprietor(s): ALFRED-WEGENER-INSTITUT, HELMHOLTZ-ZENTRUM FÜR POLAR-UND MEERESFORSCHUNG

Title of Invention: Method For Processing Ovulated Eggs Of Aquatic Animals Into Delicacy Foods And Ovulated Eggs Processed Using The Method

---

Patent No.:	**RE/R/2013/0074**
Date of Grant:	**24 August, 2010**
Annuity:	**11th Year**
Applicant(s) / Proprietor(s):	**STATOIL PETROLEUM AS**
Title of Invention:	**Shallow Marine Electromagnetic Hydrocarbon Prospecting**

Patent No.:	**RE/R/2013/0079**
Date of Grant:	**29 September, 2001**
Annuity:	**20th Year**
Applicant(s) / Proprietor(s):	**REGENTS OF THE UNIVERSITY OF MINNESOTA**
Title of Invention:	**Cultivated Agarwood**

Patent No.:	**RP/R/2003/0032**
Date of Grant:	**6 November, 2002**
Annuity:	**19h Year**
Applicant(s) / Proprietor(s):	**TWISTER B.V.**
Title of Invention:	**Removing A Gaseous Component From A Fluid**

Patent No.:	**RE/R/2017/0019**
Date of Grant:	**28 September, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**MSD K.K.**
Title of Invention:	**Bicycloaniline Derivative**

Patent No.:	**BN/N/2017/0026**
Date of Grant:	**06 November, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**ELI LILLY AND COMPANY**
Title of Invention:	**Aurora A Kinase Inhibitor**

Patent No.:	**BN/N/2018/0056**
Date of Grant:	**22 December, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**MANIFATTURA DEL SEVESO S.P.A.**
Title of Invention:	**Process For Obtaining A Cloth With High Performances For Digital Printing And Relative Cloth**

Patent No.:	**RE/R/2012/0056**
Date of Grant:	**15 November, 2011**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**HIGH SEALED AND COUPLED "HSC" FZCO**
Title of Invention:	**An Improved Seal Between Pipes**

Patent No.:	**RE/R/2015/0046**
Date of Grant:	**05 November, 2014**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**TOTAL S.A.**
Title of Invention:	**Heating Device For A Device For Transporting A Fluid Containing A Hydrocarbon**

Patent No.: RP/R/2011/0045

Date of Grant: 21 December, 2006

Annuity: 15th Year

Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: Metastin Derivatives And Use Thereof

Patent No.: BN/N/2016/0052

Date of Grant: 29 January, 2014

Annuity: 8th Year

Applicant(s) / Proprietor(s): JAPAN PALLET RENTAL CORPORATION

Title of Invention: Distribution Container Management System, Distribution Container Management Method, And Distribution Container Management Program

---

Patent No.: BN/N/2017/0041

Date of Grant: 16 December, 2015

Annuity: 6th Year

Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION
VALLOUREC MANNSMANN OIL & GAS FRANCE

Title of Invention: Threaded Joint For Pipes

Patent No.: BN/N/2014/0062

Date of Grant: 17 January, 2013

Annuity: 9th Year

Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION
VALLOUREC MANNSMANN OIL & GAS FRANCE

Title of Invention: Threaded Joint For Pipes

Patent No.:	**BN/N/2017/0063**
Date of Grant:	**12 January, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**TMA CAPITAL AUSTRALIA PTY LTD**
Title of Invention:	**System, Method And Computer Program For An Access Control System**

Patent No.:	**RE/R/2012/0005**
Date of Grant:	**31 January, 2011**
Annuity:	**11th Year**
Applicant(s) / Proprietor(s):	**SUMITOMO METAL INDUSTRIES LTD. VALLOUREC MANNESMANN OIL & GAS FRANCE**
Title of Invention:	**Tubular Threaded Joint**

Patent No.:	**RE/R/2013/0046**
Date of Grant:	**30 January, 2008**
Annuity:	**14th Year**
Applicant(s) / Proprietor(s):	**TAKEDA PHARMACEUTICAL COMPANY LIMITED**
Title of Invention:	**Solid Preparation Comprising Alogliptin And Pioglitazone**

Patent No.:	**RE/R/2014/0009**
Date of Grant:	**31 January, 2013**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Chemical Compounds**

Patent No.:	**RE/R/2015/0004**
Date of Grant:	**22 January, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**NEKTAR THERAPEUTICS**
Title of Invention:	**Monodisperse Pegylated Naloxol Compositions**

Patent No.:	**RE/R/2015/0060**
Date of Grant:	**29 January, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**KUDOS PHARMACEUTICALS LIMITED**
Title of Invention:	**Pyrido-, Pyrazo- And Pyrimido-Pyrimidine Derivatives As Mtor Inhibitors**

Patent No.:	**RE/R/2016/0016**
Date of Grant:	**08 January, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**JANSSEN SCIENCES IRELAND UC**
Title of Invention:	**Indoles As Respiratory Syncytial Virus Antiviral Agents**

Patent No.:	**RE/R/2016/0031**
Date of Grant:	**16 December, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**MERCK SHARP & DOHME CORP.**
Title of Invention:	**Iminothiadiazine Dioxide Compounds As Bace Inhibitors, Compositions, And Their Use**

Patent No.:	**RE/R/2017/0011**
Date of Grant:	**28 February, 2017**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**TAKEDA VACCINES, INC.**
Title of Invention:	**Methods And Compositions For Live Attenuated Viruses**

Patent No.:	**RE/R/2017/0045**
Date of Grant:	**1 February, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**KUDOS PHARMACEUTICALS LIMITED**
Title of Invention:	**2-Methylmorpholine Pyrido-, Pyrazo- And Pyrimido-Pyrimidine Derivatives As Mtor Inhibitors**

Patent No.:	**RE/R/2018/0002**
Date of Grant:	**16 January, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**CYTOKINETICS, INC.**
Title of Invention:	**Certain Amino-Pyridazines, Compositions Thereof, And Methods Of Their Use**

Patent No.:	**RP/R/2003/0031**
Date of Grant:	**22 April, 1999**
Annuity:	**19th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**
Title of Invention:	**Foldable Tube**

Patent No.:	**RP/R/2003/0034**
Date of Grant:	**27 April, 1998**
Annuity:	**19th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**
Title of Invention:	**Expandable Well Screen**

Patent No.:	**RP/R/2004/0003**
Date of Grant:	**4 August, 2000**
Annuity:	**20th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Pharmaceutical Compositions**

Patent No.:	**RP/R/2006/0021**
Date of Grant:	**13 January, 1998**
Annuity:	**17th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**New Formulation For Inhalation Having A Poured Bulk Density Of 0.28 To 0.38 G/Ml, A Process For Preparing The Formulation And The Use Thereof**

Patent No.:	**RP/R/2009/0028**
Date of Grant:	**15 May, 2003**
Annuity:	**15th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**C-Aryl Glucoside Sglt2 Inhibitors And Method**

Patent No.:	**RP/R/2010/0007**

Date of Grant: 3 April, 2010

Annuity: 12th Year

Applicant(s) / Proprietor(s): SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.

Title of Invention: Method For Production Metering Of Oil Wells

---

Patent No.: BN/N/2014/0074

Date of Grant: 12 August, 2014

Annuity: 9th Year

Applicant(s) / Proprietor(s): INNOVATA BIOMED LIMITED

Title of Invention: Medicament Delivery Devices

Patent No.: BN/N/2015/0079

Date of Grant: 18 April, 2014

Annuity: 8th Year

Applicant(s) / Proprietor(s): CHANNELL COMMERCIAL CORPORATION

Title of Invention: Grade Level Enclosure Conversion Assembly

---

Patent No.: BN/N/2017/0039

Date of Grant: 26 September, 2019

Annuity: 7th Year

Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.

Title of Invention: Downhole Pressure Maintenance System Using A Controller

---

Patent No.: RE/R/2012/0038

Date of Grant: 11 January, 2012

Annuity: 10th Year

Applicant(s) / Proprietor(s):	**VALLOUREC MANNESMANN OIL & GAS FRANCE**
Title of Invention:	**Method For Pressure Testing A Threaded Component**

Patent No.:	**RE/R/2015/0061**
Date of Grant:	**26 November, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**PURDUE PHARMA L.P.**
Title of Invention:	**Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising An Opioid Analgesic**

Patent No.:	**RE/R/2017/0015**
Date of Grant:	**17 April, 2017**
Annuity:	**14th Year**
Applicant(s) / Proprietor(s):	**GILEAD SCIENCES, INC.**
Title of Invention:	**Modulators Of Pharmacokinetic Properties Of Therapeutics**

Patent No.:	**RE/R/2018/0029**
Date of Grant:	**7 December, 2009**
Annuity:	**12th Year**
Applicant(s) / Proprietor(s):	**GILEAD SCIENCES, INC.**
Title of Invention:	**Modulators Of Toll-Like Receptors**

Patent No.:	**RP/R/2011/0018**
Date of Grant:	**24 May, 2011**
Annuity:	**11th Year**
Applicant(s) / Proprietor(s):	**MERCK SHARP & DOHME CORP.**

Title of Invention: **Tricyclic Thrombin Receptor Antagonist**

Patent No.: **RP/R/2011/0052**

Date of Grant: **31 December, 2008**

Annuity: **13th Year**

Applicant(s) / Proprietor(s): **ELI LILLY AND COMPANY**

Title of Invention: **Morpholine Derivatives As Norepinephrine Reuptake Inhibitors**

Patent No.: **BN/N/2015/0098**

Date of Grant: **21 June, 2016**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **SHODA SHOYU CO., LTD. and SOY & WORLD INC.**

Title of Invention: **Process For Manufacturing Soybean Paste, And Soybean Paste**

Patent No.: **BN/N/2016/0029**

Date of Grant: **12 April, 2018**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **HALLIBURTON ENERGY SERVICES, INC.**

Title of Invention: **Testable Isolation Packer**

Patent No.: **BN/N/2016/0044**

Date of Grant: **10 July, 2017**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **HALLIBURTON ENERGY SERVICES, INC.**

Title of Invention: **Dual Isolation Well Assembly**

Patent No.:	**BN/N/2017/0043**
Date of Grant:	**12 June, 2019**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title of Invention:	**Mechanical Downhole Pressure Maintenance System**

Patent No.:	**BN/N/2014/0001**
Date of Grant:	**7 January, 2014**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**CRYSTAL LAGOONS (CURACAO) B.V.**
Title of Invention:	**Localised Disinfection System For Large Water Bodies**

Patent No.:	**RE/R/2015/0050**
Date of Grant:	**1 September, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**MERCK SHARP & DOHME CORP.**
Title of Invention:	**Beta-Lactamase Inhibitors**

Patent No.:	**RE/R/2016/0034**
Date of Grant:	**8 July, 2015**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**ESTEVE PHARMACEUTICALS, S.A.**
Title of Invention:	**Pharmaceutical Compositions Of Co-Crystals Of Tramadol And Coxibs**

Patent No.:	**RE/R/2018/0001**
Date of Grant:	**13 January, 2018**

Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**CRYSTAL LAGOONS (CURACAO) B.V.**
Title of Invention:	**Efficient Filtration Process Of Water In A Tank For Recreational And Ornamental Uses, Where The Filtration Is Performed Over A Small Volume Of Water And Not Over The Totality Of The Water From The Tank**

REGISTRAR OF PATENT

BRUNEI DARUSSALAM

PATENTS RULES [S 11/2013]

PATENT GRANTED UNDER SECTION 30

Application No.:	**BN/N/2017/0022**
Date of Grant:	**11 September, 2019**
Applicant(s) / Proprietor(s):	**CRYSTAL LAGOONS (CURACAO) B.V.**
Title of Invention:	**System And Method For Maintaining Water Quality In Large Water Bodies**

Application No.:	**BN/N/2018/0047**
Date of Grant:	**11 September, 2019**
Applicant(s) / Proprietor(s):	**NIPPON SHINYAKU CO., LTD.**
Title of Invention:	**PHARMACEUTICAL COMPOSITION CONTAINING 2-{4-[N-(5,6- DIPHENYLPYRAZIN-2-YL)-N ISOPROPYLAMINO]BUTYLOXY}-N-(METHYLSULFONYL)ACETAMIDE**

Application No.:	**BN/N/2017/0022**
Date of Grant:	**11 September, 2019**
Applicant(s) / Proprietor(s):	**MOLONEY, LINDSAY AND SCOTT, GUY**
Title of Invention:	**A SYSTEM AND METHOD FOR DOCUMENT INFORMATION AUTHENTICITY VERIFICATION**
